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Abstract  
Liver disease is the fifth largest cause of mortality and is the only major cause of death 
still increasing in the UK every year. Liver disease is often associated with increased 
deposition of extracellular matrix, which leads to fibrosis and in many cases progresses 
to end stage cirrhosis. Hepatic stellate cells (HSC) are considered to be one of the 
main contributors to liver fibrosis.  
Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is a multifunctional 
TNF superfamily cytokine that signals through fibroblast growth factor-inducible 14 
(Fn14). TWEAK/Fn14 signalling has been primarily associated with liver progenitor 
cell proliferation. In this thesis I demonstrate that expression of both Fn14 and 
TWEAK were elevated in acute and chronic human liver injury, and co-localised with 
markers of activated HSCs. Fn14 expression was low in quiescent HSCs but was 
significantly induced in HSCs activated in vitro, which could be further enhanced with 
TGF-β. Stimulation with recombinant TWEAK induced proliferation, but not 
activation of HSCs. Fn14 gene expression was also significantly upregulated in CCl4 
models of hepatic injury while TWEAK KO, but not Fn14 KO, mice showed 
significantly reduced levels of liver fibrosis following acute and chronic CCl4 injury in 
vivo. Furthermore, low soluble TWEAK levels in serum levels of PSC patients were an 
independent risk factor for death or transplantation. Overall these studies demonstrate 
a previously undescribed role of TWEAK in directly mediating liver fibrosis making it 
a potential therapeutic target in fibrotic liver disease. 
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1.1 Overview of the liver anatomy and its function 
The liver is, after the skin the second largest organ of the body. It is located below the 
diaphragm mostly on the right side of the upper abdomen and has a unique dual 
blood supply from the hepatic artery and the portal vein (Figure 1.1 A). The liver 
consists of two lobes that are made up of small units, called lobules (Figure 1.1 B). In 
the centre of each lobule is a central vein. At the periphery of the lobule are portal 
triads. A portal triad consists of a branch of the hepatic portal vein, hepatic artery and 
a bile duct. The arterial and venous blood flows through the sinusoids from the portal 
triad to the central vein. The liver lobules can be divided into three zones, based on 
oxygen levels (Figure 1.1 C). Zone 1 encircles the portal triad where the highly 
oxygenated blood from hepatic arteries enters. The blood flow through zone 2 to zone 
3 that is located around the central vein where oxygenation is poor. 
 
The anatomical location of the liver allows it to perform many vital functions as it 
directly receives and metabolises nutrients from the digestive system through the 
portal vein. Some of the metabolic functions include maintenance of normal blood 
glucose levels and metabolism of fatty acids for energy production (Taub, 2004). The 
liver also serves as storage place for many essential nutrients (glycogen, fatty acids), 
vitamins (Vitamin A, E, D, K and B12) and minerals (iron and copper). Another 
important function of the liver is the production of plasma proteins including 
prothrombin, fibrinogen, and albumin. It also synthesizes bile, which is essential for 
absorption of fat and lipophilic nutrients. Furthermore, the liver is the main 
detoxifying organ of the body as it cleans the blood of many potentially harmful 
substances prior to release into the circulation. Those substances are then excreted 
either into bile that then enters the intestine or by blood for elimination by the 
 3 
kidneys. In addition, it is involved in phagocytosis of foreign particles and infecting 
organisms. During the process of blood detoxification and removal of infection some 
of the liver cells can become damaged and die. However, the liver has a unique 
regenerative potential after injury. It is able to completely reconstruct its functional 
liver mass after 70% partial hepatectomy (PH) within days in rodents and weeks in 
humans. It is also able to regenerate but to a slower extent after ischemic, toxic, and 




Figure 1.1 Structure of the liver and the liver lobules 
The liver is made up of two main lobes. It has a dual blood supply arising from the 
hepatic artery and portal vein (A). The lobes of the liver are further subdivided into 
lobules that have portal triads at the periphery containing of a branch of the hepatic 
artery, portal vein and bile duct. The blood flows from the portal triad to the central 
vein (B). Tissue in zone 1 receives more oxygenated blood than tissue in zone 3 (C). 
Image adapted from: https://gi.jhsps.org/Upload/200710290953_38845_000.jpg 
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1.1.1 Liver cell populations 
The main cell type that carries out many of the liver’s vital functions are the 
parenchymal cells called hepatocytes. Up to 80% of the liver is made up of 
hepatocytes and the remaining 20% of hepatic cells are non-parenchymal cells, 
including hepatic stellate cells (HSCs), endothelial cells, cholangiocytes, Kupffer cells 
and lymphocytes (Taub, 2004). Hepatocytes are polarised epithelial cells and are 
arranged in single cell thick chords in the liver lobules separated by blood filled 
sinusoids (Figure 1.2). In addition, tight junctions between hepatocytes form bile 
canaliculi, which are not ducts but rather dilated intercellular spaces between adjacent 
hepatocytes. Hepatocytes secrete bile into the canaliculi that then flows into the 
opposite direction of the blood flow draining into bile ducts (Müsch, 2014). Bile ducts 
are lined with another type of liver epithelial cell called cholangiocyte.  
 
Sinusoids correspond to capillary beds and are the segments of the liver where supply 
of nutrients and removal of metabolic products takes place. Fenestrated intrahepatic 
sinusoidal endothelial cells (IHECs) line the sinusoids. They are highly permeable and 
act as a selective barrier controlling the extensive exchange of materials between liver 
cells and blood (Vollmar and Menger, 2009). Within the sinusoids are Kupffer cells, 
which are anchored to the endothelium and exposed to the bloodstream. They are 
resident macrophages and responsible for phagocytosis of foreign particles and 
infecting organisms.  
 
The space between the hepatocytes and the endothelial lining is called the space of 
Disse. Within this space reside quiescent HSCs that are considered to be the pericytes 
of the liver (Pellicoro et al., 2014). The most characteristic feature of quiescent HSCs 
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is the presence of cytoplasmic lipid droplets that store vitamin A. They store over 80% 
of the total body vitamin A and maintain vitamin A blood homeostasis (Sato et al., 
2003). Other important functions of HSCs include remodelling of extracellular matrix 




Figure 1.2 The hepatic sinusoid 
In the liver lobule, hepatocytes are arranged as single cell chords. They are separated 
by blood filled sinusoids that are lined with fenestrated endothelial cells. Kupffer cells, 
the liver resident macrophages, are anchored to the endothelium. Between 
hepatocytes and endothelial cells is the space of Disse where hepatic stellate cells 
reside. Bile from hepatocytes drains into canaliculi that empty into bile ducts.  
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1.2 The burden of liver disease  
Despite the liver’s remarkable ability to regenerate itself following injury, there are 
several types of liver diseases that cause chronic injury and therefore attenuate 
regeneration. Chronic liver disease can develop in response to a number of factors 
including chronic infections with hepatitis B or C virus, chronic alcohol abuse, non-
alcoholic fatty liver disease and immune-mediated liver diseases. It is an increasing 
problem worldwide which is reflected in the United Kingdom where levels of chronic 
liver disease have been sharply increasing since the 1990s and are now amongst the 
highest in Europe (Leon and McCambridge, 2006). Chronic liver disease can lead to 
the progressive replacement of functional hepatic parenchyma with excessive ECM 
causing the deformation of normal tissue and vascular architecture, which is then 
termed cirrhosis. Cirrhosis can interfere with vital liver functions and cause organ 
dysfunction that is ultimately fatal (Friedman et al., 2013). Patients with cirrhosis are 
also at highest risk of developing primary neoplasms that can derive from hepatocytes 
(Hepatocellular carcinoma; HCC) and cholangiocytes (Cholangiocarcinoma) (Forner 
et al., 2012). As chronic liver diseases are rising, cirrhosis and liver cancer are major 
causes of death worldwide (Lozano et al., 2012). In Europe, cirrhosis and HCC 
together represent the third cause of death in adults over 50 years old (Fernández et 
al., 2009). Despite this global burden of chronic liver disease, treatment options are 
limited and currently involve either removing the underlying trigger for the liver 
disease, which is unfortunately not always possible or liver transplantation. Although 
liver transplantation can be a highly effective therapy it has also major drawbacks. 
One of the biggest issues is the increasing imbalance between demand and supply of 
donor livers (Callaghan et al., 2013). Furthermore, liver transplantation is a major 
operation and factors such as other co-existing medical issues can prevent patients 
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from being considered for transplantation. Patients that have been transplanted have 
to take life-long immunosuppressive medications to protect allografts from acute 
rejection. However, immunosuppressive medications can cause toxic effects that can 
lead to an increased risk of patient morbidity and mortality (Lechler et al., 2005). In 
addition, problems with chronic rejection can also occur, which is a major cause of 
graft loss (Neumann et al., 2002). Although the use of new immunosuppressive 
medications has generally enhanced patient’s survival rates, the recurrence of primary 
liver disease after transplantation is also a growing concern (El-Masry et al., 2011). 
This highlights the need of new preventative therapies for chronic liver disease. Most 
types of chronic liver disease follow a common pathway independent of aetiology 
leading to liver fibrosis (Schuppan and Kim, 2013). Gaining a greater understanding 
of one of the root problems such as fibrosis could therefore aid in the development of 
new treatment options.  
 
1.3 Pathogenesis of liver fibrosis  
1.3.1 Liver injury 
Hepatic fibrosis is caused by a dysregulated physiological wound-healing response to 
liver injury. The pathogenesis of liver injury is not fully understood but most types of 
liver injury damage epithelial cells (hepatocytes or cholangiocytes) that then causes the 
release of inflammatory and fibrogenic mediators (Pellicoro et al., 2014). Acute liver 
failure (ALF) for example is caused when hepatocyte death exceeds regeneration and 
is the most severe damage the liver can undergo (Chung et al., 2012). In addition, 
hepatocytes are also thought to be primarily affected in alcoholic liver disease (ALD) 
(Gao and Bataller, 2011) and non-alcoholic steatohepatitis (NASH) that is associated 
with excess free saturated fatty acids and insulin resistance (Peverill et al., 2014). 
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Autoimmune hepatitis (AIH) presents with autoreactive immune cells and also 
primarily leads to hepatocyte damage. It is likely to be caused by an environmental 
trigger in a genetically susceptible patient (Lapierre et al., 2007). In contrast, 
cholangiocytes are mainly affected in cholestatic liver diseases including primary 
biliary cirrhosis (PBC) in which the autoreactive immune response seems to be the 
most likely pathogenic mechanism (Hirschfield and Gershwin, 2013) and primary 
sclerosing cholangitis (PSC) where the trigger is unknown but thought to be immune-
mediated in individuals with a genetic predisposition (Hirschfield et al., 2013).  
Liver injury can then lead to fibrosis that involves transformation of HSCs into 
collagen producing liver myofibroblasts (LMFs) and accumulation of ECM. After 
acute injury, LMFs and ECM transiently appear but are gone once the injury is 
resolved. However, the sustained signals during chronic liver disease lead to a several-
fold increase in the production and deposition of ECM, mostly collagen type I, 
resulting in liver fibrosis (Bataller and Brenner, 2005). Excessive accumulation of liver 
fibrosis in combination with damaged epithelial cells contributes to the ongoing 
architectural distortion and the loss of organ function. The discussion that follows 
describes cellular and non-cellular mediators of liver fibrosis with an emphasis on the 
role of HSCs and LMFs during fibrogenesis. Ultimately however, liver fibrosis is a 
complex process that involves the interaction between many factors and cell types 







1.3.2 Cellular mediators 
1.3.2.1 Epithelial cells –Hepatocytes and cholangiocytes  
Damaged hepatocytes or cholangiocytes release pro-fibrogenic and pro-inflammatory 
cytokines that activate Kupffer cells and HSCs and stimulate the recruitment of 
leukocytes creating an inflammatory environment. Recruited leukocytes and Kupffer 
cells will then phagocytose dead cells and further amplify the inflammatory response 
(Bataller and Brenner, 2005). Excessive inflammation can then lead to further 
hepatocyte apoptosis or necrosis. This can partly be regulated by members of the 
tumour necrosis factor (TNF) superfamily including TNF-α, Fas ligand (FasL) and 
TNF-related apoptosis-inducing ligand (TRAIL), which are death ligands and 
therefore can directly induce hepatocyte death (Brenner et al., 2013). One source of 
those ligands are Kupffer cells that induce expression of TNF-α, TRAIL and FasL 
after phagocytosis of apoptotic hepatocytes (Canbay et al., 2003). Another TNF ligand 
that can modulate hepatocyte apoptosis is CD40 ligand (also known as CD154) 
(Afford et al., 1999). It is expressed by lymphocytes and macrophages/Kupffer cells in 
the chronically inflamed liver (Alabraba et al., 2008) and activation of the receptor, 
CD40 can induce Fas-mediated apoptosis in hepatocytes (Afford et al., 1999). 
Apoptotic hepatocytes can also be phagocytosed by HSCs during chronic liver injury 
(Zhan et al., 2006). Upon phagocytosis, HSCs increase expression of procollagen 1α 
(I) and transforming growth factor-β1 (TGF-β1) (Zhan et al., 2006) enhancing the pro-
fibrogenic response.  
 
In early stages of cholangiopathies and during severe liver injury, proliferation of 
activated cholangiocytes may also occur. They usually form small clusters or non-
functional bile ductular structures that are associated with inflammation. These are 
frequently referred to as ductular reactions (Schuppan and Kim, 2013). Ductular 
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reactions also contain a population of liver progenitor cells (LPCs) that are bipotential 
adult stem-like cells and have the capacity to differentiate into hepatocytes or 
cholangiocytes (Duncan et al., 2009). Evidence has shown that ductular reactions are 
directly proportional to levels of fibrosis (Williams et al., 2014). Activated 
cholangiocytes acquire the ability to release pro-inflammatory cytokines and 
chemokines such as TNF-α, IL-6 and chemokine (C-C motif) ligand 2 (CCL2). In 
addition they also produce growth factors such as hepatocyte growth factor (HGF), 
platelet derived growth factor-BB (PDGF-BB) and TGF-β2 that can influence HSC 
and portal fibroblast behaviours (Lazaridis et al., 2004). Therefore activated 
cholangiocytes are considered to be potential mediators of biliary fibrosis. 
 
1.3.2.2 Intrahepatic sinusoidal endothelial cells 
In a healthy liver, normal IHECs inhibit activation of quiescent HSCs and promote 
reversion from an activated to a quiescent HSC phenotype. Disruption of the 
endothelium causes fenestrated IHECs to alter their phenotype towards capillarisation 
consequently losing the ability to inhibit HSC activation (DeLeve et al., 2008; Xie et 
al., 2012). Capillarisation of IHECs is tightly associated with perisinusoidal fibrosis. 
During perisinusoidal fibrosis, IHECs contribute in small amounts to production of 
the ECM with fibronectin and collagen type I and produce pro-fibrogenic factors such 
as TGF-β1 and PDGF-BB (Schuppan and Kim, 2013). In addition, activated IHECs 
also release mediators of angiogenesis including angiopoietins and members of the 
fibroblast growth factor (FGF) family (Cong et al., 2012). Furthermore, they secrete 
endothelin-1 that is involved in vasoconstriction that can exacerbate portal 
hypertension in liver cirrhosis (Schuppan and Kim, 2013). 
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1.3.2.3 Macrophages  
Liver-resident Kupffer cells are the largest population of resident macrophages in the 
body (Pellicoro et al., 2014). As Kupffer cells reside within hepatic sinusoids they are 
in close proximity to circulating immune cells and bacterial antigens derived from the 
intestinal flora entering via the portal vein. Liver injury causes bacterial translocation 
from the intestine leading to increased levels of lipopolysaccharide (LPS) in the blood 
circulation that causes activation of Kupffer cells (Seki et al., 2007). Furthermore, 
damaged epithelial cells also lead to Kupffer cell activation (Bataller and Brenner, 
2005). In the early phases after injury, Kupffer cells secrete pro-inflammatory 
cytokines and chemokines including CCL5 and IL-1β causing activation of 
cytoprotective or apoptotic pathways in hepatocytes and amplification of the 
inflammatory response (Tacke and Zimmermann, 2014). In addition, not only 
immediate injury but also an overload of lipids can lead to secretion of pro-
inflammatory cytokines and chemokines in Kupffer cells (Leroux et al., 2012). 
 
The number of Kupffer cells is reduced during active inflammation and fibrogenesis 
and replenished again during resolution (Ramachandran et al., 2012). In contrast, the 
number of bone marrow-derived macrophages, originating from circulating 
monocytes, markedly increase in response to hepatic injury (Ramachandran et al., 
2012). Macrophages are a heterogeneous population and several subsets with distinct 
functions have been described. A simple way to classify them is by dividing the 
macrophage population into “pro-inflammatory” M1 macrophages and 
“immunoregulatory” M2 macrophages. M1 macrophages release pro-inflammatory 
factors (including TNF-α, IL-1β, IL-12, reactive oxygen species) and mediate the 
defence against pathogens and tumour cells. M2 macrophages are involved in 
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regulating tissue remodelling and secrete immune-modulatory mediators (including 
IL-10, TGF-β, IL-4, IL-13) (Tacke and Zimmermann, 2014). However, macrophages 
can adopt context-dependent phenotypes that can carry out different functions and it 
is difficult to classify them into categories as they represent a spectrum of activated 
phenotypes (Murray and Wynn, 2011).  
 
During liver fibrosis macrophages are located in close proximity to activated LMFs in 
the scar tissue (Duffield et al., 2005). They can produce a variety of different 
cytokines, chemokines and other factors that can influence HSCs and LMFs including 
TGF-β and PDGF (Wynn and Barron, 2010). Other factors that macrophages 
produce are CCL7 and CCL8 that are involved in the recruitment and activation of 
LMFs and IL-4 and IL-13 that are potent pro-fibrogenic cytokines (Wynn and 
Barron, 2010). 
Using macrophage depletion in experimental models of liver fibrosis provided further 
evidence that macrophages play an important role during fibrogenesis. The depletion 
of hepatic macrophages in rats with gadolinium chloride led to a decrease in liver 
fibrosis in response to thioacetamide-induced injury (Ide et al., 2005). Another model 
that also demonstrated the pro-fibrogenic effect of macrophages was the CD11b-DTR 
transgenic mouse model that induced selective depletion of macrophages. This model 
in combination with the hepatotoxin carbon tetrachloride (CCl4) resulted in fewer 
LMFs and less collagen (Duffield et al., 2005). 
 
It is now recognized that liver fibrosis is not an unidirectional, irreversible process and 
in accordance with that macrophages exhibit a dual role in liver fibrosis, as they can 
also be involved in resolution (Duffield et al., 2005). Next to promoting fibrosis pro-
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resolution macrophages can lead to ECM degradation by expression of fibrolytic 
matrix metalloproteinases (MMPs) such as MMP-12 and MMP-13 (Pellicoro et al., 
2012; Fallowfield et al., 2007). Furthermore, macrophages cause phagocytosis of 
apoptotic cells that leads to increased MMP production and resolution of ECM in 
models of hepatocellular and biliary fibrosis (Ramachandran et al., 2012; Popov et al., 
2010) 
 
1.3.2.4 Natural killer cells 
Natural killer (NK) cells are enriched in the liver and belong to the innate immune 
system. Between 30 to 50% of the human liver lymphocyte population are NK cells 
whereas only about 10% are present in mouse livers. They recognise and kill infected, 
injured and transformed cells and are normally present in the hepatic sinusoids in 
close proximity to non-parenchymal cells (Gao and Radaeva, 2013). NK cells can 
have a negative regulatory effect on fibrosis in two different ways. They mediate the 
direct killing of HSCs that are in the process of activation and senescent activated 
HSCs. In order to do so they release interferon-γ (IFN-γ) that induces HSC apoptosis 
and cell cycle arrest (Gao and Radaeva, 2013). However, despite the anti-fibrotic 
abilities of NK cells, chronic liver injury still leads to fibrosis. One possibility is that 
chronic alcohol consumption supresses NK cell activity, which possibly contributes to 
the progression of ALD. Indeed, patients with ALD have fewer NK cells and those 
that were present exhibited reduced cytotoxicity (Cook, 1998). In addition, alcohol 
intake also seemed to influence NK cell function in mice as a chronic ethanol diet 
caused reduced NK cytotoxicity towards HSCs, possibly caused by the reduction of 
natural killer group 2 member D (NKG2D), TRAIL, FasL and IFN-γ expression by 
NK cells (Jeong et al., 2008). Furthermore, HSCs and LMFs may use mechanisms to 
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avoid NK cell-mediated killing, as NK cells do not seem to lyse fully activated 
HSCs/LMFs as they express high levels of TGF-β, which is an inhibitor of NK cell 
cytotoxicity towards HSCs (Jeong et al., 2011). 
 
1.3.2.5 T cells  
The heterogeneity of fibrotic diseases rules out that only one subtype of T cells is 
responsible for pro or antifibrotic effects of the immune system. However, extensive 
evidence shows that CD4-positive T helper cells with a Th2 polarisation can promote 
fibrosis (Barron and Wynn, 2011). Th2 cells can produce IL-4 and IL-13 and 
experimental models of schistosomiasis have demonstrated that Th2 cells can be 
strongly pro-fibrotic. Furthermore, CD4-positive Th17 cells express IL-17 and are 
considered to be pro-fibrogenic cells. The IL-17 receptor is expressed by HSCs and 
stimulation with IL-17 leads to collagen type I production in HSCs (Meng et al., 
2012). Regulatory T cells are a subset of CD4-positive cells and seem to be pro or 
antifibrotic in a context dependent manner. Subsets can express the 
immunosuppressive cytokine IL-10 and the profibrotic mediator TGF-β (Schuppan 
and Kim, 2013). Furthermore, CD8-positive T cells have been implicated in 
promoting liver fibrogenesis (Safadi et al., 2004). However, studies with depletion of 
CD4 and CD8-positive T cells in mice have demonstrated no effect on liver 
fibrogenesis in mice treated with CCl4 (Novobrantseva et al., 2005).  
 
Natural killer T cells are a subset of T cells that express both T cell and NK cell 
markers. The percentages of NKT cells in human liver ranges between 3-15% of the 
liver lymphocyte population whereas the liver lymphocyte population in mice contain 
30-40% (Gao and Radaeva, 2013). Evidence suggests that NKT cell play complex 
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and even opposing roles during liver fibrosis in patients with different disease stages 
and different aetiologies (Gao and Radaeva, 2013). Similar to NK cells, NKT cells 
can produce IFN-γ and kill HSCs (Park et al., 2009) but they can also produce the 
pro-fibrotic cytokines such as IL-4 and IL-13 (Gao and Radaeva, 2013). Therefore, 
the precise functions of T cell populations remains unclear and data so far suggests 
that their role depends on disease aetiology.  
 
1.3.2.6 Liver myofibroblasts 
Accumulation of LMFs is a key feature of liver fibrosis. They are considered to be the 
master regulator of liver fibrosis due to their ability to produce ECM, proliferate, 
migrate, contract and modulate the immune system and phagocytose damaged cells 
(Pellicoro et al., 2014). LMFs are not found in normal liver tissue but accumulate after 
liver injury.  
There are three potential sources of LMFs consisting of resident mesenchymal cells 
(quiescent HSCs and portal fibroblasts), epithelial to mesenchymal transition (EMT) 
that involves hepatocytes or cholangiocytes, which transform into myofibroblasts or 
bone marrow derived cells (fibrocytes and mesenchymal progenitor cells). HSCs and 
portal fibroblasts are considered to be the most relevant source of LMFs in the liver 
(Brenner et al., 2012; Schuppan and Kim, 2013). In hepatocellular injury, HSCs are 
the main contributors to the LMF population. This has been demonstrated by 
Kisseleva et al. who has shown that more than 92% of LMFs derived from activated 
HSCs in response to toxic liver injury using CCl4 and fate tracing (Kisseleva et al., 
2012). Furthermore, Schwabe and colleagues confirmed that 82-96% of LMFs were 
derived from HSCs using fate tracing in chemical induced liver injury and fatty liver 
disease (Mederacke et al., 2013). In chronic cholangiopathies, where periductular 
 17 
fibrosis is prominent, portal fibroblasts are thought to be an important myofibroblast 
source. They are considered to be the first responders to biliary injury that are then 
later supplemented by HSC-derived myofibroblasts (Xu et al., 2014). Conversely, 
recent research by Schwabe and colleagues have also demonstrated that HSCs were a 
far more dominant source of LMFs than portal fibroblasts even during early 
periductular fibrosis using three well establish models of cholestasis-induced liver 
fibrosis (Mederacke et al., 2013). Despite that they suggested that due to their location 
portal fibroblasts probably perform specialised functions in cholangiopathies 
(Mederacke et al., 2013; Wells, 2014). Other sources such as bone marrow-derived 
mesenchymal cells or fibrocytes have been suggested to have a minimal contribution 
to the LMF population. However, they might still contribute to liver fibrosis in other 
ways such as modulation of the immune system (Brenner et al., 2012). Epithelial cells 
have also been proposed as progenitors of LMFs through EMT. Although EMT of 
hepatocytes has been documented in vitro (Kaimori et al., 2007), fate-mapping studies 
have failed to identify hepatocytes as a source of LMFs (Taura et al., 2010). Similarly, 
genetic labelling of CK19, a marker of cholangiocytes also demonstrated that 
cholangiocytes do not contribute to LMFs in experimental model of cholestasis-
induced liver fibrosis (Scholten et al., 2010).  
 
1.3.2.7 Hepatic stellate cells  
In a healthy adult liver, HSCs comprise approximately 15% of the total liver cell 
population and have a spindle-shaped morphology (Friedman, 2008). Their multiple 
processes extend across the space of Disse, which allows them to be in close contact 
with several hepatocytes and IHECs at once. When HSCs are quiescent their most 
prominent characteristic is their cytoplasmic storage of retinoids (lipid-soluble vitamin 
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A metabolites). HSCs not only express mesenchymal cell marker such as vimentin but 
also neural cell markers such as glial fibrillary acidic protein (GFAP), neural-cell 
adhesion molecule (N-CAM) and synaptophysin (Cassiman and Roskams, 2002).  
 
HSC activation Liver injury triggers HSC activation and the structure of quiescent 
HSCs changes considerably. They lose their characteristic vitamin droplets, 
downregulate their neural markers and transform into collagen type I and α-smooth 
muscle actin (α-SMA) expressing myofibroblastic cells (Xu et al., 2014). Induction of 
α-SMA is the most reliable marker of HSC activation in vitro and in vivo (Friedman, 
2008). HSCs develop increased proliferative, contractile and migratory potential and 
secrete large amounts of ECM. In addition they release pro-inflammatory and pro-
fibrogenic factors including TGF-β (Bataller and Brenner, 2005). HSC activation is 
caused by pro-inflammatory mediators as well as growth factors particularly TGF-β 
and cytokines that are released by cellular damage and stimulated immune cells 
(Pellicoro et al., 2014). In addition, phagocytosis of apoptotic hepatocytes and 
lymphocytes can induce HSC activation (Muhanna et al., 2008; Jiang et al., 2009). 
Furthermore, the increased density of ECM as fibrosis accumulates leads to increasing 
tissue stiffness, which is an important stimulus for HSC activation (Olsen et al., 2011). 
In accordance with that, HSC activation can be modelled in vitro by plating freshly 
isolated HSCs on uncoated plastic that resembles a stiff environment (Olsen et al., 
2011). They transform within 7 days into early activated HSCs that gradually loose 
their retinoid storage and continue to develop over a longer period into activated 
HSCs with myofibroblastic-like functionalities (Gao and Radaeva, 2013). Importantly, 
HSC activation is considered to be a continuous process, in which early changes in 
the HSC phenotype are probably distinct to changes that occur with progressive 
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disease in terms of growth characteristics, their response to soluble factors and 
apoptotic potential (Friedman, 2008).  
 
Perpetuating pathways In order to perpetuate fibrosis HSCs utilise a variety of 
positive feedback loops. During activation, HSCs induce expression of PDGF 
receptors and release PDGF to stimulate autocrine proliferation and chemotaxis 
(Friedman, 2008). Similarly, they also secrete latent TGF-β1 that, once activated, also 
further stimulates HSC activation and matrix production through autocrine 
mechanisms (Friedman, 2008). Furthermore, activated HSCs are able to respond to a 
host of cytokines, chemokines and growth factors from other cells to perpetuate 
fibrosis. HSC survival for example is promoted by the macrophage-derived cytokines 
TNF and IL-1 through activation of the nuclear factor κ-light-chain-enhancer of 
activated B cells (NF-κB) pathway (Pradere et al., 2013). Notably, not all factors that 
promote fibrosis are necessarily activated at the same time. PDGF for example drives 
HSC proliferation in some instances in parallel with fibrogenic stimulation but this is 
not always the case as DNA from apoptotic hepatocytes induces differentiation of 
HSCs but blocks PDGF-induced chemotaxis via toll-like receptor (TLR) 9 (Watanabe 
et al., 2007). Activation of TLR9 in HSCs possibly provides a stop signal that allows 
activated cells to accumulate at the site of damaged hepatocytes where they can 
deposit scar tissue. Furthermore, in order to maintain ECM deposition activated 
HSCs also secrete tissue inhibitors of metalloproteinases (TIMPs), in particular TIMP-
1 that blocks a variety of MMPs that would normally degrade ECM (Iredale et al., 
2013). The importance of HSCs in driving fibrosis was emphasised in a study using a 
mouse model in which HSCs were specifically depleted (Puche et al., 2013). Depletion 
of HSCs caused a significant reduction in fibrosis but also led to decreased expression 
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of cytoprotective cytokines IL-10 and IFN-γ and an altered intrahepatic leukocyte 
population.  
 
HSC immunomodulation The immune response plays a critical role in the 
progression of liver fibrosis. HSCs can mediate a range of inflammatory effects by 
secreting chemokines and other factors including CCL2, CCL3, CCL5, CXCL1, 
CXCL8, CXCL9 and CXCL10 (Lee and Friedman, 2011). Interestingly, HSCs also 
express CCR5 and respond to CCL5 stimulation with proliferation and migration 
identifying the cells as a source as well as a target for CCL5 (Schwabe et al., 2003). 
CCL5 seems to be an important mediator of liver fibrosis as CCL5 knock-out (KO) 
mice had decreased levels of fibrosis induced by CCl4 or methionine- and choline-
deficient (MCD) diet (Berres et al., 2010). Furthermore, HSCs express other 
chemokine receptor including CXCR3 and CXCR4 (Bonacchi et al., 2001; Hong et 
al., 2009) and can function as antigen presenting cells in liver injury to stimulate 
lymphocytes (Winau et al., 2007; Bomble et al., 2010). 
 
1.3.2.8 Loss of LMFs during fibrosis regression 
Liver fibrosis has not evolved to cause disease but is rather a protective response to 
liver injury. Under optimal circumstances, especially after acute injury, the excess 
ECM that accumulated is degraded and removed and normal liver architecture and 
function can be restored. It has been questioned in the past whether liver fibrosis that 
develops progressively during chronic injury is also reversible. Studies have now 
shown that if the underlying source of the injury can be controlled, liver fibrosis can 
regress (Ellis and Mann, 2012).  
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Regression of liver fibrosis is characterised by the removal of LMFs (Iredale et al., 
1998). Two recent independent studies using genetic tracking in experimental models 
have revealed the fate of HSCs after liver fibrosis (Troeger et al., 2012; Kisseleva et 
al., 2012). The studies demonstrated that approximately 50% of activated 
HSCs/LMFs underwent apoptosis during fibrosis regression. The rest of HSCs on the 
other hand were shown to downregulate fibrogenic genes and adopted a more 
quiescent phenotype. However, those cells were not identical to the quiescent HSCs 
that had never been activated before as they had an increased capacity to reactivate 
when treated with TGF-β. Whether these cells stay in this intermediate state or 
whether they eventually revert to fully quiescent HSCs is not known. Nevertheless, it 
supports the data that HSCs are a heterogeneous population with different functional 
plasticity (Geerts, 2001; D'Ambrosio et al., 2011).  
 
1.3.3 Non-cellular mediators 
1.3.3.1 Extracellular matrix 
The ECM is one of the most important regulators of cellular function in the body. 
ECM proteins can function as signalling molecules but are also architectural 
components and are involved in maintaining hepatocytes and non-parenchymal cells 
differentiated (Schuppan et al., 2001). Under homeostatic conditions sinusoids contain 
a basement membrane matrix, which is mainly made up of collagen type IV and 
fibronectin (Hahn et al., 1980). During liver fibrosis this matrix is slowly replaced by a 
denser and continuous matrix rich in collagen type I and III, with an accompanying 
loss of the fenestrated endothelium (Iredale et al., 2013). The changes in ECM 
composition during liver fibrosis elicit several positive feedback pathways that then 
lead to more accumulation of ECM. For example membrane receptors on HSCs, in 
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particular integrins, sense the changes in ECM and induce HSC activation and 
migration (Yang et al., 2003; Zhang et al., 2006). In addition, the increased density of 
the ECM leads to a stiffer environment that is also involved in HSC activation (Olsen 
et al., 2011). Furthermore, degradation of the ECM by MMPs leads to the release of 
matrix-bound reservoirs of growth factors and chemokines that can potentially 
stimulate fibrogenesis (Schuppan et al., 1998; Bauvois, 2012). As fibrosis progresses 
the ECM becomes progressively denser and stabilised due to thickening of fibrotic 
septae and increased crosslinking making it less susceptible to MMP degradation, thus 
interfering with normal remodelling (Xu et al., 2012). The denser matrix can also act 
as a barrier for infiltrating immune cells and there is evidence that aberrant expression 
of ECM molecules can influence activation, differentiation and survival of immune 
cells (Sorokin, 2010).   
 
1.3.3.2 Tissue proteases 
The turnover of ECM is controlled by MMPs and their inhibitors TIMPs. MMPs are 
a family of zinc and calcium dependent proteases that are involved in matrix 
degradation. In addition, they are involved in a variety of other processes including 
leukocyte activation, cell migration, antimicrobial defence and chemokine processing. 
Due to their variety of functions, some MMPs are not only involved in inhibiting 
fibrosis but also in stimulating it (Giannandrea and Parks, 2014). Even during liver 
fibrogenesis increased expression of MMPs can be detected and there is evidence of 
matrix degradation. MMP expression has been detected in HSCs, hepatocytes, 
Kupffer cells and infiltrating macrophages (Iredale et al., 2013).  
They have been grouped into categories including collagenases, gelatinases, 
stromelysins and others according to their enzymatic substrate. Collagenases play a 
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key role in remodelling fibrotic tissue. They include MMP-1, -8 and -13 that are able 
to cleave the native helix of collagens I and III, rendering the product (gelatine) 
susceptible to degradation by other MMPs. MMP-1 and MMP-8 have been described 
to be expressed by inflammatory cells in human liver whereas MMP-13, the 
counterpart of MMP-1 in rodents, has been described in HSCs and macrophages 
(Iredale et al., 2013). The gelatinases, MMP-2 and -9 are also important as they 
degrade collagen type IV, fibronectin and elastin in addition to denatured collagens 
(gelatine). Furthermore, they can also increase the biological activity of pro-
inflammatory cytokines such as IL-1β and TNF-α (Kurzepa et al., 2014). The key 
source of MMP-2 are activated HSCs (Arthur et al., 1992) whereas MMP-9 has been 
shown to be expressed by HSCs, Kupffer cells and infiltrating macrophages (Han et 
al., 2007; Winwood et al., 1995). In experimental models of liver fibrosis induced by 
either CCl4 or bile duct ligation, MMP-2 and MMP-9 expression significantly 
increases compared to healthy controls (Kurzepa et al., 2014). Experimental liver 
injury in MMP-2 KO mice using CCl4 or bile duct ligation suggested that MMP-2 is 
antifibrotic as more collagen deposition was detected in MMP-2 KO mice compared 
to wild type (WT) controls (Onozuka et al., 2011). This was possibly through the 
ability of MMP-2 to suppress collagen type I expression rather than a possible 
collagenolytic ability (Radbill et al., 2011). In contrast, other data has demonstrated 
that MMP-2 can also induce HSC proliferation and migration (Hemmann et al., 
2007). Overall, the findings so far indicate that MMP-2 can have pro and antifibrotic 
functions and that these functions might be separate in time. Similarly, MMP-9 seems 
to be involved in HSC activation but also HSC apoptosis. IL-1-induced activation was 
prevented in HSCs from MMP-9 KO mice when cultured in a three-dimensional 
ECM model compared to HSCs from WT mice (Han et al., 2007). Furthermore, 
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MMP-9 was also able to activate latent TGF-β (Yu and Stamenkovic, 2000) the main 
growth factor for HSC activation and collagen deposition. Conversely, a mouse model 
with CCl4-induced injury with overexpression of MMP-9 demonstrated reduced 
fibrogenesis caused by apoptosis of activated HSCs (Roderfeld et al., 2006).  
 
Importantly, TIMPs are able to inhibit the activity of MMPs as they can bind in a 
reversible manner to the active sites of MMPs. During fibrosis, ECM continues to 
accumulate because high levels of TIMPs block MMP activity (Iredale et al., 1996). 
There are four TIMPs, TIMP-1, -2, -3 and -4 (Kurzepa et al., 2014). TIMP-1 and -2 
are both expressed by activated HSCs and the expression levels of TIMP-1 are closely 
associated with the numbers of activated HSCs (Iredale et al., 1996). The different 
expression levels of TIMP-2 between quiescent and activated HSCs are less 
pronounced than TIMP-1 levels as quiescent HSCs already express TIMP-2 (Iredale 
et al., 2013). The importance of TIMP-1 has been demonstrated in a mouse model 
overexpressing TIMP-1 in the liver that had significantly more ECM accumulation 
than their WT controls after treatment with CCl4 (Yoshiji et al., 2000). In addition, 
blocking TIMP-1 in a mouse model of fibrosis induced fibrolysis (Nie et al., 2001). 
 
1.3.3.3 Growth factors 
TGF-β1 The key cytokine involved in fibrogenesis is TGF-β1. During liver injury, 
TGF-β1 is highly upregulated and is released primarily by Kupffer cells and 
infiltrating macrophages but also apoptotic hepatocytes (Cong et al., 2012). It is a 
potent pro-fibrogenic cytokine that induces HSC transformation from a quiescent into 
an α-SMA-positive active phenotype that expresses collagen type I. Once HSCs are 
active they also contribute to TGF-β1 production. To mediate the activity of TGF-β1 
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it undergoes several post-translational changes. Large amounts of the non-active form 
are stored outside of cells through cross-links in the ECM. Some of the factors that 
can change TGF-β1 into its active form include MMP-2, and -9 (Cong et al., 2012). 
The importance of TGF-β1 has been demonstrated in genetically altered mice. TGF-
β1 KO mice had significantly less collagen deposition compared to their WT controls 
after treatment with CCl4 whereas overexpression of TGF-β1 alone in normal mice 
caused a 15-fold increase in collagen type I compared to controls (Hellerbrand et al., 
1999). Theoretically TGF-β1 would make an attractive target for antifibrotic therapy. 
However, general and untargeted inhibition of TGF-β1 poses a risk as it has 
important anti-inflammatory effects (dampening excessive T cell activation) and roles 
in cellular differentiation and growth regulation within the liver (Yang et al., 2010; 
Baek et al., 2010). 
 
PDGF. PDGF is the most potent mitogen for HSCs described so far that is secreted 
by platelets, macrophages and HSCs causing proliferation and migration of HSCs to 
the site of injury (Bonner, 2004). It is known to work synergistically with TGF-β1 to 
enhance migration and expression of MMPs (Fibbi et al., 2001; Yang et al., 2003). 
There are four isoforms of PDGF (PDGF A, B, C and D) that signal through the 
PDGF receptor composed of α- and β-subunits (PDGFR-α and PDGFR-β). PDGF-B 
and -D act as potent mitogen in activated HSCs in vitro (Pinzani et al., 1991; 
Borkham-Kamphorst et al., 2007). Induction of PDGF-B and PDGFR-β has been 
well documented in liver injury induced by CCl4 administration or bile duct ligation 
(Pinzani et al., 1994; Wong et al., 1994; Borkham-Kamphorst et al., 2008). 
Upregulation of PDGFR-β is a hallmark of early HSC activation that is followed by 
the transformation into myofibroblast-like cells (Bonner, 2004). Downstream 
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consequences of PDGF signalling in HSCs lead to activation of the PI3K-Akt and 
ERK signalling pathways and other pathways (Cong et al., 2012).  
 
FGF The fibroblasts growth factors comprise a family of 23 reported members that 
bind to four FGF receptor kinases (FGFR1 to FGFR4). FGF1 and basic (b)FGF (also 
known as FGF2) are the most widely studied members of the FGF family that have 
been implicated in liver fibrogenesis. Basic FGF has been implicated in HSC 
activation, proliferation and migration in vitro (Pinzani et al., 1989; Fibbi et al., 1999). 
In contrast, FGF1/bFGF-deficient mice did not demonstrate an apparent difference 
in the number, activation and recruitment of HSCs following CCl4-induced liver 
injury in vivo (Yu et al., 2003). However, FGF1/bFGF deletion caused a decrease in 
Col1a1 (Collagen type I) induction during HSC activation after acute CCl4 injury and 
significantly decreased fibrosis that resulted from chronic CCl4 injury (Yu et al., 2003).  
 
1.4 TNF superfamily  
The TNF superfamily consists of cytokines that interact with a corresponding 
superfamily of receptors, the TNFR superfamily. There are 29 receptors and 19 
ligands that can modulate numerous cellular functions including cell survival, 
differentiation, growth and production of inflammatory cytokines and chemokines 
(Croft et al., 2013) (Figure 1.3). The specific response depends on the receptor, the 
type of cell and other signals received by the cell from their surrounding. Most of the 
TNF superfamily receptors and ligands are expressed by or primarily target cells of 
the immune system but they are also detected on other cell types including epithelial 
cells, endothelial cells and mesenchymal cells (Croft et al., 2012). TNF receptors are 
typically type I transmembrane proteins with one to six cysteine rich domains (CRDs) 
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in their extracellular domain (Bremer, 2013). All of the TNF ligands have a 
characteristic TNF homology domain (THD) that initiates formation of homotrimers. 
They are normally expressed as type II transmembrane proteins that can be cleaved 
to form a soluble ligand. Certain members of the TNF family elicit different responses 
depending on whether they are membrane-bound or soluble. Only the membrane-
bound form of FasL for example is efficient in inducing cytotoxicity (Reilly et al., 
2009). As soluble FasL can compete with the membrane-bound FasL it can even act 
as an antagonist by preventing apoptosis induction by the membrane-bound form 
(Suda et al., 1997). In a similar way, membrane-bound CD40L is more potent in 
inducing cytotoxicity than the soluble form of the ligand (T Georgopoulos et al., 2006; 
Elmetwali et al., 2010). However, the difference in bioactivity of the soluble compared 
to the membrane-bound form is not necessarily attributable to all TNF members. For 
example TNF receptor 1 (TNFR1) is comparably well activated by both the soluble 
and membrane-bound forms of TNF- α (Grell et al., 1995).  
 
The members of the TNF superfamily have mainly been associated with 
inflammatory and autoimmune diseases (Croft et al., 2012). However selected 
members also have an involvement in fibrosis. TNF-α is probably the most widely 
studied cytokine of this family and next to its pro-inflammatory roles it has been 
demonstrated to be involved in fibrogenesis (Distler et al., 2008).  
In the liver, TNF-α has been demonstrated as a direct mediator of liver injury and 
subsequent fibrosis as demonstrated by TNF-α KO mice and TNFR1 KO mice that 
had reduced liver injury and less fibrosis after bile duct ligation compared to controls 
(Gäbele et al., 2009; Tarrats et al., 2011). Liver injury was assessed by serum levels of 
alanine aminotransferase (ALT) or aspartate transaminase (AST). Other studies have 
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shown, using different experimental models of injury, that TNF-α can also influence 
fibrosis directly without affecting levels of injury. For example, liver fibrosis was 
reduced in TNFR1 KO mice after CCl4 treatment with no changes in liver injury as 
indicated by similar ALT levels compared to control mice (Sudo et al., 2005). 
Furthermore, TNF-α KO mice had similar levels of injury and inflammation but less 
fibrosis compared to their WT controls after a combination of bile duct ligation with 
cystic duct ligation (Osawa et al., 2013). Indeed, TNF-α seems to play a key role in 
HSC homeostasis by regulating both pro- (via caspase activation) and anti-apoptotic 
(via NF-κB pathways) signals (Cong et al., 2012). Although knocking out TNF-α 
reduces liver injury and fibrosis, clinical trials with TNF-α antibodies in patients with 
PSC or alcoholic hepatitis have not shown consistent results (Spahr et al., 2002; 
Naveau et al., 2004; Boetticher et al., 2008; Hommes et al., 2008; Sharma et al., 
2009). PSC patients that received the TNF-α inhibitor infliximab did not demonstrate 
any treatment benefits (Hommes et al., 2008). In addition, some studies showed that 
inhibiting TNF-α with antibodies caused patients to be more susceptible to infections 
(Naveau et al., 2004; Boetticher et al., 2008). Indeed, patients with alcoholic hepatitis 
that were treated with etanercept, an antibody that inhibits the TNF receptor, had a 





Figure 1.3 Ligands and receptors of the TNF superfamily 
The TNF superfamily is a group of structurally related proteins. The receptors 
contain a characteristic cysteine rich domain (CRD) that can bind the TNF homology 
domain (THD) of the ligands. Some receptors have death domain that can induce 
apoptosis and other receptors have TRAF binding motifs.  
Image adapted from: (Aggarwal, 2003) 
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1.5 TWEAK and Fn14 
Two members of the TNF/TNFR superfamily that have been more recently 
discovered are the ligand TNF-like weak inducer of apoptosis (TWEAK) and its 
cognate receptor fibroblast growth factor inducible 14 (Fn14). TWEAK was 
discovered in 1997 by Chicheportiche et al. who demonstrated that it was pro-
apoptotic on IFN-γ-treated human HT-29 colon carcinoma cells and therefore named 
it TWEAK (Chicheportiche et al., 1997). Fn14 was discovered in 1999 in murine 
NIH3T3 fibroblasts (Meighan-Mantha et al., 1999) and was later cloned from a 
HUVEC cDNA expression library and shown to be a receptor for TWEAK (Wiley et 
al., 2001). It was named Fn14 as its expression was upregulated when quiescent cells 
were exposed to FGF1 or bFGF and because its predicted molecular mass was about 
14 kDa before peptide cleavage (Meighan-Mantha et al., 1999; Feng et al., 2000). 
 
1.5.1 TWEAK structure and expression   
Like other ligands of the TNF superfamily, TWEAK is expressed as a type II-
transmembrane protein (Figure 1.4). The membrane-bound form of TWEAK consists 
of 249 amino acids. Extracellularly it comprises of a C-terminal region that contains a 
stalk region and a characteristic THD domain that is highly conserved between 
human and mice (Chicheportiche et al., 1997). Intracellularly it has a N-terminal 
domain that is connected to the C-terminal domain with a transmembrane domain 
(Chicheportiche et al., 1997; Marsters et al., 1998). As in other ligands of the TNF 
family, the THD of TWEAK mediates trimerisation and binding to the receptor. 
TWEAK is proteolytically released on the stalk region by a furin endoprotease to 
function primarily as a soluble homotrimeric cytokine. However, expression of 
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TWEAK has also been found on the cell surface of some cells. (Wajant, 2013) and it 
has recently been reported that membrane-bound TWEAK can bind to Fn14 on 
neighboring cells in a juxtacrine manner and activate the NF-κB signaling pathway 
(Brown et al., 2010). 
Leukocytes are the main source of TWEAK including human resting and activated 
monocytes, dendritic cells and NK cells (Maecker et al., 2005). Other cell types that 
can express TWEAK include endothelial cells, astrocytes and renal tubular epithelial 
cells (Dohi and Burkly, 2012). Upregulated TWEAK expression has been detected in 
tissues from patients with inflammatory disease and experimental models of such 
diseases. These include rheumatoid arthritis, multiple sclerosis, ulcerative colitis and 
systemic lupus erythematosus (Burkly et al., 2011).  
 
1.5.2 Fn14 structure and expression  
Fn14 is the smallest receptor of the TNF receptor superfamily and the only known 
signalling receptor for TWEAK. It is a type-I transmembrane protein that is initially 
synthesised as a 129 amino acid protein and then proteolytically processed by signal 
peptidase into a 102 amino acid cell surface receptor (Winkles, 2008) (Figure 1.4). 
There is a 90% homology between the human and mouse mature Fn14 protein 
(Wiley and Winkles, 2003). The extracellular ligand binding region contains only one 
CRD (Wiley et al., 2001) and TWEAK is the only known ligand of the TNF family 
that can bind to Fn14 (Bossen et al., 2006). The cytoplasmic domain of Fn14 is 28 
amino acids in length and is lacking a classical death domain. Like many other TNFR 
superfamily members that are lacking a death domain, Fn14 has a TNF receptor-
associated factor (TRAF) binding motif. Several members of the TRAF family have 
been shown to be able to bind to this site including TRAF1, TRAF2, TRAF3, and 
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TRAF5 (Winkles, 2008). In normal tissue, Fn14 expression is low but becomes quickly 
upregulated locally during injury and disease. In acute injury, Fn14 is transiently 
expressed whereas expression of Fn14 is maintained in chronic tissue injury (Burkly, 
2014). Parenchymal cells, stromal cells, vascular cells and progenitor cells have been 
described to express Fn14. Furthermore, expression has also been detected in many 
tumour cells (Burkly, 2014) and in some instances even in macrophages (Kim et al., 
2004; Schapira et al., 2009). Fn14 gene expression can be induced in endothelial and 
mesenchymal cells by several growth factors and cytokines including FGF-1 and -2, 
PDGF-BB, TGF-β1, TNF-α, IL-1β and IFN-γ (Winkles, 2008).  
 
 
Figure 1.4 Structure of TWEAK and Fn14 
TWEAK is a type II transmembrane protein with a TNF homology domain that 
mediates trimerisation. Furin can cleave TWEAK to release it from the membrane 
and make it a soluble cytokine. Fn14 is expressed as a type I transmembrane protein 
that is thought to trimerise upon TWEAK binding.  
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1.5.3 Function of TWEAK and Fn14 
TWEAK signalling has been shown to regulate several biological processes including 
proliferation, differentiation, migration, fibrosis and inflammation. After acute injury 
Fn14 is transiently upregulated and involved in inflammation, angiogenesis and 
fibrogenesis (Burkly, 2014). It has a beneficial effects in acute skeletal muscle and 
pancreatic injury as demonstrated by Fn14 KO mice having delayed inflammatory 
and regenerative responses (Girgenrath et al., 2006; Wu et al., 2013). In contrast, the 
TWEAK and Fn14 pathway in chronic injury has been described to promote 
pathological tissue changes including chronic inflammation, fibrosis and angiogenesis. 
The pathological role of TWEAK and Fn14 has been described in experimental 
models of rheumatoid arthritis, atherosclerosis, ischemic stroke and systemic lupus 
erythematosus and other diseases associated with inflammation (Burkly et al., 2011).  
 
One important aspect in many chronic diseases is accumulation of fibrosis. TWEAK 
and Fn14 are elevated in several different experimental models that feature fibrosis 
including renal ischemia reperfusion injury, skeletal muscle atrophy and chronic 
kidney disease (Hotta et al., 2011; Mittal et al., 2010; Novoyatleva et al., 2010; Son et 
al., 2013; Ucero et al., 2013). Studies have shown that overexpression of TWEAK in 
mouse models led to cardiac and kidney fibrosis (Jain et al., 2009; Hotta et al., 2011; 
Ucero et al., 2013), and that deletion of Fn14 protected against cardiac fibrosis 
(Novoyatleva et al., 2013). Evidence that TWEAK can directly affect fibroblasts has 
been given in several studies. TWEAK induced proliferation in cardiac and renal 
fibroblasts in vitro (Novoyatleva et al., 2010; Ucero et al., 2013). In addition, studies 
have also demonstrated that TWEAK induced collagen expression in cardiac 
fibroblasts via Fn14 (Chen et al., 2012; Novoyatleva et al., 2013) and 
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transdifferentiation of cardiac fibroblasts into myofibroblasts (Novoyatleva et al., 
2013). In contrast, TWEAK inhibited transformation of keratocytes into 
myofibroblasts (Ebihara et al., 2009) and decreased expression of collagen type I and 
fibronectin in renal fibroblasts in vitro (Ucero et al., 2013) suggesting that TWEAK can 
induce different responses in cell type of the same lineage.  
 
1.5.4 Hepatic expression of TWEAK and Fn14 
TWEAK In the liver, expression of TWEAK mRNA has been primarily detected in 
macrophages and NK cells. In addition, low levels of TWEAK mRNA are also 
present in CD4-positive and CD8-positive T cells and NKT cells (Tirnitz-Parker et 
al., 2010) and TWEAK was also expressed and released by HCC cell lines (Kawakita 
et al., 2004). 
Experimental liver injury caused by the choline-deficient, ethionine-supplemented 
(CDE) diet or by acute ethanol exposure did not change levels of TWEAK mRNA in 
the liver (Tirnitz-Parker et al., 2010; Affò et al., 2012). Furthermore, TWEAK 
transcription levels did not change significantly in patients with NASH, HCV 
infection or alcoholic hepatitis (Affò et al., 2012). In contrast, TWEAK mRNA levels 
dropped significantly after 12 hours of PH and then levelled out again after 96 hours 
(Karaca et al., 2014). Apart from these observations, little else is known about the 
expression of TWEAK in the liver. In addition, nearly all of those studies have looked 
at the transcriptional levels of TWEAK and not further investigated the protein 




Fn14 Expression of Fn14 in the liver has mainly been associated with liver epithelial 
cells and LPCs. Fn14 expression has been detected in cholangiocytes and LPCs in 
mouse livers and livers from patients with ALD and NASH (Jakubowski et al., 2005; 
Bird et al., 2013). In addition, Fn14 expression in primary mouse LPCs and an 
immature cholangiocyte cell line (603B cells) has also been described in vitro (Tirnitz-
Parker et al., 2010; Karaca et al., 2014). Furthermore, Fn14 was shown to be 
expressed by immature hepatocytes (Affò et al., 2012; Karaca et al., 2014) but not by 
primary mature hepatocytes (Karaca et al., 2014) suggesting that it is involved in 
progenitor cell function but not directly in maintenance of mature hepatocytes. 
Although research has focused on epithelial cells and their progenitor cells other cell 
types have also been mentioned in the literature. Smooth muscle cells in normal 
human liver were Fn14-positive (Jakubowski et al., 2005) and a sub-population of α-
SMA-positive cells has been described as Fn14-positive (Tirnitz-Parker et al., 2010). In 
contrast, CD68 and CD45-positive inflammatory cells isolated from injured mouse 
livers did not seem to express Fn14 (Tirnitz-Parker et al., 2010). Lastly, Fn14 was 
present in HCC cell lines and human HCC tissue (Feng et al., 2000; Kawakita et al., 
2004; Wang et al., 2012; Li et al., 2013).  
 
In accordance with research in other injuries and diseases, Fn14 becomes quickly 
upregulated in several different experimental liver injury models including PH (Feng 
et al., 2000; Ochoa et al., 2010; Karaca et al., 2014), acute CCl4 injury, acute 
acetaminophen (also called paracetamol) and acute ethanol exposure (Affò et al., 
2012). Also, liver injury caused by the 3,5-diethoxycarbonyl-1,4-dihydrocollidine 
(DDC) or CDE diets that are associated with LPC expansion induced an upregulation 
of Fn14 mRNA expression (Jakubowski et al., 2005; Tirnitz-Parker et al., 2010). 
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Enhanced Fn14 gene expression was also present in high-precision cut livers from 
healthy mice after treatment with TGF-β1. However, this was not detected when 
high-precision cut livers were treated with TWEAK or TNF-α (Affò et al., 2012) 
suggesting that Fn14 can be induced by pro-fibrogenic rather then pro-inflammatory 
cytokines. Furthermore, patients with alcoholic hepatitis but not NASH or HCV 
infection had significantly more Fn14 gene expression compared to normal livers (Affò 
et al., 2012).  
 
1.5.5 Role of TWEAK and Fn14 in the liver 
TWEAK has been demonstrated to be a direct mitogen for LPCs and cholangiocytes 
in vitro (Jakubowski et al., 2005; Tirnitz-Parker et al., 2010; Karaca et al., 2014). 
TWEAK-induced LPC proliferation was regulated through NF-κB pathway as it was 
reduced by siRNA against the p50 NF-κB subunit (Tirnitz-Parker et al., 2010). In 
contrast, TWEAK did not induce proliferation of mature hepatocyte in vitro 
(Jakubowski et al., 2005; Karaca et al., 2014), which is in accordance with mature 
hepatocytes not expressing the receptor.  
 
In vivo studies have demonstrated that genetic overexpression of TWEAK or 
administration of exogenous TWEAK into healthy mice induced LPC expansion 
(Jakubowski et al., 2005; Bird et al., 2013). Also, TWEAK further induced LPC 
proliferation and infiltration of CD45-positive cells in mice on the CDE diet (Tirnitz-
Parker et al., 2010) and proliferation of LPCs was inhibited by Fn14 deletion or by 
administration of TWEAK blocking antibodies in mice on the DDC diet (Jakubowski 
et al., 2005). Furthermore, administration of TWEAK-expressing bone marrow-
derived cells into Fn14 KO mice or administration of bone marrow-derived cells from 
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TWEAK KO mice into WT mice showed both times a reduction in LPC expansion 
(Bird et al., 2013) demonstrating that TWEAK-induced LPC proliferation is indeed 
Fn14 dependent. 
 
Tirnitz-Parker et al. also demonstrated reduced LPC expansion in Fn14 KO mice 
after 14 days on the CDE diet (Tirnitz-Parker et al., 2010). A co-regulation of the 
inflammatory response and fibrogenesis with LPC proliferation has been 
demonstrated in other models using the CDE diet (Knight et al., 2007; Van Hul et al., 
2009). Therefore, they investigated whether this was also the case during TWEAK-
regulated LPC expansion. Indeed, Fn14 KO mice on the CDE diet had reduced 
collagen deposition, fewer CD45-positive and F4/80-positive inflammatory cells and 
lower transcript levels of tissue inhibitor of Timp1 and 2 and other inflammatory 
cytokines (Tirnitz-Parker et al., 2010). However, a reduced response could only be 
demonstrated after 14 days but not 21 days on the diet suggesting that other 
mechanisms can influence LPC proliferation and the associated fibrotic and 
inflammatory response. Expanding on potential therapeutic roles of TWEAK 
signalling, Kuramitsu et al. performed a PH in CCl4-treated fibrotic mice with 
administration of exogenous recombinant TWEAK or TWEAK-blocking antibodies 
(Kuramitsu et al., 2013). Liver regeneration is generally considered to be impaired in 
fibrotic livers and indeed mice with fibrotic livers compared to non-fibrotic control 
mice had increased liver weight loss and worse survival rates after PH (Kuramitsu et 
al., 2013). The authors then demonstrated that administration of TWEAK to fibrotic 
mice after PH induced LPC proliferation but did not affect liver weight compared to 
control mice. In contrast, TWEAK-blocking antibodies inhibited LPC proliferation 
but enhanced hepatocyte proliferation and liver regeneration (Kuramitsu et al., 2013). 
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In addition, a downregulation of transcript levels of several pro-fibrogenic markers 
including Tgfb1 and 2, Col1a1, Acta2 and Timp1 were detected in mice treated with 
TWEAK-blocking antibodies whereas exogenous TWEAK caused an upregulation of 
those genes (Kuramitsu et al., 2013). This not only emphasised on the link between 
LPC proliferation and fibrosis but also indicated that blocking TWEAK improved 
liver regeneration. Conversely, Karaca et al. demonstrated that deficiency of TWEAK 
and Fn14 led to a decline in hepatocyte proliferation after PH (Karaca et al., 2014). 
However, in contrast to Kuramitsu et al., they used healthy mice instead of fibrotic 
mice and investigated earlier time points. As mature hepatocytes do not express Fn14, 
they investigated how the TWEAK and Fn14 pathway might affect hepatocytes 
through indirect mechanisms. They demonstrated that mice deficient in TWEAK or 
Fn14 had reduced levels of the pro-regenerative cytokines TNF-α and IL-6 and the 
hepatocyte mitogen HGF (Karaca et al., 2014). Furthermore, Fn14 KO mice seemed 
to have liver failure after PH as indicated by a significant increase in infarcted areas of 
the liver and three fold higher serum bilirubin levels and most Fn14 KO mice died 
after PH (60% of Fn14 KO mice compared to 5% of WT mice) (Karaca et al., 2014). 
The data indicates that TWEAK and Fn14 signalling is beneficial after PH but it 
might be dysregulated in fibrotic mice undergoing PH. 
 
1.5.6 Signalling pathways for Fn14 
TWEAK treatment of Fn14-positive cells have been shown to activate several 
different signalling pathways but the NF-κB pathway seems to be the most commonly 
reported pathway (Winkles, 2008). The NF-κB family of transcription factors bind to 
DNA and induce gene transcription. They control the transcription of many genes 
encoding proteins that regulate immune and inflammatory processes (Napetschnig 
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and Wu, 2013). In unstimulated cells, NF-κB dimers are present in the cytoplasm as 
latent transcription factors as a consequence of their association with members of a 
family of proteins called inhibitors of κB (IκB). Upon stimulation with an extracellular 
stimulus a series of event occurs that involves the recruitment and activation of the 
IκB kinases (IKKs) that phosphorylate IκB leading to the subsequent degradation of 
IκB and the release of NF-κB. In the canonical NF-κB pathway, IκBα is degraded 
resulting in the translocation of mainly p65-containing heterodimers into the nucleus. 
In the non-canonical pathway on the other hand, IKKα phosphorylates p100 that is 
associated with RelB, which in turn promotes nuclear translocation of p52/RelB 
(Oeckinghaus et al., 2011). Both, the canonical and non-canonical pathway can be 
activated by TWEAK (Brown et al., 2003; Saitoh et al., 2003; Roos et al., 2010). 
Furthermore, the NF-κB pathway is also involved the pathogenesis of several liver 
diseases and prevents HSC apoptosis (Robinson and Mann, 2010). In addition, 
TWEAK treatment of several cell types has been shown to activate other signalling 
pathways including MAPK/ERK, PI3K/Akt, Wnt/GSK3β, Rho GTPases and 
JAK/STAT pathways (Burkly, 2014). TWEAK-independent Fn14 signalling has also 
been reported when Fn14 is ectopically overexpressed in vitro (Winkles, 2008). 
However, the importance for this interaction in vivo remains unclear. 
 
1.5.7 Potential TWEAK signalling independent of Fn14  
A number of reports suggest that TWEAK and Fn14 interaction is not exclusive. A 
study in 2003 showed that TWEAK was able to induce differentiation of the murine 
macrophage cell line RAW264.7 independent of Fn14 (Polek et al., 2003). Besides 
Fn14 another receptor called CD163 has been reported to interact with TWEAK. 
CD163 is a scavenger receptor with expression restricted to the 
 40 
monocyte/macrophage lineage and has been demonstrated to bind and internalise 
TWEAK (Bover et al., 2007; Moreno et al., 2009). However, no evidence of signal 
transduction to my knowledge has been reported. Furthermore, it has been 
demonstrated that the intracellular N-terminal domain of TWEAK contains several 
nuclear localisation sequences and that TWEAK may enter the nucleus (De Ketelaere 
et al., 2004; Baxter et al., 2006; Al-Sawaf et al., 2014). In addition, the intracellular 
domain of the membrane bound form of TWEAK also contains a furin recognition 
site indicating that TWEAK can be cleaved intracellularly (Brown et al., 2010). 
However, the biological significance of any of these findings is not yet known. 
 
1.5.8 Clinical relevance of TWEAK  
A disease-driving role of the TWEAK and Fn14 pathway has been described in 
several different diseases. Research is now occurring to identify and develop treatment 
options to either inhibit or activate this receptor/ligand pathway dependent on the 
type of disease (Wajant, 2013). The first clinical study for the efficacy and tolerability 
of the monoclonal antibody BIIB023 that is used to block TWEAK in patients with 
rheumatoid arthritis (phase I) has previously been published (Wisniacki et al., 2013). 
Furthermore, the efficacy of BIIB023 is currently further explored in a phase II 
clinical trial in patients with systemic lupus erythematosus (Bertin et al., 2013). 
 
Next to the possibilities of direct modulation of the TWEAK/Fn14 pathway with 
therapeutics, other research is investigating the potential role of soluble TWEAK 
(sTWEAK) as a marker for diagnosis and prognosis of various diseases (Bertin et al., 
2013). For example, sTWEAK levels served as a predictor of disease progression in 
patients with systemic lupus erythematosus and advanced non-ischemic heart failure 
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(Schwartz et al., 2009; Richter et al., 2010). Due to its potential interaction with 
CD163, other research has focused on the correlation of soluble CD163 and 
sTWEAK levels in disease outcome. Indeed, high soluble CD163 and low sTWEAK 
concentrations have been correlated to type 1 diabetes mellitus diagnosis and 
cardiovascular mortality in peripheral arterial disease (Llaurado et al., 2012; 
Urbonaviciene et al., 2011). The role of sTWEAK in association with acute or 
chronic liver disease has not been investigated so far. However, research by Li et al. 
has demonstrated that hepatic expression levels of Fn14 served as a predictor of 
poorer surgical outcome in patients with HCC (Li et al., 2013). In addition, a study by 
Affò et al. demonstrated that alcoholic hepatitis patients with higher hepatic Fn14 
mRNA expression had a worse 90-day survival rate than patients with lower Fn14 
mRNA levels (Affò et al., 2012). 
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1.6 Thesis hypothesis and aims 
Chronic liver disease is an increasing problem worldwide. Excess accumulation of 
fibrosis is a key driver in the progression of liver disease. TWEAK and Fn14 have 
been implicated in the involvement of fibrosis in several diseases but an immediate 
role for TWEAK and Fn14 during liver fibrosis has not been investigated in depth. 
Therefore, we hypothesised that TWEAK and Fn14 expression may be increased in 
several human liver diseases and that the pathway directly affects HSC behaviour and 
progression of fibrosis. Furthermore, we also hypothesised that TWEAK can be a 
predictor of disease outcome in patients with chronic liver disease.  
 
Aims 
I. To characterise the expression of TWEAK and Fn14 in human liver 
disease 
II. To examine Fn14 and TWEAK expression in HSCs and to assess the 
effect of TWEAK on HSC function in vitro 
III. To investigate the role of TWEAK and Fn14 in CCl4-induced acute and 
chronic liver injury in vivo 
IV. To determine the expression levels of TWEAK in a chronic liver disease 
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2 Materials and Methods 
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2.1  Methods for Chapter 3,4 and 6: Human studies 
2.1.1 Human tissue and serum samples 
Explanted human liver tissue and normal donor liver surplus to surgical requirements, 
or generated as by-product of surgical resection for secondary liver malignancy were 
obtained from patients as part of the liver transplant programme based at the Queen 
Elizabeth Hospital, Birmingham, UK. All patients gave informed, written consent and 
studies were approved by the Local Research Ethics Committee (reference number 
06/Q2702/61). Liver tissue and/or serum samples were obtained from healthy 
individuals and patients with NASH, ALD, PBC, PSC, AIH, ALF and inflammatory 
bowel disease (IBD). 
 
2.1.2 Antibodies and cytokines used for human studies 
Primary, isotype control and secondary antibodies for the human studies are outlined 
in Table 2.1, Table 2.2 and Table 2.3. Cytokines used for various experiments are 
detailed in Table 2.4. 
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Specificity Isotype Clone  Supplier Working con. 
Fn14 mouse IgG1 mP4A8 Biogen Idec 3.7 μg/mL 
TWEAK mouse IgG2a mP2D10 Biogen Idec 3.24 μg/mL 
α-SMA mouse IgG2a 1A4 Dako 0.7 μg/mL 
Vimentin mouse IgG1 V9 Vector Labs 0.6 μg/mL 
CD90  mouse IgG1 eBio5E10 eBioscience 5 μg/mL 
CD31 mouse IgG1 JC70A Dako 5.15 μg/mL 
CK19  mouse IgG2a Ks19.1 Progen 5 μg/mL 
Hepatocyte mouse IgG1 OCH1E5 Dako 1.65 μg/mL 
CD68 mouse IgG2b Y1/82A BioLegend 2.5 μg/mL 
Table 2.1 Primary antibodies used for immunostaining 
 
Isotype Supplier Working con. 
Mouse IgG1 Life Tech. Appropriate to primary antibody 
Mouse IgG2a Life Tech. Appropriate to primary antibody 
Mouse IgG2b R&D Systems Appropriate to primary antibody 
Table 2.2 Isotype controls used for immunostaining 
 
Antibody Conjugate Host Supplier Working con. 
ImmPRESS Anti-
mouse Ig HRP / Vector Labs / 
Anti-mouse IgG1 Alexa Fluor 546 Goat Life Tech. 4 μg/mL 
Anti-mouse IgG2a Alexa Fluor 488 Goat Life Tech. 4 μg/mL 
Table 2.3 Secondary antibodies used for immunostaining 
 
Cytokines Final conc. Supplier Application 
bFGF 10 ng/mL Peprotech qPCR, IF, FC 
TGF-β1 10 ng/mL Peprotech qPCR, IF, FC, ELISA 
TNF-α 10 ng/mL Peprotech qPCR, FC, ELISA, Luminex 
IFN-γ 100 ng/mL Peprotech qPCR, FC 
IFN-γ 10 ng/mL Peprotech ELISA 
PDGF 10 ng/mL Miltenyi ELISA, Proliferation 
IL-1β  10 ng/mL Peprotech ELISA 
IL-13 10 ng/mL Peprotech ELISA 
TWEAK 1 - 500 ng/mL Biogen Idec qPCR, WB, Luminex, Proliferation 
Table 2.4 Cytokines used to stimulate HSCs  
Hepatic stellate cells were treated with cytokines for various different applications 
including quantitative polymerase chain reaction (qPCR), immunofluorescent staining 
(IF), flow cytometry (FC), enzyme linked immunosorbent assay (ELISA) and western 
blot (WB) 
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2.1.3 Isolation of human hepatic stellate cells 
Primary human HSCs were isolated as described previously (Holt et al., 2009). A 
wedge of approximately 150 g from normal donor liver or from resected uninvolved 
liver tissue was used for HSC isolation. The perfusion circuit was set up using a 
peristaltic pump set to 40 RPM (Model IP 505Du, Watson-Marlow Ltd, Falmouth, 
UK) (Figure 2.1). All buffers were pre-heated to 42°C in a water bath. The wedge was 
perfused with Buffer I (Table 2.5) in order to remove any residual blood. This was 
followed by perfusion with Buffer II (Table 2.5), supplemented with 0.235 mg/mL 
pronase (Roche, Hertford, UK). After perfusion with approximately 300 mL of 
supplemented Buffer II, 5 mL of 3 mg/mL collagenase A was added (Roche). 
Perfusion continued with the enzyme solution for approximately 15 min until the liver 
became flaccid. The tissue was then transferred to a sterile beaker and manually 
dissociated in 100 mL of enzyme solution supplemented with 10 mL of 3.5 mg/mL 
pronase and 1 mL of 1 mg/mL DNase I (Sigma, Dorset, UK). The homogenate was 
then passed through a sterile nylon mesh of 60 μm (John Staniar Ltd, Manchester, 
UK) and washed four times with Buffer II supplemented with DNase I with 
centrifugation at 1400 x g for 7 min. To enrich the HSC population, the cell pellet was 
resuspended with 16.6% (v/v) Optiprep (Sigma) diluted in Dulbecco’s Modified 
Eagle’s Medium (DMEM, Gibco, Paisley, UK) and buffer II was then gently overlaid. 
The cells were separated via centrifugation at 1400 x g for 20 min. After 
centrifugation a white band of cells was visible just below the buffer II layer. This 
band was aspirated and washed with buffer II at 1400 x g for 7 min. The HSC 
suspension was further purified via negative magnetic selection. Specifically, the cell 
suspension was incubated with mouse anti-human CD31 antibody directly conjugated 
to Dynabeads (Life Technologies, Paisley, UK) for 15 min at room temperature in 
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order to select and remove endothelial cells and phagocytic macrophages. The 
remaining cells were then cultured with complete HSC medium comprising DMEM, 
16% (v/v) heat inactivated foetal calf serum (FCS), 2 mM L-glutamine, 100 units/mL 
penicillin and 100 μg/mL streptomycin (all Sigma) and incubated overnight at 37°C. 
The following day cultures were washed with sterile phosphate buffered saline (PBS, 




Figure 2.1 Schematic diagram illustrating the set-up for liver perfusion 
This is the typical set-up for perfusion of liver wedges in order to isolate hepatic 
stellate cells. The relevant perfusion buffer was passed through a peristaltic pump and 
connected to the liver wedge. The liver wedge and buffer were kept sterile in a class II 
microflow safety cabinet. The liver was placed on a funnel covered with fine nylon 
mesh to allow the waste to be removed. Once the liver was adequately perfused with 
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Reagent Volume Supplier 
1x HBSS 1000 mL Gibco 
1 M HEPES 6 mL Sigma 
7.5% (w/v) NaHCO3  4.6 mL Sigma 
Buffer II 
Reagent Volume Supplier 
Buffer I (as above) 1000 mL / 
1 M CaCl2  1 mL Sigma 
Table 2.5 Buffers for liver perfusion 
 
2.1.4 Isolation of human liver myofibroblasts 
Isolation of LMFs was performed using explanted end-stage diseased liver tissue. Liver 
tissue was finely chopped with two scalpels and further digested with 0.4 mg/mL 
collagenase 1A (Sigma). The homogenate was passed through a sterile 60 μm nylon 
mesh (John Staniar Ltd), washed several times in PBS and then purified on a 33/77% 
Percoll gradient (GE Healthcare, Buckinghamshire, UK) at 550 x g for 30 min. The 
layer of cells at the interface was removed and washed in PBS several times. LMFs 
were extracted from the cell suspension after negative selection of IHECs and 
cholangiocytes. Here, the cell suspension was incubated with mouse anti-human 
EpCAM antibody (clone HEA125, Progen Biotechnic, Germany) bound to magnetic 
goat anti-mouse Dynabeads (Life Technologies) for 30 min at 37°C with agitation to 
eliminate cholangiocytes. The captured cells were removed with a magnet and the 
remainder of cells were incubated with mouse anti-human CD31 antibody directly 
conjugated to Dynabeads (Life Technologies) for 30 min at 37°C with agitation to 
remove IHECs. After removal of CD31-positive cells with a magnet, the remainder of 
the cells were washed and cultured in complete LMF medium (DMEM, 16% (v/v) 
FCS, 2 mM L-glutamine, 100 units/mL penicillin and 100 µg/mL streptomycin). 
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2.1.5 Cell culture and maintenance 
2.1.5.1 General cell culture work 
Tissue culture was carried out in a class II microflow safety cabinet. Sterile pipettes, 
25 and 75 cm2 culture flasks, 6-well and 24-well plates and 15 and 50 mL tubes were 
obtained from Corning Costar, Bucks, UK. Twenty mL plastic tubes and 5 mL bijoux 
were obtained from Greiner Bio One, Stonehouse, UK. 
 
2.1.5.2 Cell culture and passage 
HSCs and LMFs were grown in standard uncoated tissue culture flasks at 37°C in a 
humidified atmosphere of 5% CO2. Cell growth and morphology was monitored with 
an inverted phase contrast microscope (IX50, Olympus, Southend-on-Sea, UK). 
Cells were passaged at a confluence of about 80%. The medium in the flask was 
removed and the cells were washed with sterile PBS. After the cells had been washed 
an appropriate amount of TrypLE Express (1X; Life Technologies) was added to the 
flask to cover the cell layer. The cells were then incubated for approximately 5 min 
and gently agitated in order to detach them from the plastic. They were washed in 
sterile PBS at 550 x g for 5 min. The pelleted cells were resuspended in complete 
culture medium and transferred to a new culture flask.  
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2.1.5.3 Freezing cells for long-term storage 
TrypLE was used to remove the cells from the flask as described above. The cells were 
pelleted and resuspended in 10% (v/v) dimethyl sulfoxide (DMSO; Sigma) diluted in 
FCS. The cell suspension was aliquoted into cryovials and stored in a Mr Frosty™ 
freezing container (Wessington Cryogenics, Houghton le Spring, UK) at -80°C 
overnight to allow gradual controlled freezing of the cells. The next day, cells were 
transferred to liquid nitrogen for long-term storage.  
 
2.1.6 Characterisation of HSCs and LMFs 
HSCs and LMFs were characterised using phase contrast microscopy to assess 
morphology and immunohistochemistry or immunofluorescence to confirm 
expression of phenotypic markers. To assess morphology of HSCs, cells were seeded 
into a 6-well plate after isolation and were allowed to adhere to the plastic for 24 
hours. HSCs activated spontaneously in culture over 10 days with loss of lipid 
vacuoles and phenotypic changes, which could be visualised using an IX50 inverted 
microscope (Olympus). Phase contrast images were captured using a Canon EOS 
40D digital camera at various time points in culture.  
In order to determine the purity of the HSC and LMF cultures, cells were 
immunostained for various phenotypic markers for activated HSCs and 
myofibroblasts including α-SMA, Vimentin and CD90. CD31, CK19, Hepatocyte 
marker (staining a mitochondrial-associated antigen in hepatocytes (Wennerberg et 
al., 1993)) and CD68 were used to detect potential contamination with IHECs, 
cholangiocytes, hepatocytes and macrophages, respectively. A list of antibodies can be 
found in Table 2.1, Table 2.2 and Table 2.3 and an outline of the staining process can 
be found in section 2.1.9.  
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2.1.6.1 Oil Red O staining 
Following isolation lipid droplets containing retinoic acid are present in the HSC 
cytoplasm. The lipid droplets were visualised with Oil Red O (Sigma) according to a 
standard protocol. Briefly, Oil Red O stock solution (0.5% (w/v) Oil Red O in 100% 
2-propanol) was diluted to 60% (v/v) in distilled (d)H2O (ORO working solution). 
Cells were fixed with 4% formalin solution and incubated with 60% 2-propanol for 5 
min. The 2-propanol was aspirated and cells were incubated at room temperature for 
30 min with freshly prepared ORO working solution. This was followed by 60% 2-
propanol for 5 min and two washes with dH2O. Images were captured at x20 
magnification using an IX50 inverted microscope (Olympus) and a Canon EOS 40D.  
 
2.1.7 Quantitative polymerase chain reaction  
To quantify transcript levels in human livers, fresh normal or diseased liver tissue was 
cut into 1 cm3 blocks, snap frozen in liquid nitrogen and stored at -80°C. Total RNA 
was isolated from 30 mg of snap frozen liver tissue using the RNeasy mini kit (Qiagen, 
Crawley, UK) according to manufacturer’s instructions. GentleMACS M-tubes 
(Miltenyi Biotec, Surrey, UK) were used to homogenise tissue. As part of the isolation 
protocol all RNA was treated with RNase-free DNase (Qiagen) as an on-column 
digestion step. RNA was also extracted from HSCs, which were stimulated with 
cytokines detailed in Table 2.4 for 24 hours using the same kit. Cells treated with 
media alone were used as a control. RNA quantity and quality were assessed with a 
Nanophotometer (Implen Geneflow). An OD260/280 value between 1.8-2 was 
deemed acceptable. All human RNA samples were transcribed into cDNA with 1 μg 
of total RNA using the iScript cDNA synthesis kit including a blend of oligo(dT) and 
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random primers (BioRad, Hemel Hempstead, UK) according to manufacturer’s 
instructions. 
Quantitative polymerase chain reaction (qPCR) analysis of relative mRNA expression 
was performed with Roche gene expression assays using cDNA and target specific 
primers (Alta Biosciences, Birmingham, UK) and FAM/VIC labelled probes (Roche) 
(Table 2.6). Assays were run in 96-well white plates in a LightCycler 480 II (Roche) 
with the settings outlined in Table 2.7. Expression levels of the target genes were 
normalised to GUSB (β-glucuronidase, Roche). A study by Yamaguchi et al. has 
demonstrated that GUSB, out of 12 investigated housekeeping genes, was the most 
suitable housekeeping gene for qPCR studies on normal and diseased livers 
(Yamaguchi et al., 2013). Gene expression values are stated as 2-ΔCt (Livak and 
Schmittgen, 2001). Negative controls contained RNase/DNase-free water or non-
reverse transcribed RNA instead of cDNA. 
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(Fn14) GACCGCACAGCGACTTCT CACGAAGGTCAGGCTCAGA 26 
TNFSF12 
(TWEAK) ATCGCAGCCCATTATGAAGT CTCACTGTCCCGTCCACAC 85 
ACTA2 CTGTTCCAGCCATCCTTCAT TCATGATGCTGTTGTAGGTGGT 58 
COL1A1 GGGATTCCCTGGACCTAAAG GGAACACCTCGCTCTCCA 67 
Housekeeping gene     
GUSB Roche Cat# 05190525001     
Table 2.6 Human primers and probes used for qPCR 
 
Reagents Volume (μL) Source 
2x Probes Master 10 Roche 
Nuclease-free H2O 7.2 Roche 
Forward primer 0.2 Alta Bioscience 
Reverse primer 0.2 Alta Bioscience 
Probe 0.4 Roche 
DNA 2 Tissue/Cells 
Total for one reaction 20   
 
Cycle Temp. (°C) Time (min:sec) 





x45 60 00:30 
72 00:01 
Cooling 40 00:10 
 Table 2.7 qPCR mix and thermal profile for human samples 
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2.1.8 Western blot 
2.1.8.1 Protein lysates from liver tissue 
To investigate Fn14 expression, protein lysates were prepared from 30 mg of snap-
frozen human liver samples. Liver tissue was homogenised in CelLytic™ MT lysis 
buffer (Sigma) containing proteinase inhibitor (Roche) and DNaseI (Sigma) according 
to the manufacturer’s instructions. M tubes (Miltenyi Biotec) were used for 
mechanical homogenisation of the tissue in a gentleMACS system. Protein 
concentrations were calculated using the Biorad-DC protein assay (Biorad) according 
to manufacturer’s instructions using bovine serum albumin (BSA; Sigma) as protein 
standard. Samples were stored at -80°C prior to use. 
 
2.1.8.2 Extraction of cellular fractions from HSCs 
In order to determine activation of NF-κB in HSCs, cells were stimulated with 100 
ng/mL recombinant TWEAK (Biogen Idec, Cambridge, MA, USA) for 5, 30 min, 1, 
2, 4, 8, 16 and 24 hours and prepared according to the NE-PER Nuclear and 
Cytoplasmic Extraction Reagents kit (Thermo Fisher Scientific, Cramlington, UK). 
Briefly, to purify the cytoplasmic fraction cells were detached from plastic and diluted 
in 50 μL CER I containing protease/phosphatase inhibitor and EDTA. Cells were 
vortexed and incubated on ice for 10 min before adding 2.75 μL CER II. After 
centrifugation at 16,000 x g for 5 min, the supernatant containing the cytoplasmic 
proteins was removed and kept at -80°C. To purify the nuclear fraction the remaining 
pellet was resuspended in 25 μL NER containing protease/phosphatase inhibitor and 
EDTA and vortexed four times with 10 min incubation times on ice in between. After 
centrifugation at 16,000 x g for 5 min, the supernatant containing the nuclear proteins 
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was removed and kept at -80°C for further analysis by western blotting as outlined in 
section 2.1.8.3 using antibodies detailed in Table 2.10. 
 
2.1.8.3 SDS-PAGE and Western Blot 
Protein samples were separated by a SDS-PAGE gel using a standard protocol. All 
buffers used for the western blot are described in Table 2.8 and stacking and resolving 
gels were prepared as described in Table 2.9. A maximum of 50 μg per protein 
sample was diluted in 5x sample buffer with β-mercaptoethanol (β-ME) and incubated 
for 10 min at 100°C. The samples were run on a 5% stacking/10 or 15% resolving 
SDS-PAGE gel and the separated proteins were electrotransferred onto nitrocellulose 
membrane (VWR International, Leighton Buzzard, UK) for 1 hour at 100 V. A 
molecular weight marker (size range 12-225 kDa; GE Healthcare) was run along with 
the samples. To check for successful protein transfer, the nitrocellulose membrane was 
stained with Ponceau Red solution (Sigma). The membrane was then blocked with 
blocking buffer for 1 hour at room temperature followed by incubation with primary 
antibodies (Table 2.10) diluted in antibody dilution buffer at 4°C overnight with 
constant agitation. After several washes in Tris buffered saline (TBS )/0.1% Tween20 
the blots were incubated for 1 hour at room temperature with a peroxidase-
conjugated secondary antibody diluted in antibody dilution buffer. The blots were 
washed several times with TBS/0.1% Tween20 and developed with enhanced 
chemiluminescence (ECL) western blotting substrate (Thermo Fisher Scientific) 
according to manufacturer’s instructions. Enhanced chemiluminescence detection film 
(GE Healthcare) was exposed to the membrane and developed using a Kodak X-
Omat 1000 processor. For re-probing, bound antibodies were removed from the 
membrane with stripping buffer for 45 min at 50°C. After washing the membrane 
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under running dH2O for 1 hour it was blocked and re-probed with new antibodies. 
ImageJ software v.1.64 was used to analyse western blot images. The data are 
expressed as density of Fn14 relative to β-actin as a loading control. To investigate 
NF-κB activation, data are expressed as density of phosphorylated NF-κB relative to 
total NF-κB. β-tubulin was used a loading control. 
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Solution Reagent Quantity Source 
1.5 M Tris-base (pH 
to 8.8 with HCl) 
Tris-base 181.71 g Sigma 
dH2O Make up to 1 L / 
0.5 M Tris-base (pH 
to 6.8 with HCl) 
Tris-base 60.57 g Sigma 
dH2O Make up to 1 L / 
10x Running buffer Glycine 144 g Sigma 
Tris-base 30.3 g  Sigma 
SDS 10 g Sigma 
dH2O Make up to 1 L / 
Transfer buffer Glycine 28.8 g Sigma 
Tris-base 6 g Sigma 
Methanol 400 mL 
Fisher 
Scientific 
dH2O Make up to 2 L / 
5x Sample buffer 200 mM Tris 242 mg  Sigma 
20% Glycerol 2 mL  Sigma 
SDS 1 g  Sigma 
Bromphenol blue 5 mg   Sigma 
dH2O Make up to 10 mL  / 
10x TBS (pH to 7.4 
with pure HCl) 
Tris HCl 24 g Sigma 
Tris-base 5.6 g Sigma 
NaCl 88 g Sigma 
dH2O Make up to 1 L / 
Blocking buffer 5% Non-fat milk 5 g Marvel 
0.1% Tween20 0.1 mL Sigma 
1x TBS 




5% BSA 5 g Sigma 
0.1% Tween20 0.1 mL Sigma 
1x TBS 
Make up to 100 
mL / 
Stripping buffer 10% SDS 20 mL Sigma 
0.5 M Tris-base 
(pH 6.8) 12.5 mL / 
β-ME 0.8 mL Sigma 
dH2O 67.5 mL / 
Table 2.8 Solutions for western blotting 
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Stack Resolving gel 
5% 10% 15% 
30%:0.8% degassed 
Acrylamide:Bis-acrylamide 
(BioRad) 0.83 mL 3.3 mL 5 mL 
0.5M Tris-base pH 6.8 0.63 mL / / 
1.5M Tris-base pH 8.8 / 2.5 mL 2.5 mL 
10% SDS 40 μL 0.1 mL 0.1 mL 
dH2O 3.4 mL 4 mL 2.3 mL 
10% APS 0.1 mL 0.1 mL 0.1 mL 
TEMED 20 μL 20 μL 20 μL 
Table 2.9 Components of SDS-PAGE gel 
 
 
Specificity Isotype Supplier Dilution 
Fn14 rabbit Ig New England Biolabs 1 in 1000 
phospho-NF-κB p65 
(Ser536) rabbit Ig New England Biolabs 1 in 1000 
total NF-κB rabbit Ig New England Biolabs 1 in 1000 
β-actin mouse IgG1 Sigma 1 in 15000 
β-tubulin rabbit Ig New England Biolabs 1 in 2000 
Anti-mouse HRP / Dako 1 in 2000 
Anti-rabbit HRP / Dako 1 in 1000 
Table 2.10 Antibodies used for western blotting 
 
2.1.9 Immunostaining and histochemistry 
Liver tissues for immunostaining were obtained from the same patients as those used 
for qPCR and western blot. Snap-frozen liver samples were embedded in Tissue-
Tek™ OCT (Fisher-Scientific, Loughborough, UK) and 5-7 μm thick sections were 
cut on a cryostat (Bright OTF). Freshly cut sections were fixed in acetone (Fisher-
Scientific) for 5 min before storing them at -20°C. For immunostaining, sections were 
placed in a Shandon Sequenza unit (Thermo Shandon Limited, Runcorn, UK). This 
standardised system uses capillary action to reproducibly apply, incubate and 
sequentially remove reagents from microscope slides.  
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Immunostaining was also performed on cultured cells. Here, HSCs and LMFs were 
grown in 24-well plates on glass coverslips or on 12-well Ibidi chamber slides (Thistle 
Scientific, Glasgow, UK). In some instances HSCs were stimulated with bFGF and 
TGF-β1 as outlined in Table 2.4 for 24 hours. Prior to immunostaining cells were 
washed with PBS and fixed in 100% methanol for 5 min. After washing the cells twice 
with PBS they were stored in PBS at 4°C until required.  
 
2.1.9.1 Immunohistochemistry 
Immediately after removal of sections from -20°C, they were briefly incubated with 
acetone (5 min) and then placed in a Shandon Sequenza unit. Sections were washed 
with TBS and then incubated with 0.03% H2O2 in methanol for 10 min to quench 
endogenous peroxidase. They were then washed with TBS and blocked with 2x 
Casein (Vector Laboratories, Peterborough, UK) diluted in dH2O for 10 min. 
Primary antibodies or isotype matched control antibodies (Table 2.1 and Table 2.2) 
diluted in TBS were added for 1 hour followed by two wash steps for 5 min with 
TBS/0.1% Tween20. The specimens were then incubated with species-specific 
horseradish peroxidase (HRP) conjugated-secondary antibody (ImmPRESS kit, Table 
2.3) for 30 min followed by three wash steps for 10 min with TBS/0.1% Tween20. 
This was followed by incubation with 3,3′-diaminobenzidine (DAB; Vector 
Laboratories) for 5 min, rinsed with tap water and the sections were then 
counterstained with 25% (v/v) Mayer’s Haematoxylin (VWR International) diluted in 
tap water for 2 min. Sections were then dehydrated and subsequently mounted in 
DPX (Leica Biosystems, Peterborough, UK).   
Cells were stained in a similar way, except that they were stained within their culture 
vessel and not treated with 0.03% H2O2. Following incubation with the secondary 
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antibodies and the washing step they were incubated with 3-amino-9-ethylcarbazole 
(AEC; Vector Laboratories) for 20 min, rinsed with tap water and counterstained with 
25% Mayer’s Haematoxylin. The cells were mounted with aqueous immunomount 
(Thermo Fisher Scientific).  
Staining was viewed with a light microscope and Axiovision 4.4 software was used to 
capture images (both Carl Zeiss Ltd, Cambridge, UK).  
 
2.1.9.2 Immunofluorescent staining for confocal microscopy 
Prior to staining, sections were washed with acetone. This was followed by washing 
with TBS/0.3% Triton-X100 (Sigma) for 5 min and blocking with 10% goat serum 
(GS; Vector Laboratories) diluted in TBS/0.1% Triton-X100. Primary antibodies or 
isotype matched control antibodies (Table 2.1 and Table 2.2) diluted in 10% 
GS/TBS/0.1% Triton-X100 were added for 1 hour and then washed off with 
TBS/0.1% Triton-X100. This was followed by incubation with a fluorescent species-
specific secondary antibody (Table 2.3) diluted in TBS/0.1% Triton-X100 for 1 hour 
protected from the light. After three washing steps with TBS/0.1% Triton-X100 for 
10 min, 4’,6-diamidino-2-phenylindole (DAPI, Life Technologies) was added as a 
nuclear counterstain and specimens were mounted in fluorescent mounting medium 
(Dako, Ely, UK). The same protocol was used for cells except for the initial wash with 
acetone. The staining was viewed with a LSM 510 confocal microscope and images 




2.1.9.3 Picrosirius red staining for quantification of fibrosis 
Liver fibrosis was visualised and quantified using picrosirius red staining (PSR) of liver 
tissue sections. Snap-frozen sections were hydrated with dH2O and then incubated 
with 5% (v/v) phosphomolybdic acid (PMA; Sigma) diluted in dH2O for 5 min. This 
was followed by incubation in 0.1% (w/v) PSR (Direct red 80 in saturated picric acid) 
for 30 min. The slides were then dipped in 0.1 M HCl (Sigma) and dH2O before 
dehydrating them with 100% ethanol. Sections were mounted in DPX. To quantify 
PSR staining, five non-overlapping images of each section were taken using a light 
microscope (Carl Zeiss Ltd) with identical illumination and exposure. Axiovision 4.4 
software was used to capture images. Digital image analysis was performed using 
ImageJ 1.46r software. All images were analysed with equivalent threshold settings. 
The threshold pixels were expressed as percentage of the total pixel count. This was 
then used to represent the percentage positive area for collagen. 
 
2.1.10 Flow Cytometry 
Cell surface and intracellular expression of Fn14 and in some instances cell viability 
were assessed using flow cytometry. Baseline expression of Fn14 was determined in 
HSCs, LMFs and IHECs. To study the regulation of Fn14, HSCs were cultured to 
80% confluence and treated with various cytokines (Table 2.4) for 24 hours. Cells 
were detached from the plastic with TrypLE Express and washed in PBS at 550 x g 
for 5 min. For cell surface expression, cells were resuspended in flow buffer (PBS/2% 
FCS/1mM EDTA) and filtered to remove cell clumps. Surface marker staining was 
preformed using unconjugated mouse anti-human Fn14 antibody (3.7 μg/mL; 
mP4A8, Biogen Idec) diluted in flow buffer. Control samples were treated with 
isotype-matched IgG1 (Life Technologies) diluted in flow buffer to the same 
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concentration as mouse anti-human Fn14 antibody. Following incubation with 
primary antibodies for 30 min at 4ºC with constant agitation, samples were washed 
twice in flow buffer and then labelled with the secondary antibody rat anti-mouse PE 
(1:100, BD Biosciences, Oxford, UK) for 30 min with constant agitation at 4ºC in the 
dark. Cells were washed twice and then resuspended in flow buffer. Labelled cells 
were analysed on a Cyan ADP analyser (Dako) using FlowJo software v. 8.7. About 
10,000 events were recorded within the gated region of the scatter plot for each cell 
preparation in all experimental conditions. The pulse width scatter plot was then used 
to gate individual cells. Only the cells within the gated region were then used to 
calculate percentage positive cells and Median fluorescent intensity (MFI).  
For intracellular staining the BD Cytofix/Cytoperm kit (BD Biosciences) was 
used according to manufacturer’s instructions. Briefly, cells were resuspended in BD 
Cytofix and fixed for 20 min at 4ºC. This was followed by cell permeabilization with 
BD Cytoperm. From then on cells were treated the same as for the cell surface stain 
except that permeabilization buffer was used throughout until cells were resuspended 
in flow buffer prior to analysis.  
In some instances a Live/Dead violet dye (Life Technologies) was used to differentiate 
between live and dead cells. After the cells were detached from the culture flask and 
resuspended in 1 mL PBS, 1μL Live/Dead dye (stock 50 μg/mL) reconstituted in 
DMSO was added and cells were incubated for 30 min at room temperature in the 
dark. The cells were then washed twice in flow buffer and fixed for 20 min at 4ºC with 
BD Cytofix. The intracellular staining protocol was then followed as described above. 
Dead cells were identified by their uptake of the viability dye represented by increased 
fluorescence intensity in the violet channel.  
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2.1.11 Detection of soluble TWEAK using ELISA 
2.1.11.1 Samples 
Serum samples were collected from 64 newly diagnosed PSC patients attending the 
Liver Clinic (Queen Elizabeth hospital, Birmingham, UK) between January 2010 and 
November 2013. Clinical and laboratory data were collected at time of diagnosis and 
each subsequent clinic visit (3-12 monthly). Severity of liver disease was classified as 
pre-cirrhotic and cirrhotic. Given that liver biopsy is no longer standard practice of 
care in PSC, in the absence of histological data the presence of cirrhosis was identified 
according to a combination of clinical characteristics (ascites, varices, hepatic 
encephalopathy), laboratory parameters (hypoalbuminaemia, thrombocytopenia, 
prolonged prothrombin time/international normalised ratio (INR)), radiological 
features (coarse, irregular liver ± reversed portal vein flow, splenomegaly, intra-
abdominal varices, ascites) and/or transient elastography (>14.4kPa) (Corpechot et 
al., 2014). Patients with active ascending cholangitis, evident cholangiocarcinoma or 
colonic cancer were excluded from sampling. 
Serum samples from patients with IBD alone (n=24) and healthy individuals (HC) 
without evidence of liver or gastrointestinal disease (n=22) served as controls. The 
distribution of intestinal inflammatory activity in IBD patients was classified as 
predominantly large bowel (colitis), small bowel or peri-anal disease.  
To measure endogenous sTWEAK in culture supernatant, HSCs were seeded 
at 30,000 cells per well of a 24-well plate then serum starved in DMEM containing 
0.5% BSA (Sigma) for 24 hours. Cells were stimulated with various cytokines (Table 
2.4) diluted in complete HSC medium for 24 hours. Unstimulated macrophages were 
used as a positive control. Macrophages were isolated as described previously 
(Fletcher et al., 2014). The supernatant was filtered after collection to remove cell 
debris and subsequently stored at -80°C.  
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2.1.11.2 ELISA 
Soluble TWEAK levels were quantified using human TWEAK instant ELISA 
(eBioscience, Hatfield, UK) according to manufacturer’s instructions. Briefly, pre-
coated standard and sample wells of the provided 96-well plate were hydrated with 
dH2O. Then, 50 μL of human serum diluted 1 in 2 with sample diluent or undiluted 
cell supernatant were added. After a 3 hour incubation on a microplate shaker at 400 
RPM the plate was washed six times with wash buffer. Any residual wash buffer was 
removed by inverting the plate and gently tapping it on a paper towel after the last 
wash. Upon addition of TMB substrate solution, a blue colour developed which was 
monitored with a Synergy HT microplate reader (BioTek Instruments, Potton, UK) 
set at 620nm until the highest standard had reached an optical density of about 0.9. 
Stop solution was added once colour development had occurred (typically 8 min) and 
absorbance was measured with the microplate reader set at 450 nm with a reference 
wavelength set to 620 nm. Each sample was run in duplicate and the sTWEAK 
concentration was determined by comparison to the standard concentration curve.  
 
2.1.12 Luminex measurement of CCL5 in HSC supernatant 
Secretion of the chemokine CCL5 by HSCs into the culture media was measured 
using a custom-made multiplex array kit (R&D Systems, Abingdon, UK). HSCs were 
seeded at 30,000 cells per well into a 24-well plate and serum starved with 
DMEM/0.5% BSA before stimulation with 100 ng/mL TWEAK diluted in complete 
HSC medium (Table 2.4). The experiment was performed according to 
manufacturer’s instructions by Dr Elizabeth Humphreys (University of Birmingham, 
UK) on a Luminex 100 plate reader (Luminex Corporation, USA).  
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2.1.13 Proliferation of HSCs in response to TWEAK 
In order to investigate HSC proliferation upon TWEAK stimulation, HSCs were 
seeded at subconfluence (10,000 cells per well) into 24-well plates and serum-starved 
for 24 hours in DMEM/0.5% BSA. The medium was replaced by complete medium 
with or without TWEAK (1-500 ng/mL) or PDGF-BB (10 ng/mL; Table 2.4). 
Repeated phase contrast images of pre-determined representative fields were taken 
over 36 hours with the Cell-IQ imaging system (CM Technologies, Finland). Cell 
count per field was determined by counting nuclei at the beginning and the end of the 
incubation period. The baseline cell count was subtracted from the final value and 
data were expressed as percentage increase above the number of untreated cells.  
HSC proliferation was also determined with a commercially available 
CyQUANT NF Cell Proliferation Assay Kit (Life Technologies). A range of HSC cell 
counts was tested before the optimal density of 4000 cells per well of a 48-well plate 
was determined. HSCs were stimulated in duplicate with recombinant TWEAK 
(100ng/mL) or PDGF-BB (10ng/mL; Table 2.4). This quantification method relies on 
a fluorescent dye, which exhibits strong fluorescence when bound to DNA as a 
marker of changes in cell number. Proliferation was determined after 48 hours when 
medium was removed and the detection reagent added to each well. Plates were then 
incubated at 37°C for 40 min, and fluorescence was measured at 480/520 nm on a 
Synergy HT plate reader. Background fluorescence was subtracted and data was 






2.1.14 Migration assays 
HSCs were seeded into a 24-well plate (10,000 cells per well) and serum-starved for 24 
hours in DMEM/0.5% BSA. To inhibit endogenous TWEAK, HSCs were treated 
with 0.125 to 2 μg/mL blocking anti-TWEAK mAb (mP2D10, Biogen Idec) (Sanz et 
al., 2008). Matched concentrations of mouse IgG2a were used as an isotype control. 
Both antibodies were diluted in complete HSC medium. Cells were then monitored 
with the Cell-IQ imaging system for 48 hours. Analysis was carried out with Cell-IQ 
analyser 4 Pro-Write software v. AN4.3.0.HW and data were expressed as area 
occupied by cells.  
 
2.2  Methods for Chapter 5: Murine studies 
2.2.1 Mouse models (TWEAK KO and Fn14 KO) 
Male 6-8 week old homozygous Fn14 KO mice (Jakubowski et al., 2005) and 
TWEAK KO mice (Campbell et al., 2006) were used for acute and chronic liver 
injury experiments which were performed in the Biogen Idec Laboratory in 
Cambridge, MA, USA. Age and sex matched WT littermates for each KO strain 
(Fn14 WT and TWEAK WT) were used as controls. To ensure that the KO mice had 
the same microbiome as their matched WT controls, KO mice were backcrossed to 
Balb/c mice for 10 generations. The heterozygous (HET) mice were then intercrossed 
and homozygous KO and WT mice selected. The KO mice were then intercrossed to 
maintain a homozygous KO line and likewise for the WT line. All animal procedures 
were conducted in accordance with Cambridge, MA laws and the ethic committee of 
the Institutional Animal Care and Use Committee (IACUC). All mice were on a 
Balb/c background and maintained in 12 hour light/12 hour dark cycle with free 
access to food and water. 
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2.2.2 Genotyping of Fn14 KO mice 
Genomic DNA was isolated from the tail or the liver of the mouse using a 
REDExtract-N-Amp Tissue PCR Kit (Sigma) according to manufacturer’s 
instructions. All mice were genotyped using primers (Table 2.11) designed to 
distinguish Fn14 WT, Fn14 KO and HET genotypes. Details of the reagents and the 
thermal PCR profile are described in Table 2.12. Amplified products were run on a 
2% agarose gel containing SYBR safe (Life Technologies) at 100 V and visualised 
under UV light. The PCR products were identified by their sizes; the Fn14 WT gene 
was a 600bp fragment, the disrupted Fn14 gene (KO gene) was a 400bp fragment and 
HET animals displayed both bands (600bp and 400bp) (Figure 2.2). The 
HyperLadder 100bp (Bioline, London, UK) was used as an amplicon length marker. 
 68 




Table 2.11 Fn14 KO and WT primers 
 
 
Reagents Volume (μL) Source 
2x REDExtract-N-Amp PCR mix 10 Sigma 
Nuclease-free H2O 5 Promega 
Forward primer 1 Biogen Idec 
Reverse primer 1 Biogen Idec 
Neomycin primer 1 Biogen Idec 
DNA 2 Mouse tail 
Total for one reaction 20   
 
Cycle  Temp. (°C) Time (min:sec) 
Pre-incubation 95 15:00   
Denaturation 94 01:00 
Cycling x29 Annealing 60 00:30 
Extension 72 01:00 
Final extension 72 10:00   




Figure 2.2 Genotyping of Fn14 WT, KO and HET mice 
The 400 bp Fn14 knock-out (KO) gene, the 600 bp Fn14 wild type (WT) gene was 
detected with PCR. When both the KO and WT gene were detected mice were 
considered heterozygous (HET).  
 
 69 
2.2.3 Genotyping of TWEAK KO mice 
Genomic DNA was extracted from the tail of the mouse with 0.4 mg/mL proteinase 
K (Bioline) diluted in lysis buffer (Table 2.13) using an 18 hour incubation step at 
60°C followed by a 10 min incubation step at 94°C. The extracted DNA was then 
amplified with primers to distinguish TWEAK WT, TWEAK KO and HET 
genotypes (Table 2.14). Details of the qPCR are outlined in Table 2.15. Amplified 
products were run on a 2% agarose gel containing SYBR safe (Life Technologies) at 
100 V and visualised under UV light. The PCR products were identified by their 
sizes; the TWEAK WT gene was 400 bp, the disrupted TWEAK gene (KO) was 250 
bp and HET animals displayed both bands (400 bp and 250 bp) (Figure 2.3).  
 
Reagent  Quantity (g) Final concentration Source 
Tris-HCl pH 8.5 12.11 100 mM Sigma 
NaCl 11.69 200 mM Sigma 
SDS 2 0.2 % Sigma 
EDTA 1.46 5 mM Sigma 
ddH2O Make up to 1 L     
Table 2.13 Lysis buffer for DNA extraction 
 
 
Target Primer (5’→3’) 
TWEAK KO primer GGAGACTGCACCTTTGGAAG 
Common primer CGGGGAGGTTGGAGTTTAAT 
TWEAK WT primer TGCTTCTCTGCACTTTCTGC 
Table 2.14 TWEAK KO and WT primer 
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Reagents Volume (μL) Source 
Nuclease-free H2O 11 Promega 
10X HiFi PCR buffer 2 Life Tech. 
10 mM dNTP 1 Life Tech. 
DMSO (molecular grade) 1 Sigma 
50 mM MgSO4 0.8 Life Tech. 
10 μM TWEAK KO primer 1 Biogen Idec 
10 μM Common primer 1 Biogen Idec 
10 μM TWEAK WT primer 1 Biogen Idec 
Platinum HiFi Taq polymerase 0.2 Life Tech. 
DNA 1 Mouse tail 
Total for one reaction 20   
 
Cycle  Temp. (°C) Time (min:sec)   
Pre-incubation 95 02:00   
Denaturation 95 00:30 
Cycling 
x39 Annealing 56 01:00 
Extension 69 01:00 
Final extension 69 05:00   
Table 2.15 PCR mix and programme cycle for TWEAK genotyping 
 
 
Figure 2.3 Genotyping of TWEAK WT, KO and HET mice 
The 250 bp TWEAK knock-out (KO) gene, the 400 bp TWEAK wild type (WT) gene 
was detected with PCR. When both the KO and WT gene were detected mice were 







2.2.4 Harvesting of mouse tissue and serum samples 
After animals were sacrificed by CO2 overdose, blood was collected by cardiac 
puncture and serum was prepared for analysis of ALT activity. The liver lobes were 
excised and either fixed in 10% Neutral Buffered Formalin for paraffin sections, snap 
frozen in Tissue-Tek™ OCT for frozen sections or snap frozen only for RNA or 
protein extraction.  
 
2.2.5 Liver injury model (CCl4) 
To determine expression and function of TWEAK and Fn14 during liver injury, mice 
were treated with CCl4. CCl4 is a toxic chemical that induces hepatocyte necrosis 
between 24 and 48 hours after administration (Karlmark et al., 2010). Liver 
regeneration becomes evident between 48 and 72 hours during which time activated 
HSCs significantly increase and infiltration of inflammatory cells occurs (Ikejima et 
al., 2001; Karlmark et al., 2010). Therefore, CCl4 (Sigma; 1 in 4 dilution in mineral 
oil) or vehicle (mineral oil) was administered orally at a dose of 1 mL/kg body weight. 
Each mouse was weighed before administration of each dose and given the correct 
concentration of CCl4 for their weight. In acute study 1, Fn14 WT mice were dosed 
once and sacrificed 24, 48, 72, or 96 hours after gavage. Naïve mice were used as a 
baseline control (Figure 2.4 A). In acute study 2, TWEAK KO and Fn14 KO mice 
along with their WT controls received one dose of CCl4 or vehicle and were sacrificed 
after 72 hours of injury (Figure 2.4 B). For the chronic model, mice were administered 
CCl4 or vehicle once a week for four weeks (total of four doses) and were sacrificed 
three days after the last dose (Figure 2.4 C).  
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Figure 2.4 Outline of acute and chronic liver fibrosis models 
Liver injury was induced with oral doses of 1 mL/kg CCl4. One dose was 
administered and Fn14 wild type mice (WT) were sacrificed at the indicated time 
points (acute study 1) (A). Fn14 and TWEAK knock-out (KO) and corresponding 
WT mice were scarified after 72 hours of one CCl4 dose (acute study 2) (B). For the 
chronic study, Fn14 and TWEAK KO and corresponding WT mice were dosed 4 
times over a period of three weeks and sacrificed three days after last CCl4 dose (C). 
Serum and tissue was collected after the sacrifice.  
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2.2.6 Liver function test (ALT) 
To determine liver function, ALT activity was measured in serum samples. ALT is an 
enzyme that is released after hepatocellular injury. It catalyses the transfer of an 
amino group from alanine to α-ketoglutarate and thereby generates pyruvate and 
glutamate. ALT was measured using an ALT activity assay (Sigma) as per 
manufacturer’s instructions. Pyruvate standards and samples were diluted in ALT 
assay buffer and the master mix containing ALT assay buffer, peroxidase substrate, 
ALT enzyme mix and ALT substrate were added and mixed with a microplate shaker 
for 2 min. The colorimetric change was then measured every 5 min for 1 hour at 570 
nm with a Synergy HT microplate reader (BioTek Instruments) set at 37°C. The ALT 
activity was determined by the colorimetric change between the first reading and the 
final reading once the most active sample was greater than the highest standard. 
Background levels were subtracted and the levels of pyruvate between the two 
measurements were calculated by comparison to the standard concentration curve. 
The ALT activity of the samples was then expressed as mU/mL. 
 
2.2.7 RNA isolation and cDNA synthesis for murine studies 
RNA from snap-frozen mouse tissue was isolated as described in section 2.1.7. All 
RNA samples were transcribed into cDNA with 2 μg of total RNA using the 




2.2.7.1 GeNorm housekeeping genes 
To identify a stable housekeeping gene for use in the qPCR experiments, the geNorm 
Reference gene selection kit (Primerdesign) was used to evaluate 6 commonly used 
reference genes with representative samples in each study (acute 1, acute 2 and 
chronic study). The cDNA of the samples was measured by qPCR in duplicate wells 
using PrecisionPLUS master mix premixed with SYBRgreen (Primerdesign) in a 
LightCycler 480 II (Roche) with the settings described in Table 2.16. The 
housekeeping genes tested were Gapdh (Glyceraldehyde 3-phosphate dehydrogenase), 
Rn18s (18S ribosomal RNA subunit), Actb (β-actin), B2m (β-2 microglobulin), Cyc1 
(Cytochrome c1) and Ywhaz (tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta polypeptide). The amplification specificity for 
each qPCR analysis was confirmed by melting curve analysis (Figure 2.5). The 
stability of the housekeeping genes were analysed with the Biogazelle qbase+ software 
v.2.6.1 and the geNorm algorithm that has been designed to analyse the expression 
stability of a list of selected housekeeping genes in all samples. The genes were ranked 
according to geNorm stability measurements (geNorm M) with a low geNorm M 
value indicative of a more stable housekeeping gene. Based on geNorm analysis (see 
data in Figure 2.6), Rn18s was used as a housekeeping gene for acute study 1 and the 
chronic study and Gapdh was used for acute study 2. 
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Reagents Volume (μL) Source 
2x PrecisionPLUS mix 
(SYBRgreen) 5 Primerdesign 
Primer mix 0.5 Primerdesign 
Nuclease-free H2O 2 Promega 
cDNA (25 ng) 2.5 Mouse liver 
Total for one reaction 10   
 
Cycle Temp. (°C) Time (min:sec) 
Pre-incubation 95 02:00   
Amplification 95 00:15 Cycling x50 60 01:00 
Melt curve 
95 01:00   
65 02:00   
95 Continuous   
Cooling 40 00:10   








Figure 2.6 Expression stability of housekeeping genes 
Candidate reference genes for normalization in liver samples from acute study 1 (n=9) 
(A) acute study 2 (n=16) (B) and chronic study (n=8) (C) Experimental designs are 
described in Figure 2.4. Data are expressed as geNorm stability measurements 




2.2.7.2 Quantitative PCR for murine studies 
Quantitative analysis was performed using cDNA prediluted with PCR-grade water to 
20-40 ng/μL. Quantitative PCR was carried out using Taqman gene expression 
assays; Fn14 gene (Tnfrsf12a, Mm01302476_g1), TWEAK gene (Tnfsf12, 
Mm02583406_s1), Acta2 (Mm00808218_g1), Col1a1 (Mm00801666_g1), Timp1 
(Mm00441818_m1), Mmp2 (Mm00439498_m1), Mmp9 (Mm00442991_m1), Tgfb1 
(Mm01178820_m1), and Rn18s (Mm03928990_g1) or Gapdh (Mm99999915_g1). 
Assays were run on a LightCycler 480 II (Roche) in duplicate on 384-well plates using 
the settings outlined in Table 2.17. Expression levels of the target genes were 
normalised to a housekeeping gene as determined in section 2.2.7.1 using 2-ΔCt. 
Negative controls contained RNase/DNase-free water or non-reverse transcribed 
RNA instead of cDNA.  
 
Reagents Volume (μL) Source 
2x PrecisionPLUS mix 5 Primerdesign 
Primer/Probe mix 0.5 Applied Biosystems 
cDNA (50-100 ng) 2.5 Mouse liver 
Nuclease-free H2O 2 Promega 
Total for one reaction 10   
 
Cycle Temp. (°C) Time (min:sec)   
Pre-incubation 95 02:00   
Amplification 95 00:15 Cycling x50 60 01:00 
Cooling 40 00:10   








Fixed mouse livers were dehydrated, embedded in paraffin and sectioned on a 
microtome to 3 μm thickness. After dewaxing, sections were stained with 
haematoxylin and eosin (H&E; Pioneer Research Chemical, Essex, UK) to identify 
general morphological changes. Briefly, sections were washed in water and then nuclei 
were stained with haematoxylin for 4 min, rinsed with water and incubated with 0.3% 
acid alcohol for 30 seconds. Following a further wash in water, sections were 
incubated in Scott’s water, then washed in water and incubated in eosin for 2 min. 
Following washing the sections in water, they were dehydrated and mounted in DPX. 
Mouse livers from acute study 2 and the chronic study were stained with H&E by 
Premier Laboratory, LCC (Colorado, USA).  
 
2.2.8.1 Myofibroblast quantification 
Myofibroblasts were detected in paraffin tissue sections from Fn14 and TWEAK KO 
mice and their corresponding WT mice from the chronic study. 
Immunohistochemical staining was performed by Dr Gary Reynolds (University of 
Birmingham, UK) on an automated immunostainer (Dako) using a mouse-on-mouse 
ImmPRESS HRP kit (Vector Laboratories) according to manufacturer’s instruction 
and an antibody against α-SMA (1:200 dilution, ASM-1, Vector Laboratories) or an 
isotype matched control antibody (Life Technologies).  
Ten non-overlapping fields at x20 magnification from each section were captured 
using a light microscope (Carl Zeiss Ltd) with identical illumination and exposure. 
Digital image analysis was performed using ImageJ 1.46r software. Positive staining 
was identified with the threshold tool and all images were analysed with equivalent 
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settings. The pixels in the threshold were expressed as percentage of the total pixels. 
This was taken to represent the percentage area staining positively for α-SMA. 
 
2.2.8.2 Picrosirius red staining on mouse liver tissue 
Snap frozen OCT-embedded liver tissue from both acute studies was cut to 7 μm 
thick sections on a cryostat (Bright OTF) and fixed in acetone. To visualise collagen 
deposition livers were stained with the PSR protocol outlined in sections 2.1.9.3. For 
the chronic study paraffin embedded sections were stained with PSR and quantified 
by Bob Dunstan and Stefan Hamann (Biogen Idec, USA).  
 
2.2.8.3 Von Kossa staining to detect mineralisation 
The Queen Elizabeth hospital pathology department (Birmingham, UK) stained 
paraffin-embedded sections using von Kossa stain with a standard staining protocol. 
Slides were visualised at x10 magnification and images from each section were 
captured using a light microscope (Carl Zeiss Ltd) with identical illumination and 
exposure. 
 
2.2.9 Hydroxyproline assay 
Snap-frozen liver samples were weighed (about 80 mg), homogenised in 1 mL dH2O 
and incubated with 125 μL of 50% trichloroacetic acid (Sigma) on ice for 30 min. 
After centrifugation at 16,000 x g for 5 min, the pellet was hydrolysed in 500 μL of 6 
M HCl (Sigma) at 120°C in sealed borosilicate glass tubes overnight and then up to 48 
hours in total in unsealed tubes at 75°C until the samples were dry. The precipitate 
was resuspended in 500 μL deionised (d)dH2O and filtered in 0.45 μm centrifuge tube 
 80 
filters (Sigma) at 2,000 x g for 2 min. Fifty μL of each sample were diluted in 950 μL 
ddH2O. Hydroxyproline standards were prepared by serial dilutions of trans-4-
hydroxy-L-proline (Sigma) starting from 2 μg/mL. One mL of sample or standard 
solution was then added to 500 μL of 1.75% (w/v) chloramine-T (Sigma, diluted in a 
solution containing 10% water, 10% n-propanol and 80% dilution buffer, see Table 
2.18). The samples or standards were vortexed and incubated for 20 min at room 
temperature. Next, 500 μL of Ehrlich's solution (Table 2.18) was added, vortexed and 
incubated at 65°C for 15 min. Once the samples had returned to room temperature, 
the optical density was measured at 561 nm in triplicate in a 96-well plate using a 
BioTek plate reader. The hydroxyproline concentrations were calculated against a 
standard curve and expressed as μg/g wet liver. 
 
Solution Reagent Quantity 
Diluion buffer 
(pH to 6.8 
with HCl or 
NaOH) 
Citric acid monohydrate 25 g 
Sodium acetate trihydrate 60 g 
Sodium chloride  17 g 
Glacial acetic acid 6 mL 
dH2O Make up to 500 mL 
Ehrlich's 
solution 
4-(Dimethylamino)benzaldehyde 7.5 g 
60% Perchloric acid 13 mL 
N-propanol Make up to 50 mL 
Table 2.18 Solutions for hydroxyproline assay 
All reagents were supplied by Sigma 
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2.3 Statistical analysis 
Results are presented as medians unless otherwise stated. The statistical significance 
between medians was assessed using Kruskall-Wallis test or non-parametric Mann-
Whitney U-test. Correlations between continuous variables were assessed with the 
Spearman’s rho. The Chi-squared test was used to study significance between 
categorical variables. This analysis was carried out using Prism v6.0a software 
(GraphPad, CA, USA). 
 
The optimal sTWEAK cut-off levels to predict short-term transplant free survival 
were calculated by an Area under the receiver operator characteristic (AUROC) 
curve analysis. Transplant-free survival was assessed using the Kaplan-Meier method 
and the log-rank test was performed to compare the survival curves of individual 
groups. Univariate and multivariate Cox proportional hazard models were used to 
determine impact of clinical parameters on short-term transplant free survival. The 
reported results included hazard ratios (HR) and 95% confidence intervals. This 
statistical analysis was carried out by Dr Palak Trivedi (University of Birmingham, 
UK) using SPSS v21 software (SPSS, Chicago, IL, USA). A p value of <0.05 was 
considered statistically significant.  
 
Power calculations were performed to determine the number of animals in each 
treatment group. Based on PSR stain in earlier studies we determined significant 
differences between KO and WT mice in terms of 50% alteration in total collagen at 
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Fn14 is highly regulated in vivo with low levels in healthy tissue and increased 
expression during injury and inflammation. It is a cell surface receptor present on a 
broad variety of different cell types including endothelial cells, epithelial cells and 
fibroblasts (Burkly et al., 2011). In the liver, Fn14 becomes quickly upregulated in 
experimental models of liver injury (Feng et al., 2000; Tirnitz-Parker et al., 2010). So 
far expression has been mainly associated with LPCs in mice (Tirnitz-Parker et al., 
2010; Bird et al., 2013; Jakubowski et al., 2005) but there have also been suggestions 
that Fn14 is expressed by a subpopulation of myofibroblasts (Tirnitz-Parker et al., 
2010). TWEAK, the ligand for Fn14 is highly expressed in leukocytes and has been 
detected in tissues during acute injury and inflammation (Serafini et al., 2008; van 
Kuijk et al., 2010). In the liver, TWEAK transcript levels did not alter significantly 
after injury with the CDE diet, and the highest TWEAK mRNA levels were seen in 
NK cells and macrophages (Tirnitz-Parker et al., 2010). Observations from human 
studies have shown that Fn14 was significantly upregulated in patients with alcoholic 
hepatitis compared to normal liver and expression was detected in intermediate 
hepatocytes, progenitor cells (Affò et al., 2012) and duct like structures (Jakubowski et 
al., 2005). 
 
Despite these initial reports, a detailed analysis of TWEAK and Fn14 expression in 
human liver disease has not been performed. Therefore, the aim of this chapter was to 
investigate the localisation and expression levels of TWEAK and Fn14 mRNA and 
protein in normal and diseased livers. 
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3.2 Results 
3.2.1 TWEAK and Fn14 gene expression are elevated in human liver 
disease 
Real-time qPCR analysis of whole liver extracts detected low levels of Fn14 mRNA in 
normal liver tissue with significantly higher levels in ALF and chronic end stage liver 
disease (p<0.01). Furthermore, Fn14 mRNA was significantly higher in ALF 
compared to chronic liver disease (p<0.05) (Figure 3.1 A). TWEAK mRNA was also 
low in normal liver tissue, with significantly higher levels in chronic liver disease 
(p<0.01) but no significant differences in acute liver failure were detected (p=0.13) 
(Figure 3.1 B). TWEAK mRNA was considerably more abundant in liver tissue than 
Fn14 mRNA (Figure 3.1). 
 
Comparison of chronic liver diseases demonstrated that the levels of Fn14 mRNA 
were significantly increased in immune-mediated liver diseases (PBC, PSC and AIH) 
compared to normal livers (p<0.05). Fatty liver diseases including NASH and ALD 
showed no significantly different expression of Fn14 mRNA to normal liver (NASH 
p=0.18, ALD p=0.08) (Figure 3.2 A). However, levels of TWEAK mRNA were 
significantly higher in fatty liver diseases (p<0.05) and in PBC (p<0.01) whereas 
expression in PSC (p=0.18) and AIH (p=0.13) livers were similar to normal livers 
(Figure 3.2 B).  
 
Although the levels of TWEAK and Fn14 mRNA upregulation varied between 
chronic liver diseases when compared to normal livers, there was a significant positive 





Figure 3.1 Fn14 and TWEAK mRNA is increased in acute and chronic 
liver disease  
Expression of Fn14 (A) and TWEAK (B) was assessed by qPCR in normal livers 
(n=6), ALF (n=5) and cirrhotic livers (n=29). Gene expression is shown relative to 
GUSB using the 2-ΔCt method (*p<0.05, ** p<0.01, n.s. not significant; Mann-Whitney U 
test). The distribution of values was significantly different across the whole population 





Figure 3.2 Fn14 and TWEAK mRNA in different chronic liver pathologies 
Expression of Fn14 (A) and TWEAK (B) was assessed by qPCR in normal livers 
(n=6), NASH (n=6), ALD (n=5), PBC (n=6), PSC (n=6) and AIH (n=6). Gene 
expression is shown relative to GUSB using the 2-ΔCt method (*p<0.05, ** p<0.01; 
Mann-Whitney U test). The distribution of values was not significantly different across 








































































































































Figure 3.3 Correlation between Fn14 and TWEAK mRNA 
Linear regression analysis of Fn14 and TWEAK mRNA in samples from normal 
livers (n=6), ALF (n=5) NASH (n=6), ALD (n=5), PBC (n=6), PSC (n=6) and AIH 
(n=6) (ρ=0.53; ***p<0.005; Spearman correlation). 
 
3.2.2 Fn14 protein levels are elevated in chronic liver diseases 
To determine whether the increased levels of Fn14 mRNA resulted in increased 
protein expression, the levels of Fn14 protein were assessed by western blot using the 
same patient tissue samples as those used for qPCR. The blots showed two major 
bands, one at 24 kDa (Figure 3.4 A) and the other at 48 kDa (data not shown). The 24 
kDa band is considered to be the main Fn14 protein (Meighan-Mantha et al., 1999) 
and the 48 kDa band a potential dimer. It has been suggested that the reason why 
Fn14 migrates at a higher apparent molecular weight is because of the amino acid 
composition that causes Fn14 to resist denaturation or to bind SDS poorly (Meighan-
Mantha et al., 1999).  
In contrast to mRNA levels Fn14 protein levels were significantly upregulated in 
chronic fatty liver diseases compared to normal livers (p<0.05). Fn14 protein levels in 
autoimmune liver diseases were also significantly higher compared to normal livers 
(p<0.05; Figure 3.4 B). 
 
























3.2.3 TWEAK and Fn14 expression correlate with liver fibrosis 
Chronic liver disease is commonly associated with significant development of fibrosis. 
Other research has shown that Fn14 protein expression correlates with peritoneal 
fibrosis in humans (Sanz et al., 2014). To investigate whether Fn14 or TWEAK 
correlate with levels of fibrosis in the liver, matched liver sections from NL, NASH, 
ALD and AIH were stained with sirius red to detect collagens (Figure 3.5 A) and 
quantified with Image J (Figure 3.5 B). Cirrhotic livers exhibited significantly more 
collagen compared to normal livers (p<0.05; Figure 3.5 B). A positive correlation was 
detected between the amount of collagen and Fn14 mRNA (Spearman ρ=0.63; p<0.05; 
Figure 3.5 C), TWEAK mRNA (Spearman ρ=0.63; p<0.05; Figure 3.5 D) and Fn14 
protein (Spearman ρ=0.66; p<0.05; Figure 3.5 E). 
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Figure 3.4 Fn14 protein levels are increased in chronic liver disease 
Representative western blot image of Fn14 and β-actin levels in normal livers, NASH, 
ALD, PBC and PSC (A) and densitometry analysis of Fn14 protein expressed in 
normal and cirrhotic livers normalised on β-actin expression (B) (NL n=3, NASH 
n=3, ALD n=5, PBC n=3, PSC n=3, AIH n=3). (*p<0.05; Mann-Whitney U test) The 





Figure 3.5 A correlation exists between the extent of fibrosis and TWEAK 
or Fn14 in human liver samples 
Normal and cirrhotic livers (NL n=3, NASH n=3, ALD n=2, AIH n=3) were stained 
using sirius red. Panel A shows images of Normal, NASH, ALD and AIH livers (A) 
Staining was digitally quantified to show amount of sirius red stain expressed as the 
percentage area of five randomly selected areas per sample (*p<0.05; Mann-Whitney U 
test) (B). Extent of fibrosis was compared to mRNA level using Spearman rho analysis 
of sirius red and Fn14 mRNA (ρ=0.63; p<0.05) (C) TWEAK mRNA (ρ=0.63; p<0.05) 





3.2.4 Localisation of TWEAK and Fn14 in human liver tissue 
3.2.4.1 Fn14 expression by immunohistochemistry 
In normal human liver tissue Fn14 expression was low in the portal area (Figure 3.6 
A) and no staining was detected in the parenchyma (Figure 3.6 B). Examination of 
normal tissue at increased magnification localised Fn14 to blood vessels, in particular 
on smooth muscle cells in the arterial wall, with low-level staining on bile ducts (Figure 
3.6 C). 
 
Histological samples from patients with ALF (Figure 3.6 D-F) demonstrated increased 
Fn14 staining compared to normal livers, which corresponded with the Fn14 qPCR 
data (Figure 3.1 A). In the portal area of ALF samples, Fn14 was present in bile ducts 
and blood vessels and in structures that appeared to be ductular reactive cells (DRCs) 
(Figure 3.6 D). In the parenchyma, cells at the fibrogenic intercept stained positive for 
Fn14 (Figure 3.6 E). Histological analysis of samples from patients with chronic liver 
disease (Figure 3.6 G-L and Figure 3.7) also showed increased Fn14 expression 
compared to normal livers. This was consistent with the results of the western blot 
(Figure 3.4). In the portal area of samples from patients with NASH (Figure 3.6 G) 
and ALD (Figure 3.6 J), Fn14 staining was again present in bile ducts and blood 
vessels. Arteries were consistently positive whereas veins showed variable staining 
intensities. In addition, neovessel-like structures in the portal area also stained positive 
for Fn14 (Figure 3.6 J). Besides staining in the portal area, Fn14 was localised to cells 
in the fibrous septum of NASH and ALD samples (Figure 3.6 H,K). Higher 
magnification of the sections demonstrated that some cells that stained positive for 
Fn14 in the fibrotic scar had a spindle shaped appearance (Figure 3.6 I,L). With this 
technique it was not possible to determine the identity of this cell type. Staining with 
an isotype matched control was negative in all areas (Figure 3.6 M,N). 
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Samples from patients with end stage PSC and PBC demonstrated strong Fn14 
staining in DRC-like structures in the portal area (Figure 3.7 D,G). In comparison to 
the Fn14-positive DRCs in ALF, those DRCs were present at the peripheral zone of 
the portal area and had often a more elongated and thin structure with no 
recognisable lumen. Similar structures were also detected in the parenchyma of PSC 
and PBC samples (Figure 3.7 E,H). In AIH, Fn14 expression was present on cells that 
appeared to be DRCs (Figure 3.7 J) but there were considerably fewer compared to 
PSC and PBC. Fn14 staining in the fibrotic scar of AIH (Figure 3.7 K,L) was similar 





Figure 3.6 Expression of Fn14 in normal livers, ALF and steatotic liver 
disease 
Immunohistochemical staining for Fn14 (brown) in human liver samples from normal 
donors (A-C), patients with ALF (D-F), NASH (G-I) and ALD (J-L). Staining of 
NASH liver with an isotype-matched control antibody is shown (M and N). 






Figure 3.7 Fn14 expression in autoimmune liver diseases 
Representative images of Fn14 staining (brown) in liver samples from normal liver (A-
C) and from patients with PSC (D-F), PBC (G-I) and AIH (J-L). Staining of PSC 
liver with an isotype-matched control antibody is shown (M). Arrows mark ductular 
reactive cells. Arrowheads indicate spindle shaped cells in the fibrotic scar. Both scale 
bars 100 μm 
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3.2.4.2 Cellular localisation of Fn14 expression measured by 
immunofluorescence 
Immunohistochemical staining of normal and cirrhotic livers demonstrated Fn14 
expression in several structures including blood vessels and spindle shaped cells in the 
fibrotic scar. In the blood vessels the Fn14 staining appeared to be present in smooth 
muscle cells (SMCs) (Figure 3.6 C) and the spindle shaped cells were reminiscent of 
LMFs (Figure 3.6 I,L). SMCs and LMFs express a number of common phenotypic 
indicators and one of the main markers is α-SMA. Dual colour confocal microscopy 
was therefore used to identify whether α-SMA-positive cells do express Fn14. Indeed, 
Fn14 did colocalise with α-SMA in the walls of blood vessels in normal and cirrhotic 
livers (Figure 3.8) and also within neovessels in cirrhotic livers (Figure 3.8 F,I) showing 
that Fn14 was expressed by SMCs. Colocalisation of Fn14 and α-SMA was also 
detected in the fibrous septa of samples from patients with NASH and ALD (Figure 
3.9) suggesting that Fn14 was expressed by LMFs. Not all α-SMA-positive LMFs were 
also Fn14-positive however, indicating that a subpopulation of LMFs express Fn14. 
Furthermore, Fn14 expression was also detected in α-SMA negative cells (Figure 3.8 
D-I). The endothelial lining of blood vessels as well as the bile ducts also appeared to 
stain positive for Fn14 (Figure 3.8 F). Colocalisation studies with Fn14 and CD31, a 
marker for endothelial cells has shown that the endothelial lining of blood vessels also 
expressed Fn14 (unpublished data by Mamoona Munir). Samples from patients with 
PSC and PBC showed a different Fn14 staining pattern compared to NASH, ALD 
and AIH. The morphology of the cells that stained Fn14 positive in PSC and PBC 
had a DRC-like appearance. To investigate this further, dual colour 
immunofluorescent staining was carried out using liver samples from PSC patients 
and antibodies against Fn14 and CK19, a biliary epithelial cell marker (Figure 3.10). 
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CK19 has been demonstrated to stain DRCs (Suda et al., 2014) but also mature bile 
ducts. Immunofluorescent staining showed colocalisation of Fn14 with CK19-positive 




Figure 3.8 Colocalisation of Fn14 with α-SMA in the portal area 
Immunofluorescent staining of Fn14 (green) and α-SMA (red) in portal areas of 
normal liver tissue (A-C) ALD (D-F) and AIH liver samples (G-I). Isotype-matched 
control is shown (G). Colocalisation of Fn14 and α-SMA is indicated in yellow and by 
arrows. Arrowheads indicate endothelial lining of blood vessels. DAPI (blue) was used 







Figure 3.9 Colocalisation of Fn14 with α-SMA in the fibrous septum 
Immunofluorescent staining of Fn14 (green) and α-SMA (red) in tissue samples from 
patients with NASH (A-C) and ALD (D-F). Isotype-matched control is shown (G). 
Colocalisation of Fn14 and α-SMA is indicated by pseudocolour yellow and shown in 
insert: digitally enlarged image. DAPI (blue) was used as a nuclear counterstain. Scale 





Figure 3.10 Expression of Fn14 by CK19+ epithelial cells 
Immunofluorescent staining of Fn14 (green) and CK19 (red) in samples from patients 
with PSC. Colocalisation of Fn14 and CK19 is indicated in yellow and by arrow. 




3.2.4.3 TWEAK expression by IHC 
To investigate where TWEAK localises in the liver, immunohistochemical staining 
was performed with the same liver samples used for Fn14 staining. Similar to Fn14 
staining, TWEAK staining in normal livers was weak (Figure 3.11 A-C). Some 
staining was detected in the portal area (Figure 3.11 A) whereas the parenchyma 
showed no immunoreactivity (Figure 3.11 B). Considerably higher levels of TWEAK 
were detected in ALF and various chronic liver diseases compared to normal controls 
(Figure 3.11 and Figure 3.12).  
TWEAK expression in ALF was abundant in the portal area around ductules possibly 
in infiltrating leukocytes (Figure 3.11 D). The ductules did not stain positively for 
TWEAK but they were positive for Fn14 (Figure 3.6 D). TWEAK staining was also 
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detected in the fibrotic septa (Figure 3.11 E). Higher magnification demonstrated that 
TWEAK was present in cells with a spindle shaped appearance but also in some cells 
at the periphery of the scar (Figure 3.11 F). In comparison with Fn14 staining 
TWEAK was more focused within the fibrotic area (Figure 3.11 E) whereas Fn14 
staining was mainly present at the periphery in liver tissue from ALF patients (Figure 
3.6 E). 
 
In samples from patients with NASH and ALD, TWEAK staining was also present in 
the portal area (Figure 3.11 G,J) but to a lesser extent than in ALF (Figure 3.11 D). In 
the fibrotic septum TWEAK was detected in cells with a spindle shaped morphology 
(Figure 3.11 H,K), similar to the Fn14 staining seen in NASH and ALD samples 
(Figure 3.6 H,K). Furthermore, TWEAK staining was observed in the sinusoids 
(Figure 3.11 K). The major cell populations within the sinusoids are HSCs, Kupffer 
cells and endothelial cells. However, it was not possible with this technique to 
differentiate which cell type(s) were expressing TWEAK.  
TWEAK staining in immune-mediated liver diseases (Figure 3.12 D-L) was similar to 
that in fatty liver diseases (Figure 3.11 G-L) and was located in both the portal region 
and in the fibrotic septum of PSC (Figure 3.12 D,E), PBC (Figure 3.12 G,H) and AIH 
(Figure 3.12 J,K). In the portal area, infiltrating leukocytes appeared to stain positive 
for TWEAK. In some instances dense accumulation of TWEAK was also detected in 
the portal areas of PSC (Figure 3.12 D) and PBC (Figure 3.12 G). TWEAK expression 
was also present in the sinusoids of immune-mediated liver diseases (Figure 3.12 
E,H,K). In addition, higher magnification of TWEAK staining (Figure 3.12 F,I,L) 
revealed expression in cells with a spindle shaped morphology in the fibrotic septum.  
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Figure 3.11 TWEAK expression in normal livers, ALF and steatotic liver 
disease 
Representative images of tissue samples from normal donors (A-C), patients with 
ALF (D-F), NASH (G-I) and ALD (J-L) were stained by immunohistochemistry for 
TWEAK (brown). Staining with an isotype-matched control antibody is shown (M 
and N). Arrowheads indicate spindle shaped cells in the fibrotic scar. Both scale bars 





Figure 3.12 TWEAK expression in autoimmune liver disease 
Immunohistochemical staining with TWEAK mAb (brown) in liver tissue from 
normal donor liver (A-C) and from patients with PSC (D-F), PBC (G-I) and AIH (J-
L). Staining with an isotype-matched control antibody of PSC liver is shown (M). 
Arrows mark dense TWEAK staining. Arrowheads indicate spindle shaped cells in the 
fibrotic scar. Both scale bars 100 μm 
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3.2.4.4 TWEAK expression by immunofluorescence 
To confirm the identity of the spindle shaped cells staining positive for TWEAK, dual 
colour immunofluorescent staining was performed in samples of ALF (Figure 3.13) 
using vimentin as a marker for HSCs/LMFs. Figure 3.13 shows colocalisation of 





Figure 3.13 Colocalisation of TWEAK with LMFs 
ALF samples were stained using dual colour immunofluorescence with TWEAK 
(green) and Vimentin (red). Colocalisation is seen as yellow. Arrow indicates 
myofibroblasts positive for TWEAK stain. DAPI (blue) was used as a nuclear 




To date few research studies have been published concerning TWEAK and Fn14 
expression in the liver with most of them being in mouse models (Bird et al., 2013; 
Jakubowski et al., 2005; Tirnitz-Parker et al., 2010). To undertake a more systematic 
approach this chapter characterises the expression of TWEAK and Fn14 in normal 
human livers and livers from patients with ALF and chronic liver disease. Fn14 
mRNA expression in mice has been shown to be low in healthy livers and upregulated 
during liver disease (Tirnitz-Parker et al., 2010; Feng et al., 2000). The human data 
presented in this chapter showed a similar pattern of expression; low levels of Fn14 
mRNA in normal livers and a significant upregulation in acute and chronic liver 
injury, which was also reflected by immunohistochemistry and western blot. Of note, 
the normal livers that have been used for this analysis have all come from donors and 
the livers often had a steatotic appearance. In addition, the tissue from chronic liver 
patients was derived from explants from patients undergoing transplantation. In these 
patients, the liver disease might have reached an end stage and the histological 
characteristics of specific types of liver diseases might have faded away. It is also worth 
mentioning that livers with chronic viral hepatitis were not included in this study. 
Globally, it is the most common type of chronic liver disease (Mokdad et al., 2014) 
and in future studies they should be included in the investigation to have a complete 
representation of chronic liver disease. 
 
In my experiments I have analysed Fn14 expression in subgroups of patients with 
chronic liver disease including fatty liver diseases, NASH and ALD and immune-
mediated liver diseases; PBC, PSC and AIH. Fn14 mRNA was similar in fatty liver 
diseases compared to normal livers whereas immune-mediated liver diseases showed a 
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significant difference compared to normal. Other research has also shown similar 
expression of Fn14 mRNA in NASH and normal livers (Affò et al., 2012). Conversely, 
semi-quantitative analysis of Fn14 protein levels by western blot demonstrated that 
Fn14 protein levels were significantly higher in fatty liver diseases and also in 
autoimmune liver diseases compared to normal livers. Fn14 has a rapid turnover as it 
is constitutively synthesized and degraded, which requires continuous de novo receptor 
synthesis (Gurunathan et al., 2014), and therefore fatty liver diseases might have high 
Fn14 protein levels despite having low Fn14 mRNA due to a defect in Fn14 protein 
degradation. The Fn14 receptor might be somehow stabilised and is therefore 
protected from lysosome degradation. This would allow the cells to maintain high 
Fn14 proteins levels without requiring mRNA synthesis.  
 
In healthy livers, Fn14 expression was localised in blood vessels and bile ducts. In ALF 
on the other hand, Fn14 staining was detected in blood vessels and bile ducts but also 
in DRCs and in cells at the periphery of the fibrotic septum. This is in accordance 
with a study by Affò et al., who showed Fn14 expression in parenchymal cells around 
the fibrogenic septum in alcoholic hepatitis (Affò et al., 2012). Using serial liver 
sections, Affò et al. suggested that Fn14 was expressed by intermediate hepatocytes 
and a subpopulation of DRCs.  
Our data has shown that Fn14-positive DRCs were also detected in samples from 
patients with end-stage PSC and PBC. DRCs are a heterogeneous cell population that 
also contains LPCs (Gouw et al., 2011). In mice, Fn14 has been identified on LPCs 
and investigations have shown that TWEAK acts as a mitogen for LPCs (Tirnitz-
Parker et al., 2010; Jakubowski et al., 2005). Overexpression of TWEAK in mice led 
to increased LPC proliferation (Jakubowski et al., 2005) whereas inducing LPC 
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proliferation with the CDE diet in Fn14 KO mice reduced the number of LPCs 
compared to their WT controls (Tirnitz-Parker et al., 2010).  
Although Fn14 staining was very prominent on DRCs in biliary liver diseases, 
examination of other chronic liver diseases including NASH, ALD and AIH 
demonstrated Fn14 expression in LMFs in the fibrotic scar. Very little is known about 
the expression of Fn14 in liver fibrosis but a study by Tirnitz-Parker et al. has shown 
that Fn14 KO mice that were fed the CDE diet had less liver fibrosis than their WT 
controls (Tirnitz-Parker et al., 2010). Studies in other organs have also shown that the 
TWEAK/Fn14 pathway affects fibrosis. Overexpression of TWEAK in mouse models 
lead to cardiac fibrosis and kidney fibrosis (Jain et al., 2009; Hotta et al., 2011) 
whereas deletion of Fn14 protected against cardiac fibrosis (Novoyatleva et al., 2013). 
This suggests that the Fn14-positive LMFs might be involved in fibrogenesis upon 
stimulation with TWEAK.  
 
Few studies have been conducted that investigate the presence of TWEAK in the 
liver. A study by Kawakita et al. has shown TWEAK staining in human livers with 
HCC (Kawakita et al., 2004) but to our knowledge nobody has yet looked extensively 
at TWEAK expression in a range of human liver diseases. In normal human livers, 
TWEAK staining was weak which was also reflected in low levels of TWEAK 
transcripts. In contrast, TWEAK transcript levels were significantly higher in fatty 
liver diseases and PBC whereas samples from patients with ALF, PSC and AIH 
demonstrated no significant differences of TWEAK mRNA levels compared to 
normal livers.  
Despite varying levels of TWEAK transcripts, acute and chronic liver diseases had 
enhanced TWEAK protein expression that was localised to infiltrating leukocytes in 
 106 
the portal area. This was consistent with published work by Tirnitz-Parker et al. who 
demonstrated the presence of TWEAK mRNA in activated monocytes, macrophages 
and NK cells in mouse livers (Tirnitz-Parker et al., 2010). My data also showed that 
TWEAK was present in the sinusoids of cirrhotic livers but it was not clear whether 
TWEAK was expressed by HSCs, Kupffer cells or endothelial cells in the sinusoids. In 
addition, TWEAK was localised to vimentin-positive HSCs/LMFs in the fibrotic 
septum of diseased liver tissue similarly to the Fn14 staining. Whether TWEAK-
positive HSCs/LMFs also express Fn14 at the same time or whether subpopulations 
of HSCs/LMFs express either Fn14 or TWEAK remains to be determined. 
 
LMFs are considered to be the main contributor of ECM in liver fibrosis. In vitro data 
has shown that TWEAK regulates fibroblast activation and collagen deposition in 
other settings (Novoyatleva et al., 2013; Dohi and Burkly, 2012). In accordance with 
that, my investigations demonstrated a positive correlation between TWEAK and 
Fn14 expression and the amount of collagen in chronic liver diseases. However, some 
samples seemed to be potential outliers but the investigated patients did not have any 
signs of infections or took unusual drugs compared to the other patients that might 
have affected Fn14 or TWEAK expression. Nevertheless, due to various other factors 
that could have affected expression levels it would be useful to increase the number of 
samples. Of note, a positive correlation between Fn14 mRNA and the numbers of 
LPCs was also detected in mice treated with the CDE diet (Tirnitz-Parker et al., 
2010).  
 
Fn14 can be expressed by both LMFs and DRCs, which indicates a possible co-
regulation of ductular reaction and fibrogenesis through the TWEAK/Fn14 pathway. 
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Evidence has shown that ductular reactions are directly proportional to levels of 
fibrosis (Williams et al., 2014) and studies in mice indicated a potential link between 
TWEAK-mediated LPC proliferation and fibrogenesis (Tirnitz-Parker et al., 2010; 
Kuramitsu et al., 2013). Fn14-deficient mice subjected to the CDE diet not only 
showed reduced LPC proliferation but also exhibited less collagen deposition and 
reduced transcript levels of TIMP 1 and 2 (Tirnitz-Parker et al., 2010). Another study 
by Kuramitsu et al. demonstrated that administration of recombinant TWEAK in 
fibrotic mice that were undergoing PH induced LPC proliferation but also increased 
levels of fibrosis (Kuramitsu et al., 2013). Despite this the mechanism by which 
TWEAK might influence fibrosis has not been investigated, and it is not known 
whether the effect occurs directly or indirectly via the ductular reaction. Nevertheless, 
liver tissue taken from patients with NASH, ALD and AIH that exhibited very little or 
no ductular reaction demonstrated expression of TWEAK and Fn14 by LMFs in the 
fibrotic scar indicating that the TWEAK/Fn14 pathway may act on fibrogenesis 
directly. 
 
In conclusion, this chapter demonstrates an upregulation of TWEAK and Fn14 in 
acute and chronic liver diseases in humans. Expression of TWEAK and Fn14 is 
directly linked to the levels of collagen deposition in end-stage liver diseases and Fn14 
and TWEAK are expressed by LMFs in the fibrotic septum. The abundance of 
TWEAK and Fn14 during liver disease raises the possibility of the TWEAK/Fn14 
pathway as a potential target for the modulation of liver disease. The next chapter will 
therefore investigate the regulation and function of TWEAK and Fn14 in HSCs and 
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Liver fibrosis is associated with excess accumulation of ECM that can progress to 
cirrhosis, which is characterised by the lack of normal liver architecture and the 
replacement of functional parenchyma with scar tissue (Schuppan and Kim, 2013). 
Research by Mederacke et al. using fate tracing confirmed that HSCs are the main 
progenitors of LMFs in fibrosis of toxic, cholestatic and fatty liver disease in vivo 
(Mederacke et al., 2013). Following liver injury HSCs activate and transdifferentiate 
into myofibroblast-like cells, which then migrate, proliferate, secrete ECM proteins 
and pro-inflammatory and pro-fibrogenic cytokines. Therefore, HSCs are prime 
targets for anti-fibrotic therapies.  
 
The interaction between TWEAK and Fn14 is known to be important in fibrosis in 
several organs (Burkly et al., 2011). Studies show that overexpression of TWEAK in 
mouse models lead to cardiac fibrosis and kidney fibrosis (Jain et al., 2009; Hotta et 
al., 2011). In vitro data has shown that TWEAK acts directly on myofibroblasts to 
induce activation and collagen production (Dohi and Burkly, 2012; Novoyatleva et al., 
2013). We therefore hypothesised that TWEAK acts on HSCs and LMFs to promote 
fibrosis. This chapter therefore investigates the expression and function of TWEAK 
and Fn14 in vitro, focusing on the regulation of Fn14 during HSC activation and the 
effect of TWEAK stimulation on HSCs. 
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4.2 Results 
4.2.1 Characterisation of HSCs and LMFs in vitro  
To investigate Fn14 expression in vitro, HSCs were isolated either from the non-
affected area of human liver samples removed for the treatment of malignant disease 
or from normal donor tissue surplus to surgical requirements (Figure 4.1). Shortly 
after isolation, HSCs were stained with Oil Red O to confirm the characteristic lipid 
vacuoles in the HSC cytoplasm. After 4 days in vitro, HSCs were more activated, 
started to lose the lipid vacuoles and acquired a spindle shaped morphology. Most of 
the experiments were carried out with HSCs that had been in culture for more than 
30 days (4th passage) and had fully transformed into activated HSCs (Figure 4.1 A). 
Immunohistochemical staining of activated HSC cultures showed that they expressed 
the activated HSC/LMF markers α-SMA, vimentin and CD90. The markers CD31, 
CK19, CD68 and hepatocyte marker were used to exclude contamination with 
endothelial cells, cholangiocytes, Kupffer cells/macrophages and hepatocytes, 
respectively (Figure 4.1 B). In addition, LMFs from end-stage liver diseases were 
isolated and phenotyped using HSC/LMF markers (Figure 4.2 A) and negative 
markers were used to assess contamination (Figure 4.2 B). The purity of the cell 
cultures was above 95%.  
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Figure 4.1 Phenotypic characterisation of primary human HSCs 
Morphology of HSCs in vitro during HSC transformation. Oil Red O (ORO) staining 
demonstrated the fat-storing abilities of HSCs. Magnification X10 and X40 (A) 
Immunohistochemistry staining of activated HSCs in vitro for HSC/LMF markers, α-
SMA, vimentin, CD90 and negative markers, CD31, CK19, CD68 and hepatocyte 




Figure 4.2 Phenotypic characterisation of LMFs isolated from human 
chronic liver diseases 
Immunofluorescent staining of LMFs in vitro for HSC/LMF markers, α-SMA, 
vimentin, CD90. Magnification X40 (A) Negative markers, CD31, CK19 and CD68 
were used to assess contamination. Magnification X10 (B) Staining with an isotype-
matched control is shown at X40 and X10 magnification (C). 
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4.2.2 Expression of Fn14 in liver derived cells in vitro is highest in HSCs 
and LMFs 
Immunohistochemical staining in diseased liver tissue demonstrated that several 
different cell types expressed Fn14 (Figure 3.6, Figure 3.7). Therefore, Fn14 transcript 
levels were quantified in different primary liver derived cell types in vitro including 
HSCs, LMFs, hepatocytes, cholangiocytes and IHECs using qPCR (Figure 4.3). All 
investigated cell types expressed Fn14 mRNA but the transcript levels were higher in 
HSCs and LMFs compared to hepatocytes, cholangiocytes and IHECs.  
To further investigate Fn14 expression in vitro, protein levels were assessed in HSCs, 
LMFs and IHECs by flow cytometry (Figure 4.4). A greater proportion of HSCs 
expressed Fn14 (74.4%) than LMFs (58.5%) and IHECs (35.6%) (Figure 4.4 B). The 
extent of Fn14 expression per cell, as indicated by MFI, was similar in HSCs and 
LMFs but lower in IHECs (Figure 4.4 C). Fn14 expression in HSCs and LMFs was 
confirmed by dual colour immunofluorescent staining of Fn14 and α-SMA (Figure 
4.5). The staining pattern suggested that Fn14 was mainly present intracellularly in 




Figure 4.3 Expression of Fn14 mRNA in different primary liver-derived 
cells 
Expression of Fn14 was assessed by qPCR in HSCs, LMFs, hepatocytes (a kind gift 
from Mr Ricky Bhogal), cholangiocytes and IHECs. Gene expression is shown relative 







































Figure 4.4 Fn14 protein levels in different liver-derived cells 
Total Fn14 protein expression was assessed with flow cytometry. Representative flow 
cytometry scatter plots, histogram of live/dead cells, scatter plots and histograms for 
HSCs, LMFs and IHECs stained for Fn14 (red in histogram) and an isotype control 
(blue in histogram) (A) Data represents percentage positive cells (B) and median 
fluorescent intensity (MFI) of cells expressing Fn14 (both surface and intracellularly) 




Figure 4.5 Immunofluorescent staining of Fn14 in HSCs and LMFs 
Immunofluorescent staining of Fn14 (green) and α-SMA (red) in methanol-fixed 
HSCs and LMFs. Isotype matched control is shown. Co-expression of Fn14 and α-
SMA is indicated in yellow. DAPI (blue) was used as a nuclear counterstain. Scale bar 
50 μm 
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4.2.3 Regulation of Fn14 in HSCs in vitro 
Expression of Fn14 in normal livers is low but becomes upregulated during injury 
(Figure 3.6). Therefore we investigated the extent of Fn14 expression during HSC 
transformation (Figure 4.6). Fn14 expression was detected as early as day 3 after 
isolation when HSCs were not yet expressing the activation marker, α-SMA. The 
staining was localised around the nucleus indicative of new Fn14 protein synthesis. 
Over a period of 14 days, HSCs became more active and started to express α-SMA. 
During HSC activation, Fn14 expression was increased and became distributed 
throughout the HSC cytoplasm at days 9 and 14 (Figure 4.6).  
 
During fibrogenesis, many cytokines are released that could potentially affect Fn14 
expression in HSCs. Fn14 expression in other cell types was increased with a range of 
cytokines including bFGF and TNF-α depending on the cell type (Winkles, 2008). To 
investigate Fn14 expression further, HSCs were treated with bFGF, TGF-β1, TNF-α 
or IFN-γ for 24 hours in vitro and Fn14 mRNA levels were measured by qPCR. 
Exposure to bFGF and TGF-β1 upregulated Fn14 mRNA whereas TNF-α had no 
effect on Fn14 expression. IFN-γ seemed to decreased Fn14 mRNA levels (Figure 
4.7).  
To gain insight into Fn14 localisation, HSCs were treated with either bFGF, TGF-β1 
or left untreated and then fluorescently stained for Fn14 and α-SMA (Figure 4.8). 
Analysis of the Fn14 staining pattern in HSCs revealed that Fn14 was mainly located 
inside the cell (Figure 4.8 A). A representative histogram is shown of Fn14 and α-SMA 
intensity throughout a cell following bFGF stimulation (Figure 4.8 B). α-SMA is an 
isoform of actin and is therefore located intracellularly with close proximity to the cell 
surface. Fn14 expression was localised throughout the cell and close to the surface but 
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no obvious differences in Fn14 localisation were detected with bFGF or TGF-β1 
stimulation compared to untreated controls. Z-stacks of HSCs also indicated that 
Fn14 was mainly located intracellularly (Figure 4.8 C).  
Immunofluorescent staining to determine Fn14 localisation did not clarify whether 
Fn14 was only located intracellularly or whether some cells also expressed it on the 
cell surface. Therefore, flow cytometry was used to investigate the localisation of Fn14 
further (Figure 4.9). Approximately 90% of HSCs contained intracellular stores of 
Fn14 and this did not change significantly following treatment with either bFGF, 
TGF-β1, TNF-α or IFN-γ (Figure 4.9 B). The total expression of Fn14 per cell, as 
indicated by the MFI, did also not change significantly with any cytokine stimulation 
compared to untreated HSCs (Figure 4.9 C). On average 35% of HSCs expressed 
Fn14 on the cell surface (Figure 4.9 E). This was significantly increased with TGF-β1 
stimulation (56% +/- 6.8%; p <0.05). Stimulation with bFGF also enhanced the 
number cells expressing Fn14 on the surface (57% +/- 9.3%) but this did not reach 
significance. TNF-α (47% +/-2.5%) or IFN-γ (37% +/- 7.9%) had little effect on 
Fn14 cell surface expression in HSCs (Figure 4.9 E). The total surface expression 
levels of Fn14 cell did not change significantly per cell with either treatment compared 





Figure 4.6 Expression of Fn14 during HSC transformation 
Immunofluorescent staining of Fn14 (green) and α-SMA (red) in HSCs during the 
activation period in vitro. Insert: image digitally enlarged. DAPI (blue) was used as a 
nuclear counterstain. Scale bar 50 μm 
 120 
 
Figure 4.7 Effect of cytokines on Fn14 mRNA in HSCs 
Expression of Fn14 was assessed by qPCR in untreated HSCs or HSCs treated with 
bFGF (10 ng/mL), TGF-β1 (10 ng/mL), TNF-α (10 ng/mL) or IFN-γ (100 ng/mL) 
for 24 hours in vitro. Gene expression is shown as fold change relative to GUSB. (n=4 




















































Figure 4.8 Localisation of Fn14 in HSCs 
Immunofluorescent staining for Fn14 (green) and α-SMA (red) in untreated, bFGF (10 
ng/mL) or TGF-β1 (10 ng/mL) treated primary HSCs for 24 hours in vitro (A). 
Representative histogram of Fn14, α-SMA and DAPI staining intensity through a 
cross sections of a bFGF-treated HSCs (B). Confocal Z-stack of bFGF-treated HSCs 




Figure 4.9 Effect of cytokines on intracellular and cell surface Fn14 
expression  
Flow cytometry analysis of intracellular (A-C) and cell surface (D-F; see next page) 
Fn14 expression in unstimulated and bFGF (10 ng/mL), TGF-β1 (10 ng/mL), TNF-α 
(10 ng/mL) or IFN-γ (100 ng/mL) stimulated HSCs for 24 hours in vitro. 
Representative histograms of Fn14 staining (red) and isotype control (blue) (A) 
percentage positive cells (B) and median fluorescent intensity (MFI) (C) of 
intracellular Fn14 expression. Representative histograms (D) of percentage positive 
cells (E) and MFI (F) of cell surface Fn14 expression. (n=3 different isolates) (*p<0.05, 





Figure 4.9 Continued 
 
 
4.2.4 The effect of recombinant TWEAK on HSCs 
After demonstrating that HSCs express Fn14 we investigated how its ligand TWEAK 
affects HSC proliferation. Activated HSCs were therefore treated with different 
concentrations of recombinant TWEAK and the nuclei were counted before and after 
TWEAK stimulation (Figure 4.10 A). Enhanced proliferation was detected in 
TWEAK-treated HSCs compared to untreated controls. The highest proliferative 
response was detected when HSCs were treated with 100 ng/mL TWEAK, which 
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induced proliferation to a similar extent as PDGF-BB dosing after 48 hours using the 
CyQuant assay (Figure 4.10 B). 
In contrast, HSC activation was reduced following TWEAK treatment. A significant 
reduction of ACTA2 (α-SMA) was detected when HSCs were treated with 100 or 500 
ng/mL TWEAK compared to untreated HSCs (p<0.05; Figure 4.11 A). Interestingly, 
COL1A1 (Collagen1a1) did not change in HSCs after stimulation with different 
TWEAK concentrations in vitro (Figure 4.11 B).  
Next to production of ECM, HSCs are involved in leukocyte recruitment by secreting 
large amounts of chemokines including CCL2, CCL3, CCL5, CXCL8, CXCL9, and 
CXCL10 (Holt et al., 2009). CCL5 not only facilitates recruitment of immune cells it 
also directly affects HSC proliferation (Liaskou et al., 2013; Schwabe et al., 2003). 
TWEAK is a pro-inflammatory cytokine and in order to get an insight on the effect of 
TWEAK on chemokine production, CCL5 levels in culture supernatant from 
TWEAK-stimulated HSCs were determined (Figure 4.12). As shown in Figure 4.12 
the levels of CCL5 were slightly but not significantly increased in HSCs upon 
TWEAK stimulation compared to unstimulated HSCs. Levels of CCL5 mRNA were 
not measured. 
 
TWEAK treatment of Fn14-positive cells activates predominantly the NF-κB pathway 
(Winkles, 2008). Furthermore, TWEAK’s sibling TNF-α plays a key role in HSC 
homeostasis by regulating anti-apoptotic signals through the NF-κB pathways (Cong 
et al., 2012). Therefore, I investigated whether TWEAK can also affect NF-κB 
signalling in HSCs. Indeed, TWEAK induced phosphorylation and translocation of 
NF-κB into the nucleus as early as 5 min (Figure 4.13). Activation of the canonical 
NF-κB pathways was then sustained for at least 24 hours. 
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Figure 4.10 HSC proliferative response upon TWEAK stimulation 
Activated HSCs were stimulated with different concentrations of recombinant 
TWEAK and nuclei were counted and normalised to cell number at the start of the 
experiment (n=1) (A). HSCs were stimulated with TWEAK (100 ng/ml) or PDGF-
BB (10 ng/ml) for 48 hrs in vitro and DNA levels were measured with the CyQuant kit 
to determine cell proliferation. (n=3 different isolates) 
 
 
Figure 4.11 Expression levels of ACTA2 and COL1A1 in HSCs upon 
TWEAK stimulation 
Activated HSCs were stimulated with different concentrations of recombinant 
TWEAK for 24 hours and expression of ACTA2 and COL1A1 were measured by 
qPCR. Gene expression is shown relative to GUSB using the 2-ΔCt method. (n=4 from 





Figure 4.12 Effect of TWEAK on CCL5 production in HSCs 
Activated HSCs were treated with TWEAK (100 ng/ml) for 24 hours. The 
concentrations of CCL5 released in the supernatant were measured by Luminex. 




Figure 4.13 Effect of TWEAK on NF-κB activation in HSCs 
HSCs were treated with 100 ng/ml TWEAK for the indicated period. Representative 
blots of cytoplasmic (A) and nuclear (B) phosphorylated (p) and total NF-κB (p65) and 
β-tubulin are shown. Quantification of p-NF-κB in relation to total NF-κB in the 



















4.2.5 TWEAK is expressed by HSCs 
To date TWEAK expression has been associated with macrophages and NK cells in 
the liver (Tirnitz-Parker et al., 2010). However, immunofluorescent staining in section 
3.2.4.4 has shown that TWEAK is also present in α-SMA-positive cells (Figure 3.13). 
To further investigate TWEAK expression, the supernatant of HSCs was collected 
and TWEAK levels were measured by ELISA (Figure 4.14). The data shows that 
TWEAK expressed by HSCs can be released into the culture media, albeit to a lesser 
extent than macrophages (a well described source of TWEAK protein) (Figure 4.14 
A). Measuring TWEAK levels in HSC culture media following stimulation with TGF-
β1 (Figure 4.14 B) TNF-α, IFN-γ, IL-1β (Figure 4.14 D-G) or IL-13 (Figure 4.14 H) 
did not demonstrate a conclusive up or downregulation of TWEAK expression in 
HSCs. Increased TWEAK levels were consistently detected in the supernatant from 
HSCs stimulated with PDGF-BB but this could be due to increased proliferation of 
HSCs (Figure 4.14 C). Detection of endogenous TWEAK in HSC supernatant led us 
to investigate how it might affect HSC behaviour. Incubation with varying 
concentrations of a TWEAK monoclonal function-blocking antibody for 24 hours 





Figure 4.14 Effect of cytokines on TWEAK expression in HSCs 
The concentration of TWEAK released in the supernatant was measured by ELISA 
in HSCs (n=3) and monocyte-derived macrophages (n=1). TWEAK levels in HSC 
growth medium alone were not detectable (n.d.) (A). TWEAK was also measured in 
supernatant of HSCs treated with TGF-β1 (B), PDGF-BB (C), TNF-α (D) or IFN-γ 
(E), or a combination of TNF-α and IFN-γ (F), IL-1β (G) or IL-13 (F) (all 10 ng/ml) 
for 24 hours. (n=3 different isolates) No significant difference was detected. (Mann-
Whitney U test) 
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Figure 4.15 Inhibiting endogenous TWEAK with mAb in HSCs 
Activated HSCs were treated with the indicated concentrations of monoclonal 
TWEAK function-blocking antibodies or a matched isotype control antibody for 24 
hours. Representative images are shown (cells outlined in pink) (A). Data are 
expressed as area occupied by cells compared to isotype-matched control (negative 
values indicate reduced area covered by cells) (B). (n=1) 
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4.3 Discussion 
In chapter 3 I have shown that TWEAK and Fn14 expression is only upregulated 
during liver disease, suggesting a regulatory role in the pathway of tissue injury and 
regeneration. Histopathological examination of different liver diseases in chapter 3 
demonstrated that Fn14 was expressed by a variety of cell types. This chapter 
supports this observation through qPCR analysis of Fn14 transcript levels in primary 
LMFs, HSCs, hepatocytes, cholangiocytes and IHECs in vitro. Furthermore this 
chapter demonstrates the regulation of Fn14 during HSC activation, and that 
TWEAK was capable of inducing HSC proliferation possibly via NF-κB signalling 
which could promote the development of liver fibrosis. 
 
Liver injury causes quiescent HSCs to become activated and to proliferate. Fn14 
expression in HSCs was detected prior to the expression of the activation marker α-
SMA suggesting that Fn14 is regulated by transcription factors that play a role in early 
transformation and that Fn14 expression might be turned on during early fibrosis. 
Enhanced Fn14 expression during cell transformation has also been demonstrated in 
the corneal stroma where quiescent keratocytes start expressing Fn14 after they had 
activated during injury (Ebihara et al., 2009). As Fn14 is expressed before α-SMA it 
could be hypothesised that Fn14 is involved in the regulation of α-SMA. However, 
isolations of HSCs from Fn14 KO mice did not seem to suggest that it does as the 
cells did express α-SMA (data not shown). Furthermore, as shown in chapter 5, α-
SMA expression in Fn14 KO was not significantly different compared to WT mice. 
 
As Fn14 expression seemed to be dependent on phenotypic transdifferentiation of 
HSCs during liver injury we investigated factors that can induce Fn14 expression 
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further. Flow cytometry demonstrated that most unstimulated HSCs had intracellular 
stores of Fn14 and a population of HSCs also expressed Fn14 on the cell surface. 
Therefore, HSCs were treated with cytokines known to induce Fn14 expression in 
other cell types (Winkles, 2008) and that have been detected in fibrotic liver tissue 
(Reeves and Friedman, 2002). FGF is a well-known cytokine to induce Fn14 
expression (Winkles, 2008). It is upregulated during liver fibrosis and is a HSC 
mitogen (Reeves and Friedman, 2002). Stimulation of HSCs with bFGF led to a slight 
increase of Fn14 mRNA and Fn14 cell surface expression but this did not reach 
significance. Stimulation of another pro-fibrogenic factor, TGF-β1 significantly 
enhanced Fn14 mRNA levels in HSCs. In addition, TGF-β1 enhanced the number of 
HSCs expressing Fn14 on the cell surface making them potentially more susceptible to 
stimulation with TWEAK and might increase the probability of ligand-independent 
signalling by the receptor (Brown et al., 2013). The pro-inflammatory cytokine, TNF-
α had little effect on Fn14 mRNA levels and cell surface expression. TNF-α has also 
been associated with HSC activation but compared to TGF-β1, TNF-α reduces 
synthesis of type I and III collagen in HSCs (Reeves and Friedman, 2002). IFN-γ, 
another pro-inflammatory cytokine, has been associated with inhibiting HSC 
activation and proliferation (Reeves and Friedman, 2002). It slightly decreased Fn14 
mRNA levels and did not affect cell surface expression in HSCs. This suggests that 
pro-fibrogenic cytokines rather than pro-inflammatory factors induce Fn14 expression 
and promote cell surface expression in HSCs. Similarly, PDGF-BB, the most potent 
mitogen for HSCs, also requires activation dependent expression of its receptor which 
can be induced by pro-fibrogenic cytokines such as TGF-β1 (Bonner, 2004).  
Since a population of HSCs expresses Fn14 on the cell surface we wanted to 
investigate the role of TWEAK on HSCs. During fibrogenesis HSCs differentiate, 
 132 
produce ECM and proliferate. My data has shown for the first time that HSCs show 
enhanced proliferative capacity in the presence of TWEAK. In contrast, ACTA2 was 
significantly downregulated in HSCs upon TWEAK stimulation suggesting that 
TWEAK is involved in enhancing HSC proliferation and decreasing HSC 
differentiation. It has been demonstrated in a number of other cell types that 
TWEAK can regulate proliferation and differentiation. In hepatoblasts, skeletal 
myoblasts and osteoblasts TWEAK promoted proliferation but inhibited 
differentiation (Ando et al., 2006; Dogra et al., 2006; Girgenrath et al., 2006). In 
addition, TWEAK inhibited transformation of keratocytes into myofibroblasts in vitro 
(Ebihara et al., 2009). Furthermore, my data also demonstrated that TWEAK 
stimulation did not have an effect on collagen synthesis in HSCs. In contrast, other 
studies have demonstrated that TWEAK induces collagen expression in cardiac 
fibroblasts via Fn14 (Chen et al., 2012; Novoyatleva et al., 2013). Although TWEAK 
appeared to inhibit activation of HSCs and did not alter COL1A1 expression, Fn14 
KO mice had reduced liver fibrosis compared to their WT controls when fed the 
CDE diet (Tirnitz-Parker et al., 2010). TWEAK might therefore be important in 
expanding the HSC population and other factors such as TGF-β1 serve to enhance 
ECM deposition of HSCs. In addition TWEAK might increase expression of protein 
but not mRNA levels of collagen I or it might alter expression of other ECM proteins 
such as collagen III, fibronectin and tenascin. These proteins could be measured with 
western blot or ELISA. In addition, collagen levels could be measured with the 
hydroxyproline assay. 
 
Liver fibrosis is closely associated with inflammation and HSCs have been shown to 
express pro-inflammatory chemokines such as CCL2 and CCL5 and chemokine 
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receptors such as CCR5 (Pellicoro et al., 2014). CCL5 facilitates leukocyte 
recruitment (Liaskou et al., 2013) and directly targets HSCs to promote proliferation 
and migration (Schwabe et al., 2003) thereby perpetuating the fibrotic response. Here, 
it appears to be a trend that TWEAK increases CCL5 expression in HSCs. Therefore 
TWEAK might not only act directly on HSCs but also increases expression of other 
factors that amplify fibrogenesis. 
TWEAK induced intracellular signalling pathways in HSCs are unknown. To explore 
the mechanism by which TWEAK stimulates HSCs, we investigated the NF-κB 
pathway. TWEAK led to a quick activation of the canonical NF-κB pathway in 
HSCs, which was as early as 5 minutes and was maintained for 24 hours. Activation 
of the canonical NF-κB pathway in HSCs has been associated with HSC survival (Cui 
et al., 2010; Wang et al., 2014) suggesting that NF-κB may promote the persistence of 
activated HSCs via TWEAK. 
 
TWEAK expression in the liver has so far been demonstrated by infiltrating 
leukocytes (Tirnitz-Parker et al., 2010). During human liver disease TWEAK 
expression was upregulated (Figure 3.1) and detected in LMFs amongst other cell 
types (Figure 3.13). Consistent with these results, activated HSCs secreted TWEAK 
into their medium, suggesting the presence of an autocrine loop. Therefore, HSCs 
were treated with a blocking antibody known to inhibit TWEAK signalling (Dohi et 
al., 2014). Indeed, blocking endogenous TWEAK demonstrated a decrease in HSC 
migration suggesting that endogenous TWEAK maintains HSCs in a migratory state. 
However, this experiment has only been carried out once and needs to be repeated 
several times. In addition, it would be useful to investigate whether the blocking 
antibody inhibits cell signalling. As shown by Yadava et al. administration of the same 
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blocking antibody in a mouse model of skeletal muscle wasting led to decreased levels 
of Nfkb2 and RelB (Yadava et al., 2015). Using this approach might then also show a 
dose response with different concentrations of TWEAK blocking antibody. 
 
In conclusion, our data supports a role of TWEAK and Fn14 interaction in 
promoting fibrogenic responses in the liver. During HSC activation Fn14 expression 
increases and both HSCs and LMFs express Fn14. TWEAK dependent Fn14 
signalling induced HSC proliferation and TWEAK blocking mAb reduced migration, 
suggesting that TWEAK could act via both autocrine and paracrine mechanisms 
driven by HSC production of TWEAK. Therefore, the next chapter will investigate 










The role of TWEAK and Fn14 in liver 
fibrosis in vivo 
 




TWEAK and Fn14 KO mice have been used in a variety of experimental models to 
assess the contribution of TWEAK and Fn14 in physiological and pathological 
settings (Karaca et al., 2014; Girgenrath et al., 2006; Jain et al., 2009). Liver 
regeneration has been investigated in Fn14 KO mice treated with the CDE diet, and 
when compared to WT mice the Fn14 KO mice had fewer LPCs and less collagen 
deposition (Tirnitz-Parker et al., 2010). Evidence has shown that a correlation exists 
between ductular expansion and the severity of fibrosis (Williams et al., 2014). 
Whether TWEAK signalling can promote liver fibrogenesis through direct 
interactions with HSCs has been investigated in chapter 4 and these in vitro studies 
showed that HSCs expressed both Fn14 and TWEAK and that they may be involved 
in the development of liver fibrosis through proliferation of human HSCs.  
 
This chapter examines the role of TWEAK and Fn14 in fibrogenesis following acute 
and chronic liver injury in vivo. In order to do so, TWEAK and Fn14 KO mice along 
with their matching WT littermate controls were dosed with the hepatotoxin CCl4. 
CCl4-induced injury has been used extensively to investigate liver injury in rodents. 
CCl4 induces centrilobular necrosis between 24 and 48 hours after administration and 
liver regeneration becomes evident after 48 and 72 hours as a results of HSC 
activation and infiltration of inflammatory cells (Ikejima et al., 2001; Karlmark et al., 
2010). Liver injury causes increased intestinal permeability and bacterial translocation 
(Fouts et al., 2012) and gut microbiota can contribute to fibrogenesis by either directly 
causing HSC activation through the LPS/TLR pathway or via recognition of 
bacterial products by Kupffer cells (Seki et al., 2007; Rivera et al., 2007).  
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Therefore, in this study each KO strain was compared to WT littermate controls to 
avoid differential results caused by a different gut microbiota. The extent of liver 
fibrosis was investigated by expression levels of fibrogenic mediators, accumulation of 






5.2.1 Regulation of TWEAK and Fn14 in acute liver injury 
To investigate the regulation of TWEAK and Fn14 in vivo, WT mice were treated 
once with CCl4 orally to induce acute toxic hepatic damage and then sacrificed after 
24, 48, 72 or 96 hours. Each mouse was weighed before the CCl4 dose (Figure 5.1 A) 
and serum ALT activity was measured at sacrifice (Figure 5.1 B). CCl4-treatment 
resulted in centrilobular necrosis and inflammation (Figure 5.1 C) with most damage 
occurring at 24 and 48 hours that was reflected by significantly elevated serum ALT 
activity (p<0.01, Figure 5.1 B). Mice treated with mineral oil had normal ALT activity 
(Figure 5.1 B) and tissue architecture (Figure 5.1 C).  
Analysis of murine livers revealed a median of 58-, 44-, 33- and 6-fold increase in 
Fn14 mRNA at 24, 48, 72 and 96 hours post CCl4 challenge, respectively compared 
to mineral oil treated controls (Figure 5.2 A). In contrast, levels of TWEAK mRNA 
did not differ significantly between experimental groups although a slight increase 
after 48, 72 and 96 hours was noticed in some animals (Figure 5.2 B). Highest levels of 
TWEAK were observed at 72 hours but they did not reach statistical significance 
(p=0.055). The HSC activation marker α-SMA (Acta2) significantly increased at all 
timepoints after CCl4 injury with the maximal level again being seen at 72 hours 
(Figure 5.2 C). Collagen 1α1 (Col1a1, a major component of collagen 1) was 
significantly upregulated after 48 hours and continued to increase until 96 hours 
(Figure 5.2 D). Of note, the pattern for upregulation of Fn14 was also present in 
chronic liver injury. In a 4 week CCl4-induced liver injury model, Fn14 mRNA was 
upregulated 3.18 fold, (p<0.01; Figure 5.3 A) whereas TWEAK mRNA was not 
elevated above baseline (p=0.412; Figure 5.3 B) as seen in the acute injury model.  
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Figure 5.1 General characteristics of wild type mice with acute liver 
injury 
To induce acute liver injury Balb/c WT mice received one oral dose of CCl4 or 
mineral oil and were sacrificed at the time points indicated. Each mouse was weighed 
before the experiment and the volume of CCl4 was adjusted accordingly (1 mL/kg 
body weight) (A). Serum ALT activity was assessed as a measure of acute liver injury 
(B). Representative images of haematoxylin-eosin staining of paraffin-embedded liver 
tissue sections is shown (C) (n=4-5 animals each per group). (**p<0.01 or n.s. non 








Figure 5.2 Fn14 but not TWEAK mRNA significantly increases following 
acute CCl4 injury 
Murine Fn14 mRNA, TWEAK mRNA, Acta2 and Col1a1 were analysed in liver tissue 
from WT animals by qPCR following acute CCl4-induced liver injury, or mineral oil 
control, at the time points indicated. Data are expressed as fold change compared to 
mineral oil control. The dashed line indicates mRNA levels of mineral oil treated WT 
mice (n=4-5 animals per group). (*p<0.05 or **p<0.01 Mann-Whitney U test) 
 
 
Figure 5.3 Chronic CCl4-induced liver injury leads to significant 
upregulation of Fn14 but not TWEAK mRNA 
Fn14 and TWEAK mRNA were analysed in liver tissue from WT animals following 
chronic CCl4-induced liver injury. Control animals were exposed to mineral oil alone. 
Gene expression is shown relative to Rn18s using the 2-ΔCt method (n=5-7 animals per 
group). (*p<0.05 Mann-Whitney U test) 
 
 141 
5.2.2 Acute liver injury in TWEAK and Fn14 KO mice 
To further assess the potential functional role of TWEAK and Fn14 in hepatic injury 
and fibrogenesis in vivo, TWEAK KO and Fn14 KO mice along with their matched 
WT controls were subjected to a single dose of CCl4 and subsequently sacrificed after 
72 hours. Prior to CCl4 administration, TWEAK KO, Fn14 KO and WT mice 
exhibited no differences in weight (Figure 5.4 A,B) or liver architecture (Figure 5.4 C). 
 
Following CCl4 administration, TWEAK KO mice had similar levels of liver injury 
compared to their WT controls as histological examination demonstrated foci of 
centrilobular necrosis and inflammation in both KO and WT mice treated with CCl4 
(Figure 5.5 A-D). No significant differences were detected in Sirius red staining 
between experimental groups (Figure 5.5 E-H). Assessing transcript levels in acutely 
injured TWEAK KO mice demonstrated significantly lower levels of Col1a1, Tgfb1, 
Mmp2 and Timp1 upregulation in response to injury compared to injured WT controls 
(Figure 5.6 B-D,F). However, levels of Acta2 (p=0.313) and Mmp9 (p=0.138) in injured 
TWEAK KO mice, although higher than uninjured animals, were not significantly 
different than injured WT animals (Figure 5.6 A,E). 
 
Analysis of H&E stained tissue showed that Fn14 KO mice also had similar levels of 
liver injury compared to their WT controls after CCl4 administration (Figure 5.7 A-
D). In addition, no obvious differences were detected in sections stained with Sirius 
red (Figure 5.7 E-H). Examination of fibrogenic mediators demonstrated that Acta2, 
Col1a1, Tgfb1, Mmp9 and Timp1 all significantly increased in Fn14 WT mice treated 
with CCl4 compared to mineral oil (Figure 5.8 A-C,E,F). Mmp2 levels remained 
similar between injured and mineral oil-treated Fn14 WT mice (Figure 5.8 D). 
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Fn14 KO mice treated with CCl4 also demonstrated significantly higher levels of 
Col1a1 and Timp1 compared to mineral oil treated controls (Figure 5.8 B,F). Acta2, 
Tgfb1, Mmp2 and Mmp9 in Fn14 KO did not show a difference between CCl4 or 
mineral oil administration (Figure 5.8 A,C-E). 
Surprisingly, injured Fn14 KO mice demonstrated no significant difference of 
fibrogenic mediators compared to injured Fn14 WT mice though there were a trend 
to reductions in the expression of Acta2, Mmp9 and Timp1 in the Fn14 KO mice 
(Figure 5.8). Further examination of collagen protein levels using the hydroxyproline 
assay also demonstrated no significant difference between Fn14 WT or KO mice 




Figure 5.4 TWEAK and Fn14 WT and KO mice display no differences in 
weight or liver tissue architecture at baseline 
Weight (A) and liver histology (B) was assessed in Balb/c Fn14 and TWEAK WT 
and KO mice. Representative images of haematoxylin-eosin staining of paraffin-




Figure 5.5 No apparent differences in liver histology between TWEAK 
WT and KO mice after acute liver injury 
TWEAK WT and KO mice were injected with a single dose of CCl4 or mineral oil 
and sacrificed 72 hours afterwards. Representative images of haematoxylin-eosin 
staining, Bar 200 μm (A-D). Representative staining using Sirius red. Bar, 100 μm (E-
H). Inserts: image digitally enlarged. 
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Figure 5.6 TWEAK is critical for liver fibrogenesis following acute 
hepatic injury in vivo 
TWEAK KO and corresponding WT mice were injected with a single dose of CCl4 
or mineral oil and sacrificed 72 hours afterwards. Expression levels of fibrogenic 
mediators were analysed by qPCR (n=5-7 animals per group). Gene expression is 
shown relative to Gapdh using the 2-ΔCt method. (*p<0.05, **p<0.01 or n.s. non 
significant, Mann-Whitney U test) 
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Figure 5.7 Fn14 KO had similar levels of liver injury compared to Fn14 
WT mice 
Fn14 WT and KO mice were injected with a single dose of CCl4 or mineral oil and 
sacrificed 72 hours afterwards. Representative images of haematoxylin-eosin staining, 
Bar 200 μm (A-D). Representative staining of Sirius red. Bar, 100 μm (E-H). Insert: 





Figure 5.8 Fn14 deletion does not affect levels of fibrogenic mediators 
after acute liver injury significantly 
Fn14 KO and corresponding WT mice were injected with a single dose of CCl4 or 
mineral oil and sacrificed 72 hours afterwards. Expression levels of fibrogenic 
mediators were analysed by qPCR (n=4-7 animals per group). Gene expression is 
shown relative to Gapdh using the 2-ΔCt method. (*p<0.05, **p<0.01 or n.s. non 




Figure 5.9 Hydroxyproline content does not change in Fn14 WT and KO 
mice following acute CCl4-induced liver injury  
Fn14 KO and corresponding WT mice were injected with a single dose of CCl4 or 
mineral oil and sacrificed 72 hours afterwards. Liver fibrosis was assessed by the 
hydoxyproline content of the liver (n=3-7 animals per group). Statistical significance is 
represented as n.s. non significant (Mann-Whitney U test) 
 
 
5.2.3 Chronic liver fibrosis in TWEAK KO mice 
To examine the effect of TWEAK on chronic liver fibrosis, TWEAK KO and 
TWEAK WT mice were treated weekly with CCl4 for 4 weeks. The weight of 
TWEAK KO mice did not differ compared to TWEAK WT mice throughout the 
period of CCl4 treatment (Figure 5.10 A). Liver injury was similar in TWEAK KO 
mice compared to TWEAK WT mice as indicated by ALT activity (p=0.944; Figure 
5.10 B). Histological examination demonstrated foci of centrilobular necrosis and 
inflammation in both TWEAK KO and WT mice (Figure 5.10 C). Necrosis was 
detected between the central veins and the hepatocytes around the portal tracts were 
unaffected. Fewer foci of mineralisation related to dead cells were present in TWEAK 
KO mice compared to TWEAK WT mice (Figure 5.10 D). 
 





























Following chronic CCl4 treatment TWEAK KO mice had a diminished induction of 
Mmp2 expression compared to injured WT controls (p<0.01; Figure 5.11 D). The 
expression of Acta2, Col1a1, Tgfb1, Mmp9 and Timp1 remained unchanged between 
CCl4-treated TWEAK KO and WT mice (Figure 5.11 A-C,E,F). Nevertheless, 
TWEAK KO mice exhibited fewer α-SMA-positive HSCs/LMFs and reduced areas 
of Sirius red staining in the liver compared to WT control animals (Figure 5.12 A,C). 
This was confirmed by image analysis which revealed significantly fewer HSCs/LMFs 
(α-SMA staining; p<0.005) and collagen deposition (Sirius red staining; p<0.005) 





Figure 5.10 Chronic liver injury is similar in TWEAK KO and WT mice 
To induce chronic liver injury TWEAK KO and WT mice received one oral dose of 
CCl4 or mineral oil per week (4 doses in total) and were sacrificed 72 hours after the 
final dose. Each mouse was weight before every dose and the volume of CCl4 was 
adjusted accordingly (1 mL/kg body weight) (A). Serum ALT activity was assessed as 
a measure of acute liver injury (B) and representative images of haematoxylin-eosin 
staining (C) and von Kossa (used to detect mineralisation) staining (D) of paraffin-
embedded liver tissue sections are shown (n=5-7 animals each per group). (**p<0.01 




Figure 5.11 TWEAK KO mice have less Mmp2 after chronic CCl4 
treatment than TWEAK WT mice 
TWEAK KO and WT mice were dosed with CCl4 once a week for four weeks then 
sacrificed three days after the final dose. Mice treated with mineral oil were used as a 
control. Levels of fibrosis-associated transcripts were analysed by qPCR (A-F). Gene 
expression is shown relative to Rn18s using the 2-ΔCt method (n=5-7 animals each per 




Figure 5.12 TWEAK KO mice present with reduced fibrosis upon chronic 
CCl4 treatment 
TWEAK KO and WT mice were dosed with CCl4 once a week for four weeks then 
sacrificed three days after the final dose. Mice treated with mineral oil were used as a 
control. Representative images of α-SMA staining (Scale bar 100 μm) (A) and digital 
quantification of α-SMA expressed as the percentage area of ten randomly selected 
areas per sample (B). Representative images of Sirius red (Scale bar 600 μm) (C) with 
digital quantification of sirius red positive areas of one whole liver section (D) (n=5-7 
animals each per group). (**p<0.01 or ***p<0.005, Mann-Whitney U test). 
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5.2.4 Chronic liver fibrosis in Fn14 KO mice 
As Fn14 is the most commonly described receptor for TWEAK we also investigated 
the effect of Fn14 KO in the CCl4 model of chronic fibrosis. Fn14 KO and WT mice 
had similar weights throughout the experimental period (Figure 5.13 A). In addition, 
ALT activity was the same in Fn14 KO mice compared to Fn14 WT mice (p=0.286; 
Figure 5.13 B). Histological examination demonstrated foci of centrilobular necrosis 
and inflammation in Fn14 KO and WT mice (Figure 5.13 C), similar to that observed 
for TWEAK KO and WT mice. Most fibrogenic mediators were significantly 
upregulated in Fn14 KO and WT mice treated with CCl4 compared to mineral oil 
(Figure 5.14). Acta2 was the only factor that was not significantly higher in injured 
Fn14 WT compared to mineral oil (p=0.073; Figure 5.14 A). Importantly, levels of all 
fibrogenic mediators did not differ significantly in Fn14 KO mice compared to Fn14 
WT mice (Figure 5.14).  
Assessing levels of α-SMA and Sirius red staining showed a significant increase in 
injured Fn14 WT mice compared to mineral oil (Figure 5.15). Fn14 KO mice treated 
with CCl4 also demonstrated more staining of α-SMA and Sirius red compared to 
Fn14 KO mice treated with mineral oil. However, Fn14 KO mice compared to Fn14 
WT mice demonstrated no significant reduction of α-SMA protein levels (p=0.412) or 





Figure 5.13 Fn14 KO and WT mice exhibit similar levels of chronic liver 
injury induced by CCl4 
Chronic liver injury was induced in Balb/c Fn14 KO and WT mice with one oral 
dose of CCl4 or mineral oil per week (4 doses in total) and mice were sacrificed 72 
hours after the final dose. Each mouse was weight before every dose and the volume 
of CCl4 was adjusted accordingly (1 mL/kg body weight) (A). Serum ALT activity 
was assessed as a measure of liver injury (B). Representative images of haematoxylin-
eosin staining of paraffin-embedded liver tissue sections (C) (n=4-7 animals each per 




Figure 5.14 Fn14 KO mice did not demonstrate a reduction in fibrogenic 
marker following chronic liver injury 
Fn14 KO and WT mice were dosed with CCl4 once a week for four weeks then 
sacrificed three days after the final dose. Mice treated with mineral oil were used as a 
control. Levels of fibrosis-associated transcripts were analysed by qPCR (A-F). Gene 
expression is shown relative to Rn18s using the 2-ΔCt method (n=5-7 animals each per 




Figure 5.15 Genetic deletion of Fn14 does not ameliorate chronic CCl4-
induced liver fibrosis  
Fn14 KO and WT mice were dosed with CCl4 once a week for four weeks then 
sacrificed three days after the final dose. Mice treated with mineral oil were used as a 
control. Representative images of α-SMA stained liver tissue sections (Scale bar 100 
μm) (A) and digital quantification of α-SMA expressed as the percentage area of ten 
randomly selected areas per sample (B). Representative images of Sirius red (Scale 
bar 600 μm) (C) with digital quantification of Sirius red positive area of one whole 
liver section (D) (n=5-7 animals each per group). (*p<0.05, **p<0.01, ***p<0.005 or 




Fibrosis is a common pathological process in most liver diseases. Insights into the role 
of TWEAK and Fn14 in liver fibrosis have arisen from experimental models of 
ductular reaction and liver regeneration (Kuramitsu et al., 2013; Tirnitz-Parker et al., 
2010). However, the effect of TWEAK and Fn14 has never been directly investigated 
in a liver injury model primarily associated with fibrosis. This chapter provides a novel 
approach by treating TWEAK and Fn14 KO mice with the fibrogenic stimulus CCl4 
in both acute and chronic settings. Fibrogenesis involves upregulation of pro-
fibrogenic factors such as TGF-β and accumulation of myofibroblasts and ECM. In 
addition, chronic fibrosis is maintained by increased synthesis of TIMP-1 and 
decreased production of fibrolytic MMPs (Popov and Schuppan, 2009). Here, I 
demonstrate the role of TWEAK as a novel stimulator of liver fibrogenesis in vivo as 
evidenced by reduced fibrosis in TWEAK KO animals subjected to acute and chronic 
CCl4 injury models. Furthermore, our data suggests that the fibrogenic effect of 
TWEAK may not exclusively be regulated through Fn14 as Fn14 KO mice had 
similar levels of fibrosis compared to their WT controls. 
 
Acute CCl4-liver injury caused a considerable degree of hepatocellular necrosis that 
was accompanied by early fibrotic changes demonstrated by increased Acta2 and 
Col1a1 expression. Fn14 mRNA peaked as early as 24 hours and was maintained at 
high levels until 96 hours whereas Acta2 was elevated the most at 48 and 72 hours 
after CCl4 administration. A similar pattern was described in chapter 4, where Fn14 
was expressed before α-SMA during HSC activation in vitro. Significantly higher levels 
of Fn14 mRNA were also observed in a chronic model of CCl4-liver injury. However, 
this was not in accordance with a study by Affò et al. who demonstrated no significant 
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increase in Fn14 mRNA after chronic CCl4 injury (Affò et al., 2012). In the study by 
Affò et al. CCl4 was administered via intraperitoneal injections twice weekly whereas 
in our study the mice received CCl4 via oral gavage once a week. Administration of 
CCl4 directly into the stomach of mice rather than the abdomen might have caused 
greater intestinal permeability and hence allowed more translocation of gut 
microbiota to the liver. This might have led to more HSC activation and therefore 
more Fn14 expressing cells (Seki et al., 2007; Rivera et al., 2007) or factors from the 
gut microbiota such as the bacterial component CpG-DNA might have caused have 
caused an upregulation of Fn14 (Dohi et al., 2009). Furthermore, my data 
demonstrated that TWEAK mRNA did not change significantly throughout acute or 
chronic CCl4 injury. These results were similar to previously published data in mice 
on the CDE-diet (Tirnitz-Parker et al., 2010).  
 
As Fn14 mRNA was significantly upregulated following acute and chronic toxic liver 
damage it was surprising that Fn14 KO mice displayed no difference in fibrogenic 
mediators compared to their Fn14 WT controls after 72 hours or 4 weeks of CCl4-
induced injury. Previously, Fn14 KO mice on the CDE-diet showed a reduction in 
collagen deposition after 14 days compared to WT mice which correlated with the 
LPC response (Tirnitz-Parker et al., 2010). Therefore, lower collagen levels might be 
linked to fewer ductular reactions in Fn14 KO mice. However, it also needs to be 
considered that the same study demonstrated no significant difference in fibrosis and 
ductular reaction after 21 days on the CDE-diet between Fn14 KO and WT mice 
(Tirnitz-Parker et al., 2010). This demonstrates that both fibrogenesis and ductular 
expansion are possible in the absence of Fn14, which is in accordance with my data. 
Furthermore my data demonstrated a significant upregulation of some fibrogenic 
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mediators including Acta2, Tgfb1 and Mmp9 in Fn14 WT mice after acute CCl4-injury 
compared to mineral oil control, which was not observed in Fn14 KO mice. This 
suggests that Fn14 might have a weak influence on fibrogenesis after acute injury. 
Furthermore, it might be possible that Fn14 signalling has more influence at a 
different time point for example at 24 hours post-CCl4 injury as it is expressed at 
considerably higher levels. Also quantification of α-SMA, TGF-β1 and MMP-9 
protein levels would be useful as a significant difference might be observed at the 
protein expression but not mRNA levels. 
 
Although genetic interruption of Fn14 did not affect fibrosis my data showed that 
TWEAK KO mice developed significantly less fibrosis following both acute and 
chronic CCl4 injury. This was demonstrated by significant reduction in fibrogenic 
mediators after acute injury and less collagen deposition and myofibroblast 
accumulation after chronic injury suggesting that TWEAK might also signal through 
alternative receptor(s) other than Fn14. CD163 a scavenger receptor that is restricted 
to the monocyte/macrophage lineage has been reported to interact with TWEAK 
(Bover et al., 2007). It is upregulated during inflammatory conditions to enhance 
hemoglobin clearance and heme degradation (Gordon, 2001). Furthermore, CD163 
may be involved in the host defense by modulating the release of cytokines by 
macrophages (Fabriek et al., 2005). In the liver, CD163 expression has been described 
as a marker of fibrosis (Kazankov et al., 2014) that can be upregulated on monocytes 
by LMFs in vitro (Zhang et al., 2014). The interaction between TWEAK and CD163 
leads to internalization of CD163-TWEAK complexes by macrophages (Moreno et 
al., 2009) thus possibly preventing CD163 from inducing removal and metabolism of 
the oxidant hemoglobin (Kristiansen et al., 2001) and the release of anti-inflammatory 
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metabolites (Otterbein et al., 2003). Furthermore, measuring sTWEAK and CD163 
in serum of patients with type 1 diabetes mellitus or peripheral arterial disease has 
shown a close correlation between high CD163 and low TWEAK levels indicating a 
possible co-regulation of those two molecules (Llaurado et al., 2012; Urbonaviciene et 
al., 2011). Therefore the presence of TWEAK might block interaction with CD163 
and its ligands in the liver leading to a pro-inflammatory and pro-fibrotic 
environment. However, it needs to be considered that the interaction between 
TWEAK and CD163 is still poorly understood and not confirmed (Fick et al., 2012). 
 
In conclusion, our findings suggest that TWEAK can regulate the fibrogenic response 
in a manner that may be at least in part independent of Fn14 in an acute and chronic 
model of CCl4 liver injury. Although Fn14 is significantly upregulated during liver 
injury, it had little effect on fibrogenesis. Therefore, targeting TWEAK in preference 
to Fn14 could be an effective way in altering fibrogenesis during liver injury. As 
TWEAK seems to be an important mediator in liver disease, the next chapter will 
evaluate the expression of sTWEAK in chronic liver disease and its potential 
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In the previous chapters I have examined the expression and role of TWEAK and 
Fn14 in association with fibrosis in acute and chronic liver disease. Now I move on to 
consider sTWEAK serum levels as a clinical marker of chronic liver disease with a 
focus on PSC. Other chronic liver diseases would also be of interest for this study and 
should be investigated in the future however serum samples from patients with PSC 
were readily available. PSC is a chronic, progressive liver disease characterised by 
ongoing inflammation, fibrosis of the intrahepatic and/or extrahepatic bile ducts and 
stricture formation of the biliary tree. The prevalence of PSC in Northern Europe and 
North America is approximately 6 to 16 cases per 100,000 people (Eaton et al., 2013). 
The pathogenesis of PSC is unknown but research so far suggests that PSC is an 
immune-mediated disease and that it can occur in individuals with a genetic 
predisposition. The majority (60-80%) of patients with PSC in northern Europe have 
IBD (Hirschfield et al., 2013). PSC is initially asymptomatic but after patients develop 
symptoms, over 50% will require liver transplantation caused by biliary cirrhosis, 
biliary obstruction and hepatobiliary malignant disease (Hirschfield et al., 2013). It is 
the fifth leading cause for liver transplantation in the USA and the leading cause in 
some Scandinavian countries (Bjøro et al., 2006).  
 
As not all patients can be transplanted due to shortage of donor livers, prioritisation of 
patients is critical. In 2008, the UK Liver Transplant Units developed the United 
Kingdom model for End-stage Liver Disease (UKELD) score as a method for 
selecting patients with cirrhosis requiring liver transplantation (Barber et al., 2007; 
Neuberger et al., 2008). The UKELD score is based on four readily available 
laboratory tests: serum total bilirubin, INR of the prothrombin time, serum creatinine 
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and serum sodium levels. A minimum UKELD score of 49 is used to put patients on 
the transplant list. A UKELD score greater than 49 predicts a 1-year mortality of 9% 
or more without liver transplantation (Neuberger et al., 2008). However, the 
components used to calculate the UKELD score can be influenced by factors other 
than the underlying severity of liver disease. Creatinine for example might be 
influenced by reduced production by the liver, increased tubular secretion or muscle 
wasting as it is proportional to muscle mass (Sherman et al., 2003; Cholongitas et al., 
2007). Furthermore, serum bilirubin levels are often normal in patients with PSC and 
are only increased when patients have significant biliary obstruction (Eaton et al., 
2013). The UKELD scoring system might therefore exclude some PSC patients for 
liver transplantation despite severe liver disease compared to other chronic liver 
conditions. In some cases the only biochemical abnormality detectable is elevated 
levels of serum alkaline phosphatase (ALP) in patients with PSC. High ALP levels are 
most commonly detected in PSC patients but values can vary throughout the disease 
in a single individual, and a small number of patients may have normal levels (Stanich 
et al., 2011). Currently, alternative prognostic tools in PSC are lacking and the 
identification of patients with a poorer long-term outlook is of critical interest to 
practicing clinicians, particularly to highlight those in need of novel therapy.  
 
Soluble TWEAK levels can then be measured in blood or urine samples and high 
levels of sTWEAK have been related to autoimmune diseases such as rheumatoid 
arthritis and lupus nephritis (Park et al., 2008; Schwartz et al., 2009). Soluble 
TWEAK levels were also predictive of disease progression in patients with systemic 
lupus erythematosus and advanced non-ischemic heart failure (Schwartz et al., 2009; 
Richter et al., 2010).  
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In this thesis, I have so far demonstrated that TWEAK and Fn14 expression are 
elevated in liver tissue of patients with chronic liver diseases including PSC, and I 
have also shown that hepatic expression levels of TWEAK and Fn14 correlated with 
fibrosis. Thus, we hypothesised that serum levels of sTWEAK may also be altered 
during liver disease. Therefore, this chapter investigates the expression of sTWEAK in 
patients with PSC and its prognostic abilities of disease outcome. 
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6.2 Results 
6.2.1 Soluble TWEAK levels are low in patients with PSC 
To investigate sTWEAK levels in a chronic liver disease setting, serum samples were 
acquired from 64 patients with PSC, 24 patients with IBD with no evidence of 
concurrent PSC and from 22 healthy individuals. A summary of the general 
characteristics is shown in Table 6.1. Patients with PSC had a median age of 36 years, 
IBD patients had a median age of 35 years and healthy controls of 34 years at the 
time of the blood sample. Most PSC patients were diagnosed with IBD (n=51, 
79.6%). Immunosuppressive medication was taken by 25 (39.1%) PSC patients and 9 
(37.5%) IBD patients.  
Soluble TWEAK serum levels as measured by a commercially available ELISA were 
significantly lower in PSC patients compared to healthy controls (p<0.01) and IBD 
patients (p<0.0001; Figure 6.1 A). The median levels of sTWEAK in patients with 
PSC were 275 pg/mL (Interquartile range; IQR 111-410), in the healthy control 
group 942 pg/mL (IQR 885-1044) and in patients with IBD 1130 pg/mL (IQR 959-
1429). Stratifying by disease severity, PSC patients with cirrhosis demonstrated 
significantly lower sTWEAK levels than those with pre-cirrhosis [189 pg/mL (IQR 
67-299) versus 632 pg/mL (IQR 391-862), respectively; p< 0.001; Figure 6.1 B]. 
Soluble TWEAK levels in patients with PSC were then compared to demographic 
and clinical data (Table 6.2 and Table 6.3). A significant positive correlation between 
sTWEAK and albumin was detected (Spearman ρ=0.252 p<0.05; Table 6.2). The 
median of albumin concentration in the investigated PSC patients was 42 g/L (IQR 
37-45), which is still in the normal range. No other tested variables such as age, colitis 
or immunosuppression demonstrated an association with sTWEAK levels (Table 6.2 
and Table 6.3). 
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  Controls IBD PSC 
Number of patients 22 24 64 
Gender, male (%) 12 (54.5) 12 (50.0) 40 (62.5) 
Age, years 34 (28-37) 35 (25-55) 36 (26-57) 
Immunosuppression:       
Steroids (%) N/A 5 (20.8) 3 (4.7) 
Azathioprine (%) N/A 4 (16.7) 5 (7.8) 
Steroids+Azathioprine (%) N/A 0 (0.0) 7 (10.9) 
Steroids+MMF (%) N/A 0 (0.0) 10 (15.6) 
None (%) N/A 14 (58.3) 39 (60.9) 
Table 6.1 Characteristics of healthy individuals and patients with IBD 
and PSC  




Figure 6.1 Soluble TWEAK levels in serum samples from healthy 
controls, IBD and PSC patients 
Soluble TWEAK levels were measured by ELISA of serum samples from healthy 
controls (HC, n=22) and patients with IBD (n=24) or with PSC (n=64) (A). sTWEAK 
levels stratified by PSC disease stages of pre-cirrhotic (n=22) and cirrhotic (n=42) (B). 
(** p<0.01, **** p<0.0001; Mann-Whitney U test). The distribution of values was 





Covariate RHO p value 
Age, years -0.124 0.329 
Laboratory findings*:     
AST (iU/L) -0.107 0.403 
ALP (ratio to ULN) -0.243 0.053 
ALT (iU/L) -0.021 0.885 
Albumin (g/L) 0.252 0.045 
Bilirubin (µmol/L) -0.241 0.055 
Platelet count (x10^9/L) 0.058 0.653 
Na+(mmol/L) -0.106 0.406 
Creatinine (μmol/L) 0.193 0.126 
IgG (g/L) 0.018 0.895 
UKELD -0.119 0.359 
Table 6.2 Continuous variables correlating with sTWEAK levels 
Abbreviations: UKELD=United Kingdom model for end-stage liver disease. 
Numbers in bold represent significant p values at the p<0.05 level (Spearman correlation). 




Median sTWEAK concentration,  
ng/mL (IQR) 
  Yes No p value 
Gender, male 278 (83-362) 267 (162-540) 0.549 
Colitis 304 (110-564) 253 (133-280) 0.239 
Active colitis 248 (83-409) 278 (127-410) 0.715 
Laboratory findings*:       
INR above normal, ≥1.2 248 (67-314) 290 (129-493) 0.121 
UKELD ≥ 49  268 (138-319) 277 (98-625) 0.372 
Medication:       
UDCA 268 (110-464) 280 (133-358) 0.987 
Immunosuppression 358 (234-522) 248 (98-331) 0.067 
Antibiotics**  260 (129-309) 278 (114-518) 0.356 
Table 6.3 Factors associated with sTWEAK levels 
Abbreviations: IQR= interquartile range, INR=international normalised ratio, 
UKELD=United Kingdom model for end-stage liver disease, UDCA= 
Ursodeoxycholic acid. *At time of taking sample ** if taken in the past 3 month 
(Mann-Whitney U test) 
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6.2.2 Low sTWEAK levels are a predictor of adverse prognosis in 
patients with PSC 
As sTWEAK levels were closely related to a more advanced disease stage in our 
patient cohort, the predictive value of sTWEAK levels for transplant-free survival was 
investigated. First, AUROC curve analysis was performed to identify optimal serum 
sTWEAK levels for potential prediction of outcome (Figure 6.2). The AUROC curve 
analysis revealed an optimal cut-off level of 330 pg/mL with a sensitivity of 86% and 
specificity of 56%. The area under the curve was 0.754 (p=0.001). By using the 
optimal cut-off threshold PSC patients were separated into two groups (low 
sTWEAK, ≤330 pg/mL; high sTWEAK, >330 pg/mL; Table 6.4). No significant 
differences were detected between the low and high sTWEAK groups and most 
clinical factors. However, as expected significantly more patients with cirrhosis were in 
the low sTWEAK group compared to the high sTWEAK group (90 vs. 26%, 
respectively, p<0.001). In addition, patients in the low sTWEAK group had 
significantly higher ALP ratios compared to patients in the high soluble TWEAK 
group [2.1 (IQR 1.1-3.6) vs. 1.0 (IQR 0.7-2.3) ALP ratio to upper limit of normal 
(ULN), respectively, p<0.05]. Bilirubin levels were also significantly higher in the low 
sTWEAK group [28 (IQR 14-53) vs. 12 (IQR 9-34) µmol/L, respectively, p<0.05]. 
The group with high sTWEAK levels had significantly more patients on 
immunosuppression compared to the low sTWEAK group (57% vs. 29%, 





Figure 6.2 Accuracy of sTWEAK at predicting transplant-free survival of 
PSC patients 
Area under the receiver operator characteristic (AUROC) curve analysis was 
performed to determine the optimal cut-off level of sTWEAK (330 ng/mL) as a 
predictor of liver transplant/death in PSC patients (n=64). 
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  ≤330 pg/mL >330 pg/mL p value 
Number of patients (%) 41 (64) 23 (36) N/A 
Gender, male (%) 27 (66) 13 (57) 0.592 
Age, years 36 (27-57) 40 (24-57) 0.370 
Cirrhosis (%) 37 (90) 6 (26) < 0.001 
No. with colitis (%) 31 (76) 20 (87) 0.346 
Colitis, active (%) 8 (20) 4 (17) 1.000 
Laboratory findings*:       
AST (iU/L) 74 (56-110) 80 (34-112) 0.580 
ALP (ratio to ULN) 2.1 (1.1-3.6) 1.0 (0.7-2.3) 0.030 
ALT (iU/L) 70 (44-113) 103 (35-156) 0.780 
Albumin (g/L) 41 (37-44) 43 (40-45) 0.220 
Bilirubin (µmol/L) 28 (14-53) 12 (9-34) 0.030 
Platelet count (x10^9/L) 187 (110-298) 245 (168-310) 0.380 
INR above normal, ≥1.2 (%) 19 (46) 4 (17) 0.055 
Na+(mmol/L) 141 (139-144) 141 (140-142) 0.522 
Creatinine (μmol/L) 68 (59-77) 71 (66-84) 0.145 
IgG (g/L) 17 (13-20) 14 (13-20) 0.710 
UKELD (continuous) 48 (46-52) 46 (44-51) 0.160 
UKELD ≥ 49 (%) 19 (46) 6 (26) 0.275 
Medication:       
UDCA (%) 33 (81) 18 (78) 1.000 
Immunosuppression (%) 12 (29) 13 (57) 0.038 
Antibiotics** (%) 9 (22) 1 (4) 0.081 
Table 6.4 Characteristics of PSC patients in relation to low and high 
sTWEAK levels 
PSC patients were divided into two groups on the basis of high sTWEAK (>330 
pg/mL) and low sTWEAK (≤330 pg/mL) levels in serum samples. Data is expressed 
as median (interquartile range). Numbers in bold represent significant p values at the 
p<0.05 level. Abbreviations: INR=international normalised ratio, UKELD=United 
Kingdom model for end-stage liver disease, UDCA= Ursodeoxycholic acid. *At time 
of taking sample ** if taken in the past 3 month (for continuous variables Mann-
Whitney U test otherwise Fisher’s exact test) 
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During the follow up period of 29 (IQR 8-41) months, 29 (45.3%) patients reached 
the endpoint. Of those patients 18 (28.1%) were transplanted, 7 (10.9%) died and 4 
(6.3%) patients died despite transplantation. Kaplan-Meier survival analysis 
demonstrated a significant difference in transplant-free survival within a 3-year follow-
up interval between the low sTWEAK and high sTWEAK groups (log rank test 
p<0.01, Figure 6.3). Within the low sTWEAK group, 25 out of 41 patients (61%) 
reached an endpoint whereas only 4 out of 23 patients (17%) of the high sTWEAK 
group reached an endpoint within the follow up period. On univariate Cox analysis, 
low sTWEAK levels were a significant predictor of death or transplantation (HR: 
4.013, 95% CI 1.395-11.545; p<0.01) (Table 6.5). Besides low sTWEAK levels, 
additional predictors of poor outcome were cirrhosis (HR: 20.830, 95% CI 2.820 – 
142.860; p<0.001), elevated baseline ALP (HR: 1.136, 95% CI 1.029-1.254; p=0.011), 
hypoalbuminaemia (HR: 1.164, 95% CI 1.092-1.241; p<0.001), elevated bilirubin 
(HR: 1.004, 95% CI 1.002-1.006; p<0.01), INR>1.2 (HR: 3.497, 95% CI 1.572-
7.819; p<0.01), low sodium levels (HR: 1.176, 95% CI 1.054-1.314; p<0.01) and 
immunosuppression (HR: 3.501, 95% CI 1.415-8.662; p<0.01). In addition, the 
UKELD score as continuous variable (HR: 1.172, 95% CI 1.105-1.243; p<0.001) and 
as dichotomous variable (HR: 7.576, 95% CI 3.300-17.241; p<0.001) with the clinical 
cut-off point of 49 was predictive of transplantation/death.  
Subsequent multivariate analysis by Cox proportional hazards regression 
demonstrated that sTWEAK levels below 330 pg/mL remained to be an independent 
predictor of death or transplantation after adjustment for other significant variables 
(adjusted HR: 3.628, 95% CI 1.033-12.746; p=0.044) (Table 6.6 A). The strong 
predictive value of sTWEAK was also retained when the UKELD score was included 
in the multivariate analysis as continuous variable (adjusted HR: 4.124, 95% CI 
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1.224-13.890, p=0.022, Table 6.6 B) or dichotomous variable with the cut-off point of 
49 (adjusted HR: 3.944, 95% CI 1.160-13.407, p=0.028, Table 6.6 C). Other factors 
such as elevated baseline ALP levels were also predictive of transplantation/death 
when the UKELD score was included in the multivariate analysis as continuous or 
dichotomous variable but not when the UKELD score was excluded (Table 6.6). In 
addition, hypoalbuminaemia was a significant predictor of transplantation/death 
when the UKELD score was excluded or applied as dichotomous variable but not as 
continuous variable. Furthermore, low sodium levels were predictive of 
transplantation/death when UKELD was excluded (Table 6.6 A). As low sodium 
levels are part of the UKELD formula they were not included in analysis containing 
UKELD.  
Finally, including cirrhosis in the multivariate analysis demonstrated that it is a strong 
predictor of transplant-free survival (adjusted HR: 16.950, 95% CI 2.290-125.000; 
p<0.01) in addition to immunosuppression (adjusted HR: 3.770, 95% CI 1.420-








Figure 6.3 Lower sTWEAK levels are associated with poorer transplant-
free survival in PSC patients  
Kaplan-Meier survivorship estimates for patients with PSC (n=64) having high (>330 
pg/mL) and low (≤330 pg/mL) sTWEAK.   
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  HR (95% CI) p value 
Gender, male 1.298 (0.601-2.802) 0.506 
Age, years 1.021 (0.998-1.044) 0.168 
Colitis 1.926 (0.375-2.288) 0.868 
Active colitis 0.922 (0.350-2.430) 0.870 
Cirrhosis 20.830 (2.820 – 142.860) <0.001 
Laboratory findings*:     
AST (iU/L) 1.000 (0.999-1.002) 0.771 
ALP (ratio to ULN) 1.136 (1.029-1.254) 0.011 
ALT (iU/L) 1.000 (0.997-1.003) 0.833 
Low albumin (g/L) 1.164 (1.092-1.241) <0.001 
Bilirubin (µmol/L) 1.004 (1.002-1.006) <0.001 
Low platelets (x10^9/L) 1.001 (0.998-1.004) 0.557 
INR above normal/1.2 3.497 (1.572-7.813) 0.002 
Low Na+ (mmol/L) 1.176 (1.054-1.314) 0.004 
Creatinine (μmol/L) 0.989 (0.963-1.015) 0.408 
IgG (g/L) 1.011 (0.964-1.060) 0.661 
UKELD (continuous) 1.172 (1.105-1.243) <0.001 
UKELD ≥ 49** 7.576 (3.300-17.241) <0.001 
Medication:     
UDCA 0.895 (0.339-2.367) 0.824 
Immunosuppression 3.501 (1.415-8.662) 0.007 
sTWEAK*** 4.013 (1.395-11.545) 0.010 
 
Table 6.5 Univariate analysis of clinical parameters for the prediction of 
transplant-free survival in patients with PSC 
Numbers in bold represent significant p values at the p<0.05 level or below. 
Abbreviations: CI= confidence interval, INR=international normalised ratio, 
UKELD=United Kingdom model for end-stage liver disease, UDCA= 
Ursodeoxycholic acid. *At time of taking sample ** clinically used cut-off point *** 




  HR (95% CI) p value 
A) UKELD excluded 
ALP (ratio to ULN) n.s. n.s 
Low albumin (g/L) 1.131 (1.056-1.211) <0.001 
Bilirubin (µmol/L) n.s. n.s. 
INR above normal/1.2 3.067 (1.323-7.143) 0.009 
Low Na+ (mmol/L) n.s. n.s. 
Immunosuppression n.s. n.s. 
sTWEAK* 3.628 (1.033-12.746) 0.044 
B) UKELD included as continuous variable 
ALP (ratio to ULN) 1.130 (1.007-1.268) 0.037 
Low albumin (g/L) n.s. n.s. 
UKELD 1.102 (1.003-1.210) 0.043 
Immunosuppression n.s. n.s. 
sTWEAK* 4.124 (1.224-13.890) 0.022 
C) UKELD included as a dichotomous variable 
ALP (ratio to ULN) 1.134 (1.006-1.279) 0.039 
Low albumin (g/L) 1.106 (1.020-1.199) 0.014 
UKELD ≥ 49** 3.658 (1.342-9.968) 0.011 
Immunosuppression n.s. n.s. 
sTWEAK* 3.944 (1.160-13.407) 0.028 
D) Cirrhosis included   
ALP (ratio to ULN) n.s. n.s 
Cirrhosis 16.950 (2.290-125.000) < 0.01 
Immunosuppression 3.770 (1.420-10.055) < 0.01 
sTWEAK* n.s. n.s 
 
Table 6.6 Multivariate analysis of clinical parameters for the prediction 
of transplant-free survival in patients with PSC 
Multivariate analysis using backward stepwise elimination. Numbers in bold represent 
significant p values at the p<0.05 level or below. Abbreviations: n.s= not significant 
CI= confidence interval, INR=international normalised ratio, UKELD=United 
Kingdom model for end-stage liver disease. * cut-off at ≤330 pg/mL **clinically used 





This chapter demonstrates that sTWEAK serum levels are altered in patients with 
PSC and that sTWEAK levels below 330 pg/mL are an independent predictor of 
transplantation or death. This is the first time that sTWEAK levels have been studied 
in a cohort of PSC patients. 
 
PSC is characterised by chronic inflammation of the biliary epithelium (Eaton et al., 
2013) and significantly higher levels of the pro-inflammatory cytokine TNF-α were 
detected in the serum of PSC patients (Neuman et al., 2002). In addition, my data in 
chapter 3 has shown that hepatic expression of TWEAK was more abundant in PSC 
liver tissue compared to normal donor tissue. Furthermore, I demonstrated in chapter 
4 that TWEAK stimulation of activated HSCs in vitro enhanced proliferation 
suggesting a potential pathological role in chronic liver disease. In support of this, I 
demonstrated a significant reduction of liver fibrosis in TWEAK KO mice in chapter 
5. Therefore, it was surprising that not only was sTWEAK significantly reduced in 
PSC patients compared to healthy controls but was present at even lower levels in 
PSC patients with cirrhosis than in those without cirrhosis − the opposite of what we 
had expected. However, this could be potentially very useful in monitoring the 
progression of cirrhosis, as it is a fast and not very invasive procedure to measure 
soluble TWEAK levels in serum samples. This would be especially useful as more 
markers, which could indicate the progression of liver cirrhosis would be required in 
clinical practice (Lefton et al., 2009). 
In agreement with my findings in PSC patients, reduced sTWEAK levels have also 
been detected in other diseases associated with increased inflammation including 
chronic heart failure, chronic kidney disease and type 1 diabetes (Chorianopoulos et 
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al., 2009; Yilmaz et al., 2009; Llaurado et al., 2012). Nevertheless, sTWEAK levels 
are not consistently decreased in all chronic inflammatory diseases. Research by Park 
et al. has demonstrated significantly higher levels in patients with rheumatoid arthritis 
(Park et al., 2008), which is consistent with my data from the IBD patients who also 
had higher levels of sTWEAK than healthy controls.  
 
Why serum sTWEAK levels were reduced in patients with PSC in spite of increased 
expression in the liver is not known. A possible explanation for lower sTWEAK levels 
in PSC is that increased Fn14 expression in the liver contributes to enhanced uptake 
of sTWEAK leading to lower serum sTWEAK concentration. This may lead to 
increased signalling through Fn14 in the tissue microenvironment thus also inducing 
more ductular reaction and fibrosis and therefore a more severe liver disease. 
Correlations between TWEAK or Fn14 expression with the severity of disease have 
been investigated previously (Affò et al., 2012; Li et al., 2013). A study by Affò et al. 
demonstrated that alcoholic hepatitis patients with higher hepatic Fn14 mRNA 
expression (and thus possibly lower sTWEAK) had a worse 90-day survival rate than 
patients with lower Fn14 mRNA levels (Affò et al., 2012). They confirmed that 
patients with alcoholic hepatitis had lower sTWEAK levels but did not show whether 
this was predictive of disease outcome. In addition, high hepatic expression levels of 
Fn14 were also suggested to be a predictor of poorer surgical outcome in patients with 
HCC (Li et al., 2013). This suggests that whilst sTWEAK levels vary dependent on 
disease type and severity they may have promise as predictors of survival in several 
chronic inflammatory diseases. Inclusion of an assessment of hepatic Fn14 expression 
may add to the predictive power of TWEAK assessment. However, investigating 
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hepatic Fn14 expression may not be a practical option clinically, as it would require a 
more invasive biopsy in order to serve as a predictor of disease outcome.  
 
Another explanation for lower sTWEAK levels could be that through some unknown 
mechanism, sTWEAK levels are reduced in chronic diseases like PSC in an attempt 
to prevent further tissue damage. A potential way through which sTWEAK is reduced 
is through CD163, a TWEAK scavenger receptor. CD163-positive inflammatory 
macrophages and monocytes can bind and internalise sTWEAK leading to low 
sTWEAK concentrations (Bover et al., 2007; Moreno et al., 2009). Research has 
shown that patients with liver cirrhosis have significantly higher serum soluble CD163 
levels than healthy controls (Holland-Fischer et al., 2011). In addition, high soluble 
CD163 and low sTWEAK concentrations have been correlated with type 1 diabetes 
mellitus diagnosis and cardiovascular mortality in peripheral arterial disease (Llaurado 
et al., 2012; Urbonaviciene et al., 2011). Thus it is possible that low levels of 
sTWEAK in PSC serum result from increased scavenging by CD163.  
 
Finally, sTWEAK levels might be decreased because membrane-bound TWEAK is 
not shed from the cell surface of leukocytes in the blood. When measuring sTWEAK 
in serum samples the cells are removed and therefore membrane-bound TWEAK 
would be excluded in the measurement. TWEAK is processed by the serine 
endoprotease, furin inside the cells (Brown et al., 2010). Therefore, decreased furin 
expression or function might lead to decreased shedding of TWEAK but this would 
need to be further investigated. Nevertheless, it has been demonstrated that TWEAK 
can be expressed on the cell surface of monocytes in patients with multiple sclerosis 
but not in control patients (Desplat-Jégo et al., 2009). However, this did not seem to 
 179 
affect sTWEAK levels as they were similar between the multiple sclerosis patients and 
the control group (Desplat-Jégo et al., 2009). Furthermore it is not know yet whether 
sTWEAK and the membrane-bound form have comparable affinities for the Fn14 or 
comparable biological activity leading to different biological responses (Brown et al., 
2010). 
 
My data has shown that sTWEAK levels in patient serum samples are predictive of 
transplant-free survival in a multivariate regression model using individual 
components and even despite including the UKELD score as a variable. PSC patients 
with low sTWEAK levels were more likely to die or require a transplant. In 
accordance with this, research by Richter et al. also demonstrated that sTWEAK 
levels in serum samples could be used as a predictive tool of mortality in patients with 
advanced non-ischemic heart failure (Richter et al., 2010). Using the multivariate 
regression model my data has demonstrated that serum albumin and INR, when the 
UKELD score was excluded as a variable, were independently associated with 
transplant-free survival. Other research has shown that serum albumin improved 
prediction of waiting list mortality in patients with liver cirrhosis when added to the 
Model for End-Stage Liver Disease (MELD) used in America (Myers et al., 2013). 
The prothrombin time expressed as INR is used to assess clotting and is included 
worldwide in almost all the prognostic models regarding transplantation for liver 
disease. Considering that patients with liver disease have a more complex 
coagulopathy and that the method for calibrating the INR calculation is based on 
serum levels from people with stable anticoagulation, the usefulness of INR seems to 
be suboptimal (Tripodi et al., 2007). However despite these limitations, INR is still 
considered a valid measure (Kamath and Kim, 2009). 
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Including the UKELD score in the multivariate analysis as a continuous or 
dichotomous variable showed that it is also predictive of patients at risk requiring 
transplantation. This was expected as the scoring system is currently used to place 
patients on the transplant list. However using the UKELD score to decide on the 
urgency of transplantation may not be useful for patients with PSC and other forms of 
cholestatic liver disease as such patients face unique clinical features that would better 
reflect the severity of illness for example ascending cholangitis due to biliary strictures 
(Goldberg et al., 2011). ALP was only significant when UKELD score was applied as 
continuous or dichotomous variable but not when it was excluded from the 
calculation. ALP fluctuations are frequent during the clinical course, influenced by a 
variety of confounding variables (Stanich et al., 2011). Nevertheless, ALP remains to 
be an important indicator of disease severity and higher ALP correlated with lower 
sTWEAK levels, which is consistent with the predictive ability of sTWEAK. 
Furthermore, a larger number of patients in the high sTWEAK group were on 
immunosuppressant but a benefit of immunosuppressive medication in inhibiting 
disease progression remains yet to be determined (Hirschfield et al., 2013).  
Substituting low albumin levels, low platelet count, high INR, UKELD score, low 
sodium levels and elevated bilirubin levels for the collective variable termed cirrhosis 
the multivariate analysis was rerun. In doing so cirrhosis and immunosuppression 
were the only significant predictors of transplant-free survival. Given the interaction 
between cirrhosis and sTWEAK it was unsurprising that TWEAK was no longer 
significant.  
 
Although sTWEAK levels seem to be an independent predictor of transplant-free 
survival in patients with PSC, it remains to be determined whether the prognostic 
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values of sTWEAK are disease specific or whether it also applies to other cirrhotic 
liver diseases such as chronic infections with HCV or HBV and ALD. Further 
investigating a broad variety of chronic liver diseases could then potentially aid in 
selecting patients for liver transplantation similarly to how the UKELD score is 
currently used. In addition, it would be interesting to determine whether sTWEAK 
levels might increase in certain types of chronic liver diseases compared to others and 
why that might be. However, so far sTWEAK could serve as a predictive tool in 
patients with PSC and improve the way patients are allocated on the transplant 
waiting list. A pragmatic approach could be to adopt sTWEAK measurements as part 
of the routine diagnostic measurements and possibly include it as a variable of the 
UKELD scoring system.  
 
In conclusion, lower sTWEAK levels distinguish patients with PSC compared to those 
with IBD alone and healthy subjects. Moreover, sTWEAK inversely correlates with 
disease severity and is an excellent predictor of poorer clinical outcome. However, 
TWEAK has been shown to be involved in liver disease processes and therefore most 
probably functions as a pathogenic cytokine rather than purely a biomarker in 
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7.1 Overview and general discussion 
Fibrosis is normally a highly regulated and protective response to tissue injury. 
Numerous pathways and molecules contribute to determine whether this process 
remains homeostatic or whether it is uncontrolled and excessive (Pellicoro et al., 
2014).  
In vivo studies demonstrated that a limited degree of liver fibrosis can be beneficial as it 
leads to greater resistance to further acute injury and offers protection to hepatocytes 
against various toxic stimuli (Bourbonnais et al., 2012). However, in response to 
chronic liver inflammation the fibrotic response becomes uncontrolled leading to the 
progressive replacement of functional hepatic tissue, which can potentially progress to 
cirrhosis and/or hepatocellular carcinoma. The burden of chronic liver disease is 
increasing in the UK and worldwide (Ellis and Mann, 2012). Therefore it is important 
to discover safe therapies that can control fibrogenesis. As our understanding of the 
pathogenesis of liver fibrosis advances an increasing number of factors are being 
explored as novel treatments. However, effective treatment strategies are difficult to 
identify, due to the involvement of many fibrotic molecules in the maintenance of 
normal tissue homeostasis. This hinders the progress of novel strategies for the 
treatment of liver fibrosis, and so it is necessary to gain a greater understanding of the 
pathways and molecules involved, in order to develop new anti-fibrotic therapies. 
 
Previous research has demonstrated that two members of the TNF superfamily, 
TWEAK and its receptor Fn14, are implicated in the pathogenesis of fibrosis. 
Overexpression of TWEAK in mouse models led to cardiac fibrosis and kidney 
fibrosis (Jain et al., 2009; Hotta et al., 2011) whereas deletion of Fn14 protected 
against cardiac fibrosis (Novoyatleva et al., 2013). However, no studies so far directly 
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address the role of TWEAK and Fn14 in fibrotic liver disease. Therefore this thesis 
examined the role of TWEAK and Fn14 in human and mouse acute and chronic liver 
injury and provides evidence that TWEAK is directly involved in the modulation of 
liver fibrosis (Figure 7.1). Furthermore, the soluble form of TWEAK was detected in 
serum samples of patients with chronic liver disease and has the potential to predict 
disease progression in patients with PSC.  
 
7.1.1 TWEAK and Fn14 expression in diseased liver 
Initially, I investigated the expression of Fn14 and TWEAK in different types of 
human liver diseases including acute, fatty and immune-mediated liver diseases and in 
experimental models of acute and chronic liver injury. 
ALF causes a rapid loss of liver function and has been associated with increased but 
restricted liver fibrosis (Dechêne et al., 2010). My data demonstrated elevated Fn14 
mRNA and protein levels in patients with ALF compared to normal livers. I also 
detected high Fn14 mRNA levels in an experimental model of acute liver injury 
induced by CCl4. Consistent with this a study by Affò et al. demonstrated high Fn14 
mRNA levels in experimental models of acute liver injury (Affò et al., 2012). 
Furthermore, my data showed that TWEAK mRNA was not significantly elevated in 
patients with ALF or in mice with CCl4-induced acute liver injury. Nevertheless, 
TWEAK protein levels were abundant around the portal area and the fibrous septum 
in patients with ALF compared to healthy controls. Following acute injury, the 
TWEAK and Fn14 pathway is considered to facilitate tissue regeneration and repair 
whereas prolonged TWEAK stimulation in diseased tissue can contribute to 
pathogenic tissue degeneration (Cheng et al., 2013). Therefore, expression of 
TWEAK and Fn14 was also investigated in chronic steatotic liver diseases including 
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ALD and NASH. Patients with ALD and NASH often have perisinusoidal fibrosis as 
ECM primarily accumulates in the space of Disse. A significant upregulation of Fn14 
protein but not mRNA expression was observed in chronic steatotic liver disease, 
which revealed the co-expression of Fn14 with α-SMA-positive myofibroblasts in the 
fibrotic scar. I also demonstrated that TWEAK mRNA and protein expression were 
significantly upregulated in chronic steatotic liver diseases, and was not only 
associated with infiltrating leukocytes but also with myofibroblasts in the fibrotic septa 
in NASH and ALD.  
 
A role for the TWEAK and Fn14 pathway in driving several different human 
autoimmune-mediated diseases including rheumatoid arthritis, multiple sclerosis and 
systemic lupus erythematosus has been described. The first phase II clinical trials in 
patients with systemic lupus erythematosus are now in progress using anti-TWEAK 
blocking therapies (Bertin et al., 2013). The chronic liver diseases PBC and AIH are 
also autoimmune-mediated liver diseases whereas PSC is idiopathic but considered to 
be an immune-mediated liver disease (O'Hara et al., 2013). Consistent with this, my 
data showed elevated Fn14 and TWEAK expression in liver tissue from patients with 
PSC, PBC and AIH compared to normal controls.  
PBC and PSC are additionally characterised as cholangiopathies. They 
present with chronic inflammation of the bile ducts causing ductular reaction that 
encompasses proliferation of biliary epithelial cells and expansion of differentiating 
LPCs that may lead to periductular and biliary fibrosis (Hirschfield et al., 2010; 
O'Hara et al., 2013). Fn14 expression has previously been described in LPCs and 
biliary epithelial cells but to my knowledge has not been investigated in PBC or PSC 
(Tirnitz-Parker et al., 2010; Jakubowski et al., 2005; Affò et al., 2012). My studies 
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demonstrated that indeed Fn14 was present in CK19-positive ductule-like structures 
in PBC and PSC samples. Overall, increased expression of TWEAK and Fn14 in 
acute and chronic liver diseases, and their association with the stromal population, 
suggested that they are involved in the disease process. 
 
7.1.2 The role of TWEAK and Fn14 in liver fibrosis  
As all of the investigated liver diseases above develop a certain degree of fibrosis, I 
then investigated the expression and function of TWEAK and Fn14 in human HSCs 
in vitro. Fn14 expression was present in quiescent and activated HSCs in vitro, which 
could be translocated to the cell surface with TGF-β stimulation. A similar pattern has 
been observed in the corneal stroma where quiescent keratocytes upregulate Fn14 
expression after TGF-β stimulation (Ebihara et al., 2009). In addition, HSCs 
constitutively produced TWEAK supporting a concept of a paracrine and/or 
autocrine loop in which TWEAK produced by HSCs feeds back on them via the 
Fn14 receptor. The co-expression of TWEAK and Fn14 has also been detected on 
primary proximal tubular epithelial cells and human blastoma cell lines (Hotta et al., 
2011; Pettersen et al., 2013). Importantly, my data showed that TWEAK induced 
HSC proliferation and NF-κB signalling suggesting an active role of this cytokine in 
the development of hepatic fibrosis.  
 
The role of TWEAK as a stimulator of liver fibrogenesis in vivo was evidenced by 
reduced fibrosis in TWEAK KO animals subjected to acute and chronic CCl4 injury. 
Following acute liver injury, Col1a1 was significantly lower in TWEAK KO mice 
compared to TWEAK WT mice. Similarly, TWEAK KO mice subjected to chronic 
CCl4 had less collagen deposition compared to their WT control. In contrast, my data 
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also demonstrated that TWEAK stimulation of human HSCs in vitro did not lead to 
changes in COL1A1. However, the microenvironment of HSCs in a fibrotic liver is 
completely different and exposes the cells to other cell types and molecules not found 
when culturing HSCs leading them to have a different gene expression profile (De 
Minicis et al., 2007). This could possibly mean that TWEAK does not have an 
immediate effect on HSC collagen production but functions via other as yet unknown 
mechanisms such as inducing secretion of TGF-β or inflammatory cytokines. Indeed, 
transcription levels of Tgfb1 were significantly reduced in TWEAK KO mice 
compared to WT mice after acute injury indicating that TWEAK might be involved 
in the regulation of Tgfb1.  
Acta2 transcription was similar in TWEAK KO and WT mice after acute liver 
injury whereas fewer α-SMA-positive LMFs were present in TWEAK KO mice after 
chronic injury. In contrast, my in vitro experiments demonstrated that TWEAK has an 
inhibitory effect on HSC activation. Again, depending on the microenvironment 
TWEAK might affect HSC activation in different ways and other research has 
demonstrated a dual role for TWEAK where it can stimulate progenitor cells after 
acute injury but also inhibit differentiation of the same progenitor cells in chronic 
disease (Burkly et al., 2007). 
 
An important group of proteins that are involved in liver fibrosis are MMPs. 
Commonly MMPs are considered to be involved in the turnover and degradation of 
ECM but they also involved in the regulation of inflammation and activation and de-
activation of myofibroblasts (Giannandrea and Parks, 2014). One group of MMPs are 
gelatinases, MMP-2 and MMP-9, that cause the degradation of collagen type IV, an 
important element of the endothelial basement membrane, facilitating the recruitment 
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of inflammatory cells and leading to the replacement by collagen type I and III after 
liver injury (Kurzepa et al., 2014). However, depending on the timing, MMPs can 
play dual roles both bad and good in liver fibrosis. MMP-2 for example can induce 
HSC proliferation and migration but is also involved in the regression of fibrosis as it 
has collagenolytic properties (Hemmann et al., 2007). MMP-9 on the other hand is 
involved in HSC activation but can also promote HSC apoptosis (Hemmann et al., 
2007).  
My data demonstrated that Mmp2, but not Mmp9, was significantly lower in TWEAK 
KO mice compared to TWEAK WT mice after acute and chronic liver injury. 
Conversely, recent research has demonstrated that TWEAK decreased or had no 
effect on MMP-2 production but increased MMP-9 production in different cell types 
including cardiac fibroblasts and macrophages (Kim et al., 2004; Li et al., 2009; 
Panguluri et al., 2010; Chen et al., 2012). Therefore, TWEAK might not directly 
affect MMP-2 production in HSCs or macrophages during liver injury. It may act 
through a secondary mechanism. MMP activity is very controlled and one way in 
which this is achieved is by stopping their catalytic activity through TIMPs. TIMP-1 is 
mainly produced by activated HSCs and is expressed as early as 9 hours after CCl4 
injury (Knittel et al., 2000). It is controlled by TGF-β but also by other pro-
inflammatory cytokines such as TNF-α (Hemmann et al., 2007). Blocking TIMP-1 in 
a mouse model of fibrosis induced fibrolysis (Nie et al., 2001). My experiments 
demonstrated that Timp1 was significantly less in TWEAK KO mice than WT mice 
after acute but not after chronic injury. Again, this might be due to different functions 
that TWEAK exhibits during acute and chronic injury.  
In addition, my data suggests that the fibrogenic effect of TWEAK may not 
exclusively be regulated through Fn14 as Fn14 KO mice had similar levels of fibrosis 
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compared to their WT controls after acute and chronic CCl4 injury. This was also 
demonstrated in Fn14 KO mice after they were fed the CDE-diet for 21 days where 
they expressed similar levels of Col1a1, Mmp2, Mmp9 and Timp1 compared to WT 
mice despite having significantly higher Fn14 mRNA expression (Tirnitz-Parker et al., 
2010). Nevertheless, the same experimental model also demonstrated that after only 
14 days on the CDE-diet immune infiltration of CD45-positive and F4/80-positive 
lymphocytes, collagen deposition and LPCs were significantly lower in Fn14 KO mice 
compared to WT mice (Tirnitz-Parker et al., 2010). This suggest that Fn14 might be 
involved at earlier time points during the development of liver fibrosis and becomes 
later on substituted with other mediators that exhibit a stronger effect on fibrosis.  
 
The inflammatory response plays a crucial role during the development of liver 
fibrosis. Research by Holt et al. has demonstrated that activated HSCs are involved in 
the recruitment of immune cells to the site of injury by secreting large amounts of 
chemokines (Holt et al., 2009). CCL5 has been identified as an important mediator of 
fibrosis (Berres et al., 2010) and it directly effects HSCs and the immune environment 
(Liaskou et al., 2013; Schwabe et al., 2003). My data demonstrated that TWEAK 
stimulation led to a trend towards an upregulation of CCL5 in HSCs. Other research 
has demonstrated the ability of TWEAK to induce expression of pro-inflammatory 
cytokines and chemokines (IL-8, CCL2 and CCL5) in human corneal myofibroblasts, 
which was further increased with co-stimulation of TGF-β (Ebihara et al., 2009). 
Similarly, IL-8 production induced by TWEAK was enhanced by TGF-β in gingival 
fibroblasts (Hosokawa et al., 2006) indicating that TWEAK and TGF-β might work 
synergistically to enhance the inflammatory response during fibrotic liver disease.  
 
 190 
7.1.3 Soluble TWEAK levels as indicator of disease severity  
My data and that generated by other groups (Tirnitz-Parker et al., 2010; Kuramitsu et 
al., 2013; Bird et al., 2013) has demonstrated that TWEAK can affect different aspects 
of liver disease including fibrogenesis and LPC proliferation. Despite being involved in 
disease progression, research has also shown that the quantity of sTWEAK in serum 
or urine samples can be a predictor of disease progression (Chorianopoulos et al., 
2009; Bertin et al., 2013). In accordance with that, I demonstrated that sTWEAK 
levels in patients with PSC could be a predictor of disease outcome. Lower sTWEAK 
levels were associated with a worse transplant-free survival. However, whether this is 
exclusively in patients with PSC or whether this can also be applied to other liver 
diseases remains to be determined.  
 
7.2 Conclusion 
In conclusion, this thesis demonstrates that TWEAK and Fn14 can be upregulated in 
various different liver diseases and that TWEAK can regulate the fibrogenic response 
at least in parts independent of Fn14 in vivo. Furthermore, TWEAK can induce the 
expansion of activated HSCs through an enhanced proliferative response in vitro. 
Targeting TWEAK could therefore be an effective way in altering fibrogenesis during 




Figure 7.1 Proposed role of TWEAK in the pathogenesis of liver fibrosis 
In the normal liver hepatic stellate cells (HSCs) are quiescent and TWEAK expression 
is low. In response to liver injury quiescent HSCs become activated and lymphocyte 
infiltrate induces TWEAK expression. TWEAK enhances HSC proliferation and 
CCL5 production. CCL5 then exacerbates lymphocyte recruitment. In addition, 




7.3 Limitations and future areas for development 
Hepatic TWEAK was expressed by a variety of cell types. I demonstrated that 
TWEAK is expressed by vimentin-positive stromal cells in the fibrotic septum and by 
HSCs in vitro. In contrast most research has demonstrated that TWEAK is expressed 
by immune cells. In the liver, TWEAK mRNA has been shown to be highly expressed 
in NK cells and macrophages but was also detected in CD4-positive T cells, CD8-
positive T cells and NKT cells (Tirnitz-Parker et al., 2010). Further work is required 
to determine lymphocyte populations in the liver that are expressing TWEAK 
protein. This could be achieved by dual staining of liver tissue or performing flow 
cytometry with antibodies against TWEAK and markers for leukocyte subpopulations 
such as CD14 (monocytes/macrophages), CD11c (Dendritic cells), CD56 (NK cells) 
and CD8 (T cells). More insight into what cell types express TWEAK at which 
timepoint in acute and chronic liver injury could give vital clues on the understanding 
of disease pathogenesis.  
 
Fn14 expression has been detected in different liver cells including HSCs, 
cholangiocytes, and IHECs whereas TWEAK can be expressed by macrophages and 
HSCs. In vitro co-culture experiments could be used to mimic the liver 
microenvironment more closely and investigate the cellular behaviour of for example 
cholangiocytes in combination with HSCs or macrophages. TWEAK or Fn14 could 
then be inhibited by function blocking antibodies or siRNA in order to determine the 
role of TWEAK and Fn14 on cell behaviour. Furthermore, dual staining of TWEAK 
and Fn14 in liver sections could be carried out to determine the proximity of 
TWEAK and Fn14-positive cells.  
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In functional assays, TWEAK was found to promote HSC proliferation but inhibited 
activation as indicated by lower ACTA2 levels. I have not investigated the effect on 
HSCs when they are stimulated with other cytokines or growth factors in combination 
with TWEAK. Co-stimulation of TWEAK and TGF-β1 would be a likely 
combination especially because Fn14 is upregulated with TGF-β1 in HSCs in vitro. In 
addition, it needs to be investigated whether TWEAK does indeed induce 
proliferation of HSCs through Fn14 signalling using anti-Fn14 blocking antibodies.  
 
Work on this thesis has focused on the role of TWEAK and Fn14 in liver fibrosis. 
There is strong evidence that TWEAK is also involved in the modulation of the 
immune system (Burkly et al., 2011). Previous work by other groups has demonstrated 
a pro-inflammatory effect of TWEAK on myofibroblasts and keratocytes expressing 
cytokines and chemokines such as IL-8, CCL2 and CCL5 (Chicheportiche et al., 
2002; Jin et al., 2004; Ebihara et al., 2009). I have investigated CCL5 expression in 
HSCs upon TWEAK treatment but this should be further investigated by increasing 
the number of repeats and looking at other pro- and anti-inflammatory cytokines and 
chemokines.    
 
So far I have demonstrated that TWEAK activates the NF-κB pathway in HSCs. To 
get further insights how TWEAK affects HSCs other pathways could be investigated. 
For example TWEAK has been shown to activate p44/p42 mitogen activated protein 
kinases (MAPK), c-jun-N-terminal kinase 1 (JNK1), and activator protein-1 (AP-1) 
and transforming growth factor beta activated kinase-1 (TAK1) in various cell types 
(Dogra et al., 2007; Polek et al., 2003; Kumar et al., 2009). Furthermore, whether the 
effect of TWEAK on HSC proliferation and activation is regulated through the NF-
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κB pathway could be investigated with agents that inhibit NF-κB pathway (Yamamoto 
and Gaynor, 2001). 
 
As discussed earlier, in vivo studies have shown that TWEAK but not Fn14 seem to be 
involved in fibrogenesis in a chemical injury model. Further studies are required to 
investigate the Fn14 KO phenotype in context of other injury models. A biliary model 
such as bile duct ligation would be of interest. Bile duct ligation causes proliferation of 
biliary epithelial cells and LPCs with an accompanying portal inflammation and 
fibrosis (Georgiev et al., 2008). Another model that could be studied is the MCD 
model, which is nutritional animal model of NASH. The MCD diet causes 
steatohepatitis and perisinusoidal fibrosis (Takahashi et al., 2012).  
 
Low sTWEAK levels were detected in serum samples from patients with PSC that 
correlated with disease progression. Other liver diseases should be investigated to 
determine whether the results are specific for PSC patients. Furthermore, it would be 
of interest whether soluble levels of CD163 inversely correlate with sTWEAK as it has 
been shown in other disease (Urbonaviciene et al., 2011; Llaurado et al., 2012; Bertin 
et al., 2013). Indeed in patients with atherosclerosis the CD163/TWEAK ratio was a 
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